Blood Pressure Management in Cardiovascular Risk Stratification. Procedure, Progression, Process. by Adiyaman, A.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/74853
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.
Blood Pressure Measurement  
in Cardiovascular Risk Stratification 
 
Procedure, Progress, Process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Adiyaman 
 
 
 
 2 
Blood Pressure Measurement  
in Cardiovascular Risk Stratification 
 
Procedure, Progress, Process 
 
 
 
 
 
 
 
 
 
 
A. Adiyaman
 3
 
Cover:  
 
The cover shows a picture which consists of three parts. It resembles the last three words of the title 
of the thesis (procedure, progress, process).  
 
In the upper part of the figure, the doctor measures the blood pressure of a patient. The procedure of 
measurement is essential for the determination of correct pressures and subsequently making 
adequate cardiovascular risk estimations. The middle part of the figure shows 24-hour trends of 
blood pressure in ambulatory monitoring. This technique is an important progress, because it 
measures pressures over the whole day and unmasks white coat hypertension and masked (hidden) 
hypertension. Additionally it provides the ratio of daytime and nighttime blood pressure, which is a 
marker of cardiovascular risk. The lower part of the figure depicts the process of indexes derived 
from blood pressure. The form of the blood pressure curve and the dynamic relation between 
diastolic and systolic pressure over 24 hours, establish indexes of arterial stiffness and 
cardiovascular risk. In the background of the cover page a watermark visualises the thorax of a 
patient, in which the heart and large arteries can be seen. 
 
 
 
 
 
 
 
 
 
Cover design:  A. Adiyaman 
Lay-out:   A. Adiyaman 
Printed:   IVA GROEP, Rotterdam 
 
 
Blood pressure measurement in cardiovascular risk stratification;  
procedure, progress, process / A. Adiyaman 
Thesis Nijmegen 
ISBN/EAN: 978-90-9024915-5 
 
 
© 2009 by A. Adiyaman, Nijmegen 
All rights are reserved. No part of this publication may be reproduced, stored in a retrieval system, or 
transmitted in any form or by any means, mechanically, by photocopying, recording or otherwise, 
without the written permission of the author. 
 
 
 
Publication of this thesis was financially supported by McSweeney Pharmacy Group, Ireland/UK 
and Spanhoff Groep Apotheken, the Netherlands. This contribution is gratefully acknowledged.  
 
Additional support was provided by APC Cardiovascular Ltd. and Zambon. 
 4 
Blood Pressure Measurement in Cardiovascular Risk Stratification 
 
Procedure, Progress, Process 
 
 
 
 
 
Een wetenschappelijke proeve 
op het gebied van de Medische Wetenschappen 
 
 
 
 
 
 
 
 
 
 
Proefschrift 
ter verkrijging van de graad doctor 
aan de Radboud Universiteit Nijmegen 
op gezag van de rector magnificus prof. mr. S.C.J.J. Kortmann 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen op dinsdag 
22 December 2009 om 10.30 uur precies 
 
 
door 
 
 
Ahmet Adiyaman 
geboren op 23 april 1981  
te Doetinchem
 5
 
Promotores:   Prof. dr. Th. Thien 
Prof. dr. J.A. Staessen (KU Leuven & Universiteit Maastricht) 
 
Copromotor:    Dr. J. Deinum 
 
Manuscriptcommissie:  Prof. dr. P. Smits  
Prof. dr. F.W. Verheugt 
    Prof. dr. M.T. Hopman 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The research presented in this thesis was carried out at the Dept of Medicine, Division of General 
Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands 
 
and 
 
the Studies Coordinating Centre, Division of Hypertension and Cardiovascular Research, 
Department of Cardiovascular Diseases, University of Leuven, Belgium. 
 
 
 
(Part of) The research described in this thesis was supported by a grant of the Netherlands Heart 
Foundation (NHF-2006SB014). Financial support by the Netherlands Heart Foundation for the 
publication of this thesis is gratefully acknowledged. 
 6 
 
 
Διαιτήμασί τε χρήσομαι ἐπ' ὠφελείῃ καμνόντων κατὰ δύναμιν καὶ κρίσιν ἐμὴν, ἐπὶ δηλήσει δὲ καὶ 
ἀδικίῃ εἴρξειν. 
Ὅρκον μὲν οὖν μοι τόνδε ἐπιτελέα ποιέοντι, καὶ μὴ ξυγχέοντι, εἴη ἐπαύρασθαι καὶ βίου καὶ τέχνης 
δοξαζομένῳ παρὰ πᾶσιν ἀνθρώποις ἐς τὸν αἰεὶ χρόνον. παραβαίνοντι δὲ καὶ ἐπιορκοῦντι, τἀναντία 
τουτέων. 
I will prescribe regimens for the good of my patients according to my ability and my judgment and 
never do harm to anyone.  
If I keep this oath faithfully, may I enjoy my life and practice my art, respected by all men and in all 
times; but if I swerve from it or violate it, may the reverse be my lot. 
 
 
 
 
 
 
 
 
Parts of the original oath of Hippocrates of 
Kos (460 BC – 370 BC), who separated the 
discipline of medicine from mystics and 
divine forces. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Voor mijn ouders 
Voor de wetenschap 
  
 7
Table of contents 
 
Chapter 1 Introduction and aim of the thesis            11 
 
Part 1  Aspects of the procedure of blood pressure measurement  
 
Chapter 2 
2.1  The position of the arm during blood pressure measurement        23 
in sitting position.  
Blood Press Monit 2006; 11(6):309-13 
 
2.2  The effect of crossing legs on blood pressure.         35 
Blood Press Monit 2007; 12(3):189-93 
 
2.3 Which physiological mechanism(s) increases blood pressure        47 
during leg crossing?  
J Hypertens 2008; 26(3):433–437 
 
Part 2  Progress of blood pressure measurement  
 
Chapter 3  
3.1 Thirty years of research on diagnostic and therapeutic thresholds        59 
for the self-measured blood pressure at home.  
 Blood Press Monit 2008; 13(6):352-365 
3.2 The physician and the hospital separately and independently        89 
influence blood pressure. 
  Submitted 
 
Part 3  Process of blood pressure: The Ambulatory Arterial Stiffness Index  
 
Chapter 4 
4.1 The Ambulatory Arterial Stiffness Index; a novel indicator of      105 
cardiovascular risk.  
Submitted  
 
4.2  Reproducibility of the ambulatory arterial stiffness index in      121 
hypertensive patients.  
  J Hypertens 2008; 26(10):1993-2000 
 
4.3  Correspondence 
  Putting a spin on the ambulatory arterial stiffness index.      137 
  J Hypertens 2008; 26(6):1266-7; author reply 1267-9 
 
  Dipping Deeper Into the Ambulatory Arterial Stiffness Index.     149 
Hypertension 2007; 50(3):e59-e60; author reply e61-e62 
 
4.4 Determinants of the Ambulatory Arterial Stiffness Index in      155 
7604 Subjects From 6 Populations. 
Hypertension 2008; 52(6):1038-1044  
 8 
Chapter 5   
 
5.1  General discussion and summary         185 
 
5.2  Samenvatting            197 
 
5.3  Dankwoord            205 
 
5.4 Curriculum Vitae           209 
 
5.5 List of publications           213 
 
 9
 10 
Chapter 1  
 
Introduction and aim of the thesis 
 11
Blood pressure measurement in cardiovascular risk stratification; 
procedure, progress, and process 
 
Introduction 
 
Atherosclerosis, with hypertension as its principal cause, is nowadays the most important risk 
factor for cardiovascular events (myocardial infarction, stroke, heart failure) and death[1]. 
The world is witnessing a remarkable demographical transition characterised by falling birth 
rates, lower mortality and increased longevity. In Europe, the proportion of inhabitants older 
than 60 years will rise from 20% now to over 35% by the year 2030. This unprecedented 
demographic revolution explains why the incidence of chronic age-related diseases, such as 
atherosclerosis and heart failure, will grow into larger proportions. These cardiovascular 
disorders will affect the quality of life of millions of Europeans. They will undermine the 
viability of the economical structure in Europe, unless appropriate preventive measures are 
implemented and therapies that are more efficacious become generally available[2].   
 
Hypertension is an established and well known risk factor both for cerebrovascular and 
cardiac disease[1]. It is thought that, over a large range of blood pressures, there is a linear 
rise of cardiovascular risk, both for higher systolic and diastolic pressures[3]. Both 
antihypertensive medication and non-pharmaceutical methods to reduce blood pressure have 
effectively been shown to reduce cardiovascular disease and mortality[4]. This accounts both 
for isolated systolic and systolic/diastolic hypertension, from younger to very elderly 
patients[5, 6].  
 
Blood pressure measurement; the procedure 
 
Traditionally, blood pressure is measured by the physician at the brachial artery inflating and 
deflating an air-filled cuff. The first and fifth (last phase of) Korotkoff sounds indicate the 
border of no flow and the point of unimpeded flow through the artery, respectively reflecting 
systolic and diastolic blood pressure [7]. The biological variability of blood pressure is quite 
high, and many factors influence blood pressure itself or the blood pressure 
measurement[8].Therefore the procedure is highly standardized nowadays. Factors that 
influence blood pressure for example are physical activity, talking, a distended urinary 
bladder, environmental noises, the presence of a doctor, coffee consumption and time of 
meals. One of the factors that influence the blood pressure reading itself is the position of the 
patient (body position: upright, sitting or supine, leg position, arm position)[9]. With brachial 
blood pressure measurement, one wants to reflect the blood pressure present in the central 
aorta. Theoretically, because of differences in altitude between the central aorta and brachial 
artery, and because of the effect of gravity on the column of mercury, arm positions could 
influence the blood pressure reading. The exact influence of different arm positions on blood 
pressure readings in the sitting position has not been investigated in a proper way before. 
Furthermore, no studies were done to investigate the influence of different positions of 
crossing the legs, which is commonly done by patients in practice. 
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Blood pressure measurement; progress 
 
Differences in the office versus at home. 
 
With the introduction of home blood pressure measurement, it has been objectified that 
differences can be present between office and home blood pressure. Home blood pressure can 
be significantly lower than in the office and conversely can be significantly higher than in the 
office[10, 11]. The clinical significance of isolated office or “white coat” hypertension 
(WCH), a condition in which blood pressure is elevated in the clinic environment but normal 
in daily life, is still controversial. Some studies have shown the prevalence and degree of 
organ damage in subjects with WCH to be similar to that of normotensives[12, 13], whereas 
others have shown them to be greater than those of normotensives or even similar to that of 
hypertensive individuals[14, 15]. Furthermore longitudinal studies have not found this 
condition to be associated with an adverse cardiovascular prognosis. These studies sometimes 
had the limitation of a small number of cardiovascular events or a relatively short duration of 
the follow-up after WCH identification[16, 17]. Surprisingly, “masked” hypertension (MH), a 
condition in which BP is normal in the clinic environment but elevated in daily life, seems to 
have a similar prevalence in the population (10-20%)[11]. For MH however, in which 
hypertension is hidden from the doctor and therefore not adequately treated, there is 
consistent evidence that the cardiovascular risk is higher than in normotensives, and almost as 
high as in hypertensives[18, 19]. Both for WCH and for MH, it is not yet known how much 
the hospital environment and the presence of the doctor contribute to the blood pressure 
differences between home and the office.   
 
Self blood pressure measurement. 
 
With the introduction of automated measurement devices, self-measured blood pressure at 
home is being increasingly used[7]. It has proven to have a better reproducibility than 
conventional measurement, because of multiple measurements at home during the day[20]. 
Moreover, it provides more accurate estimates of the daily blood pressure, and hereby a better 
prediction of cardiovascular disease[21]. Because of the different place and setting of the 
blood pressure measurement in the office versus at home, and because of different techniques 
used (oscillometric in self blood pressure measurement versus auscultatory in conventional), 
differences in cut-off values for hypertension exist[22]. At present, results of 30 years of 
research regarding cut-off limits for hypertension and normotension of the self-measured 
blood pressure are available. Still, different guidelines report different cut-off values[22-24]. 
There is a need to comprehensively review all present literature, for various population 
groups, to define threshold levels for the diagnosis of normotension and hypertension, in 
order to choose subsequent treatment strategies.   
 
Ambulatory blood pressure monitoring 
 
Clinic (office) blood pressure measurement has been the basis for the established relationship 
between elevated blood pressure and cardiovascular morbidity and mortality[25]. Clinic blood 
pressure, however, may not necessarily represent an individual’s usual BP level and 
physicians frequently misclassify patients’ blood pressure status at the office when compared 
with ambulatory blood pressure monitoring (ABPM)[18]. ABPM helps to make therapeutic 
decisions in patients who exhibit discordance between clinic and ABPM values (WCH, resistant 
hypertension and MH)[26]. 
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ABPM additionally has aided our understanding of BP circadian rhythm (24-hour period and 
night-day patterns) and has become an efficacious instrument helping to make therapeutic 
decisions in hypertensive patients and other subjects at risk of cardiovascular disease[27, 28]. 
Moreover, ABPM is more strongly correlated with target-organ damage than office BP and 
offers more accurate prognostic information of cardiovascular outcomes than office 
readings[14]. This has been clearly demonstrated in population-based surveys and both in 
treated and untreated hypertensive subjects[29]. In addition to the mean 24-hour BP level, 
variation in the day-night difference in BP (the dipping status) has also been claimed as an 
important predictor of both target-organ damage and cardiovascular events[30]. On average 
each 5% attenuation in the decline in nocturnal systolic/diastolic BP conferred approximately 
a 20% rise in the risk of cardiovascular mortality. Subjects with less than 10% BP decrease at 
night, or even an increase in BP during the night were those who exhibit a worse 
cardiovascular prognosis[27, 31, 32]. It has been claimed however that categorization of patients 
into dippers and nondippers is poorly reproducible[33]. Historically not only an attenuated 
nocturnal BP decline, but also a high nocturnal blood pressure itself was considered to be a 
determinant of an unfavourable prognosis[34]. In longitudinal studies and in meta-analyses, 
nocturnal BP seems to correlate better with signs of target organ damage and cardiovascular 
morbidity than daytime BP[34, 35]. Nondipping and high nighttime BP seem to share common 
determinants such as sympathetic overactivity, sleep apnoea, pressure-dependent natriuresis and 
underlying organ damage. Whether or not day and night blood pressures and their derived 
parameters can be targeted separately (chronotherapy), is a matter of ongoing debate[36]. 
 
Blood pressure measurement; process 
 
Arterial stiffness and ambulatory blood pressure measurement 
 
Because of ageing and atherosclerosis, normal healthy compliant arteries become stiff[37]. 
This process affects the properties of the walls of large arteries. This eventually results in 
plaque formation and ischaemic events (heart attack, stroke etc.)[38-41]. Until today 
traditional risk factors (the conventional office blood pressure, smoking, cholesterol etc.) are 
used for risk estimations. New methods are increasingly being implemented in the 
stratification of cardiovascular risk and show a better performance than the classical risk 
factors. Examples of such methods are intima media thickness (highly standardized 
measurement of arterial vessel wall thickness by ultrasonography)[42], coronary calcium 
score (CT indexed evaluation of calcium deposits in the coronary vasculature), and indexes of 
arterial stiffness, like pulse wave velocity (measurement of blood flow velocity over the large 
arteries by special equipment)[43] and the newest of them all: the ambulatory arterial stiffness 
index (AASI)[44].  
 
Cardiologists in The Netherlands generally practice active cardiology, both during and in the 
aftermath of a cardiovascular event. In this regard the adage ‘better to prevent than to cure’ is 
relatively being overlooked in the Netherlands. Preventive cardiology is practiced by the 
general practitioner (GP) and to a lesser (but more refined) extent by the vascular internist. 
Especially for the GP, but also for internists and cardiologists, easy to handle measures are 
needed for diagnostic and therapeutic decision making. All above mentioned new indexes 
have proven to predict cardiovascular disease above and beyond the traditional risk 
factors[39, 41, 45, 46], however only AASI does not require special equipment and highly 
trained technicians, since it can be derived from simple 24-hour ABPM.  
 
In 1914, MacWilliam and Melvin wrote that loss of elasticity in the arterial system influences 
the height of the diastolic BP and its relation to systolic BP[47]. Within an international group 
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of researchers, it was hypothesized that the slope of diastolic BP on systolic BP during 
ambulatory monitoring might be a measure of arterial stiffness[44]. From individual 24-hour 
recordings, the regression slope of diastolic BP on systolic BP was computed. AASI was 
defined as 1 minus the regression slope (figure 1). The slope was not forced through the 
origin, because when blood inflow from the ventricle stops during diastole, BP does not fall to 
zero, as a new ventricular contraction takes place. With the AASI, one can search to 
distinguish between low risk and high risk patients, beyond BP and pulse pressure (see figure 
2). There are already very promising results in terms of prediction of cardiovascular events 
and mortality[40, 41, 46, 48]. Before implementing this new risk-stratifying tool at large 
scale, the new technique should be validated. One way to do this is to comprehensively 
review the literature. Furthermore the determinants of the AASI should be further explored 
and the reproducibility of this new index should be determined. 
 
Figure 1. Derivation of the ambulatory arterial stiffness index from a 24-h ambulatory blood 
pressure recording in one participant, whose 24-h BP was 129 mmHg for systolic blood 
pressure and 95 mmHg for diastolic BP. 
 
 
 
Figure 2. Plots of diastolic blood pressure regressed on systolic blood pressure in 4 different 
subjects. For comparable levels of 24-h blood pressure and pulse pressure, ambulatory arterial 
stiffness index varied from 0.33 to 0.56. From left to right, the calculated mean blood pressure 
was 89, 98, 122 and 117 mmHg.  
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Aim of the thesis 
 
The aim of the first part of this thesis was to study the effect of different arm positions on the 
results of the BP measurement and of different leg positions on the BP. Firstly, in mainly 
treated hypertensives, we studied the differences of BP when the arm was positioned at chair 
support level or at desk level in the sitting position, compared to the BP measured with the 
arm at heart level. Secondly, we studied in hypertensives, diabetics and normotensives if 
crossing the legs at the level of the knee and at the level of the ankle, had an influence on BP. 
Finally we studied the physiological principle of BP changes initiated by crossing of the legs 
at the level of the knee.  
 
In the second part of this thesis, we studied BP differences between the home setting and 
hospital settings, with and without the presence of a doctor. From that we calculated the 
separate contributions of the presence of a doctor and the hospital environment itself. Further, 
we searched for defining thresholds for normotension and hypertension for the self measured 
BP at home. We comprehensively reviewed 30 years of literature to determine thresholds for 
the self measured BP at home, in order to determine levels of cardiovascular risk. We 
reviewed two meta-analyses, several prospective outcome studies in populations and in 
hypertensive patients, studies in pregnant women, three clinical trials, and the thresholds 
proposed in previous and current hypertension guidelines. With this review, we have tried to 
provide an insight into the present literature in order to choose optimal treatment strategies.   
 
In the last part of the thesis we focussed on the newest evolution of 24-h ABPM, namely the 
AASI, a new non-invasive marker of arterial stiffening, and thereby of cardiovascular risk. 
We reviewed the already large number of studies reported after 2006, and provided a 
comparison with the gold standard of non-invasive determination of arterial stiffness, the 
pulse wave velocity. Furthermore, we studied the short-term reproducibility of the new index, 
which is essential for the implementation of the AASI into daily clinical practice. We 
included a few communications and analyses, which is only part of the vast amount of debate 
generated by this new index. Finally we investigated whether the goodness of fit of the AASI 
regression line (see figure 3) could possibly be a marker of the quality of the AASI 
measurement, and whether it enhances the power of AASI in reflecting arterial stiffness and 
cardiovascular disease.    
 
Figure 3. Three patients with the same ambulatory arterial stiffness index (0.50), 
approximately the same number of blood pressure readings (49-56), however a different 
goodness of fit of the regression line (r² of 0.23 up to 0.86) determining the ambulatory 
arterial stiffness index. The less scatter around the fitline, the higher the goodness of fit 
(right). 
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Abstract 
 
Objective Determining the influence of the position of the arm on blood pressure 
measurement in the sitting position. 
 
Methods Blood pressure of 128 individuals (the majority being treated hypertensive patients) 
visiting the outpatient clinic was measured simultaneously on both arms with arms in two 
different positions. First, both arms were placed at the chair support level and blood pressure 
was measured three times on both arms after 10 min of rest. Subsequently, while still 
remaining in the same sitting position, five blood pressure measurements were made 
simultaneously at both arms with one arm placed on the desk and one arm placed and 
supported at heart level (mid-sternal). The arm placed at heart level served as the reference 
arm. The choice of which arm was placed at desk level and which arm was placed at heart 
level was randomized. 
 
Results Both at desk level and at chair support level, mean (± SD) systolic and diastolic blood 
pressures were higher than blood pressure at heart level by 6.1/5.7± 4.6/3.1 and 9.3/9.4 ± 
5.4/3.4 mmHg, respectively. The effect of the height differences between the arm positions on 
the blood pressure readings was smaller than predicted (0.49mmHg/cm systolic and 
0.47mmHg/cm diastolic). No significant correlation was found between blood pressure 
difference in the different arm positions (desk and heart level) and age, sex, weight or baseline 
blood pressure. 
 
Conclusions Different arm positions below heart level have significant effects on blood 
pressure readings. The leading guidelines about arm position during blood pressure 
measurement are not in accordance with the arm position used in the Framingham study, the 
most frequently used study for risk estimations. 
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Introduction 
Blood pressure (BP) measurement is considered an easy routine procedure, but carries many 
potential errors. Generally, few of the many factors that can affect the results of BP 
measurement are taken into account [1–3]. One of the often-neglected factors is the position 
of the arm and the body of the patient during BP measurement [4–6]. These might have 
substantial effects on BP readings.  
 
In some guidelines, BP in sitting and supine positions is regarded as identical, sometimes with 
the addition that the arm must be positioned at heart level (right atrium or tricuspid valve) 
[7,8]. Earlier studies of our group [9,10] showed that body position has influence on BP, so 
this factor must be taken into account. Although previous research concluded that the arm 
position had a great influence on BP readings [11–20], in many studies the arm position is not 
sufficiently mentioned [5,21]. In daily practice, we commonly observe that the arm is placed 
on the desk, on the chair support or is even left hanging. BP is measured to give an estimation 
of the risk for long-term cardiovascular complications. One of the main studies in this field is 
the Framingham study [22]. In that study, the arm position during BP measurement was at 
desk level. According to the latest guidelines of the British Hypertension Society [23] and 
American Heart Association [24], BP must be measured with the upper arm (and center of the 
cuff) at heart level (mid-sternal). Although this is theoretically correct, it is at variance with 
the method of BP measurement in the Framingham study. If BP measured with the arm at 
desk level, as used in the Framingham study, differs from BP measured with the arm at heart 
level, as advised in the recent guidelines, the guidelines should be adjusted or the 
Framingham study should not be used for risk estimation. To our knowledge, the difference 
between BP measurement with the arm at heart level (guidelines) and the BP measurement 
according to the Framingham study has not been investigated earlier. Therefore, in the present 
study, we investigated the difference of BP readings, with the arm position at desk level and 
at chair support level, to compare these to the ‘gold standard’: BP measurement with the 
upper arm at heart level. 
 
Study participants 
Participants were patients visiting the outpatient clinic routinely (most of them were treated 
hypertensive patients) and medical students. The two exclusion criteria were cardiac 
arrhythmias and a left/right BP difference of more than 10mmHg. 
 
Methods 
First the whole investigational procedure was extensively explained to the patients, to prevent 
muscle exercise, talking, movements or emotions from inducing falsely high BP readings. The 
investigator started with a simultaneous BP measurement on both arms with a validated 
oscillometric BP measurement device (Omron CP 705; Omron Healthcare Inc., Bannockburn, 
Illinois, USA) [25] in order to exclude a significant left/right arm difference. We used 
different cuffs of 23 x 13 and 36 x 13 cm for upper arm circumferences of <30 and ≥30 cm, 
respectively. Subsequently, the patients were placed in a comfortable chair with the arms on 
the chair support. In the type of chair we used (Fig. 1), the back and the head were supported. 
We standardized the height of both the chair support and the desk, measuring 67.5 and 77 cm 
above the floor, respectively.  
 
Before starting with BP measurements, a self-built stand was prepared to make sure the arm 
later used as reference value was precisely at heart level. This stand had an arm support that 
could easily be changed in height. The position of the stand and thus the centre of the cuff of 
the BP measurement device had to be at heart level (mid-sternal) as exactly as possible (Fig. 
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1). This was checked by using a water level. The arm support consisted of soft material in 
order to prevent irritation. The precise height differences between arm positions (at desk level 
or chair support) compared with heart level were measured.  
 
Fig. 1 
 
 
 
The set-up of measurements in different arm positions. On the left, the participant has both 
arms at chair support level. On the right, the participant has one arm at desk level and the 
other arm placed at heart level (with a specially developed support). Three lines are drawn on 
the T-shirt of the participant. The upper line reflects the jugular notch and the lower line the 
xiphoid process. Mid-sternal is defined as halfway between these two lines. 
 
After these preparations, the investigator left the room for an acclimatization period of at least 
10 min. Subsequently, the investigator re-entered and BP was measured simultaneously three 
times at both arms (2 x 3) with arms on the chair support. Then, the patients were asked to put 
one arm on the desk and the other on the self-built stand functioning as the control arm (at 
heart level). The choice of which arm was supported by the stand was randomized.  
 
Consequently, 1–2 min after changing the arm positions, simultaneously five BP 
measurements were performed bilaterally, leading to average BP values for the arm at desk 
level and at heart level. All measurements were carried out in a quiet room with constant 
temperature by the same investigator (R.V.), who was instructed and trained before the study, 
in order to prevent factors influencing BP, such as talking, movements, etc.  
 
Statistical analysis  
The average of the three readings with the arm on the chair support was compared with the 
averages of the five readings with the same arm lying on the desk or the five readings at heart 
level (reference value). So, always the readings in the same arm were compared with each 
other. Simultaneous readings in different arms were only used in comparison between BP at 
heart level and BP at desk level. Mean differences of BP between arm positions were 
calculated with their SDs. The 95% confidence intervals were calculated to look for 
significance between all differences of BP (arm at heart level versus arm at desk level and 
arm at chair support level). We looked for the influence on BP of the absolute height 
difference from the heart (with arm both at desk level and at chair support level). The 
correlations between height, weight, age, baseline BP and difference of BP in different arm 
positions were investigated. All correlations were corrected for the other variables. 
Furthermore, the influence of sex on BP differences was analysed, after correction for length. 
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Results 
When the first BP reading showed a left–right difference of more than 10mmHg, the further 
procedure was stopped. Owing to a left–right BP difference of more than 10mmHg (systolic 
or diastolic; mean of the three BP readings at chair support level), however, we had to exclude 
another four patients. Finally, 128 patients participated: 63 female and 65 male. Table 1 
shows the clinical characteristics. 
 
 
 
No significant left–right difference was present in the mean of the three readings with the 
arms on the chair support. When analysed individually, 64% of the systolic blood pressure 
(SBP) readings and 84% of the diastolic blood pressure (DBP) readings had a left–right 
difference of <4.0mmHg. Table 2 shows the average BP values of the sessions with both arms 
on the chair support, on the desk and at heart level (Fig. 1).  
 
 
The BP at desk level was SBP/DBP 6.0/5.8mmHg higher than that at heart level. The 
difference was even larger when the BP with the arm on the chair support was compared with 
the BP with the arm at heart level; 9.3/9.4mmHg. The 95% confidence intervals (Table 2) 
show that the differences of BP between arm position on the chair support and arm position at 
desk level were both significant compared with the BP with the arm at heart level. The BP 
difference between the arm on the chair support and the arm on the desk was also highly 
significant. Eighty-nine percent of the study population had a higher SBP and DBP when the 
arm was at desk level and 95% of the study population had a higher SBP and DBP when the 
arm was at chair support level than the readings taken with the arm at heart level.  
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No significant differences were present between men and women. Statistical analyses showed 
no correlation at all of BP differences with age, weight or baseline BP, after correction for 
each other. A weak correlation (SBP: r=0.17, P=0.04; DBP: r=0.16, P=0.06) was found 
between the height of the participant and the BP difference between arm positions, only for 
the BP difference between desk and heart level.  
 
The mean absolute height difference between the arm at desk level and at heart level was 12.2 
cm. The difference between heart level and chair support level amounted to an average of 
21.7 cm. This means that, when compared with heart level, at desk level there was a mean 
difference (mean absolute height difference/mean BP difference) of 0.49/0.47mmHg/cm and 
at chair support level this was 0.43/0.43mmHg/cm. 
 
Discussion 
The present study shows that BP readings with the arm at chair support level and at desk 
level, as used in the Framingham study, differs significantly and relevantly from BP reading 
with the arm at heart level. The difference increases when the arm is placed at a lower level, 
and logically the difference at chair support level is larger than that at desk level.  
 
In our study, the absolute height difference of the arm between desk and heart level varied 
from 6 to 23 cm, depending on the height of the participant. This resulted in substantial 
differences of BP readings. In theory, the physiology of this effect can be explained by gravity 
on the column of blood causing a 0.74mmHg rise of BP reading for each centimetre below 
heart level. In our study, we found a smaller rise per centimetre. Hypothetically, the minimal 
effort made when placing the arm from chair support level to heart and desk level could have 
increased the BP, thereby reducing the difference of BP reading found. Only a SBP decrease 
of 1.8 mmHg, however, was observed during the course of the five BP readings. We have no 
other plausible explanation for the discrepancy between theory and practice. This suggests 
that possibly other factors besides gravity play a role. If only gravity would play a role, one 
could adjust BP for the height difference from the mid-sternal level. The fact that such an 
adjustment is not possible underlines the importance of guidelines to advise measurement of 
BP with the upper arm at heart level.  
 
In this study, we worked with a standardized height of chair support and desk. In our clinic, 
the desk heights varied from 75 to 77 cm, and the chair supports varied from 66 to 69 cm with 
the height of the sitting compartment varying from 45 to 48 cm. This resembles the situation 
in other clinics. Simple manoeuvres to reduce the deviation from BP at heart level could be 
adjusting the height of the chair when the arm is on the desk, or raising the chair support when 
the arm is on the chair support.  
 
A weakness of our study is that heart level was determined subjectively by the investigator 
(although always with the same criterion, mid-sternal). An advantage of our study is the use 
of an automated validated device that circumvents observer bias. In addition, we had one 
trained investigator, multiple readings, standardized facilities and a large number of 
participants. We also compared both chair support level and desk level with heart level, which 
has not been done previously.  
 
When we consider previous studies regarding the influence of arm positioning on BP 
performed with patients in a sitting position, we see that all studies support our findings (see 
Table 3 [11–20]). Generally, the influence on BP of placing the arm on the chair support or 
placing the arm hanging were compared with that of placing the arm at heart level. ‘Heart 
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level’, however, was not always precisely defined and/or determined. In a number of studies, 
details about essential aspects of BP measurement were not mentioned (Table 3). An 
incomplete reporting of the BP measurement method frequently occurs in the literature. A 
previous publication [3] shows that rather frequently important aspects of BP measurement 
are ignored by doctors and nurses. In general medical journals and even in specialized 
hypertension journals, important details about BP measurement are often not mentioned [1,2]. 
 
 
Some of the guidelines [23,24] advise one to measure BP with the arm supported at heart 
level (mid-sternal). As cardiovascular risk calculations are based on the Framingham study, 
however, it is important to realize that during the BP measurement in the Framingham study, 
the arm was not supported at heart level. In the Framingham study, BP was measured as 
follows: ‘The blood pressures were taken with the patient in sitting position, the left arm 
resting on the examiner’s desk.’ On the same page the authors state that BP is measured once 
by a nurse and twice by a doctor (one at the beginning of the physical examination and a 
second at completion). This is not an ideal situation and is certainly not comparable to the 
present BP measurement guidelines. Do we, however, really want to measure according to the 
reference BP? The main purpose of measuring BP is to give a good risk estimation of 
cardiovascular disease in the future. The guidelines and the studies with the best risk 
estimations must be in agreement with each other. After all, ‘true’ BP is not important, but the 
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prognostic value of the measured BP is. When BP is measured at heart level, it underestimates 
the risk on morbidity and mortality, compared with measuring at desk level (like in the 
Framingham study).  
 
Therefore, arm positioning in the study with most reliable risk estimations should be 
 conclusion, our findings indicate that important differences of BP reading in sitting 
re not 
synchronized with the leading guidelines.  
 
In
position can be present when measuring BP in different arm positions. The guidelines a
in conformity with those of the Framingham study. More attention should be paid to the arm 
position during BP measurement and to the description of the method/protocol used for BP 
measurement in scientific journals. 
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Abstract 
 
Objective To determine whether crossing of the legs at the knee or at the ankles during blood 
pressure measurement in sitting position has an effect on blood pressure. 
 
Methods One hundred and eleven patients, 60 women, mean age 52± 17 years (19–80): 49 
chronically treated hypertensives, 28 treated diabetics and 34 normotensives were measured 
by one trained investigator, with an oscillometric device (Omron 705CP) on the left arm. We 
looked for the difference of blood pressure with the ankle or the knee crossed versus the 
uncrossed position. 
 
Results Leg crossing at the knee during blood pressure measurement increased systolic blood 
pressure significantly by 6.7 (95% confidence interval 5.0–8.4) mmHg in the hypertensives 
and 7.9 (4.0–11.8) mmHg in the treated diabetics. Diastolic blood pressure increased by 2.3 
(0.8–3.8) mmHg in the hypertensives and 1.7 (0.1–3.4) mmHg for the treated diabetics. 
Normotensive participants showed a smaller, though significant, increase of systolic blood 
pressure 2.7 (1.2–4.2) mmHg, but not significant for diastolic blood pressure, – 0.1 ( – 1.5–
1.3) mmHg, respectively. In all groups there was no effect of crossing the ankles on blood 
pressure. No differences were found between men and women. No significant correlation 
between the increase of the blood pressure when the knees were crossed and BMI, age or 
baseline blood pressure was present. 
 
Conclusions Blood pressure increased when legs were crossed at the knee in the sitting 
position. No significant increase of blood pressure was found when crossing the legs at the 
ankles. Leg position during measurement of blood pressure should be standardized and 
mentioned in publications. 
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Introduction 
Blood pressure (BP) measurement is one of the most commonly used techniques in the 
diagnosis and treatment of various medical problems. When hypertension is suspected, with 
its lifelong consequences for treatment, accurate measurement of BP is crucial. Therefore, all 
efforts should be made to eliminate errors in measuring BP.  
 
Many physiological stimuli influence BP measurement, varying from talking during BP 
measurement to food intake before BP measurement [1]. Previously we have demonstrated 
that both body and arm position considerably influence BP [2]. Another potential effect on BP 
measurement in the sitting position is the effect of crossing the legs. Some guidelines on BP 
measurement (JNC VII, AHA, nursing guideline) contain recommendations on the position of 
the feet by advising to keep both feet on the floor [3–5], whereas other important guidelines 
(BHS and ESH) do not mention leg position [6,7].  
 
In daily practice, BP is measured in a chair with the back supported. As it seems a 
comfortable position, we frequently see that patients spontaneously cross their legs at the 
knee, at the ankles, or even with the ankle over the knee.  
 
In limited previous studies assessing the effect of crossing the legs on BP, only crossing the 
legs at the knee and ankle over knee was investigated [8–12]. These studies had some 
methodologic shortcomings and the results were not equivocal. The most unnoticed and most 
frequently used crossing of the legs, at the ankles, was not evaluated. For this reason we 
wanted to assess the effect on BP of crossing the legs at the ankles. Moreover, we wanted to 
reconfirm previous findings in other studies about the influence on BP of crossing the legs at 
the knee, using a meticulous methodology. Further we wanted to study the effects of crossing 
the legs in three different subgroups, respectively normotensives (Nt), treated hypertensives 
(Ht) and diabetics (DM).  
 
Therefore, the aim of this study was to investigate the effects of crossing the legs at both the 
ankles and the knees in Nt, Ht and in patients with diabetes. Patients and methods  
 
Sample 
The study group comprised 111 patients: 49 treated Ht, 28 DM (diabetes mellitus type 1 or 2) 
and 34 Nt. Participants were excluded from this study if they had a history of peripheral 
vascular disease or surgery of lower extremities. Other exclusion criteria were renal failure 
(serum creatinine >150 mmol/l), cardiac rhythm disorders and an upper arm circumference 
above 33 cm (no bladder was available). Informed consent was obtained from all participants 
before their participation in the study. The local ethics committee approved the protocol.  
 
Measurement of blood pressure  
One investigator (N.T.) performed all BP measurements. The investigator was informed and 
trained immediately before the study to prevent factors influencing BP. BP measurements 
were done in the outpatient clinic in a quiet room, which was at a constant temperature. 
Patients were seated in a comfortable chair with stable back and arm support. To eliminate 
observer bias we measured BP using a validated, new purchased and fully automated Omron 
705CP oscillometric device (Omron Healthcare Europe B.V., Hoofddorp, The 
Netherlands)[13]. Arm circumference was measured and a bladder was used fitting arms 22.9 
to 33 cm in circumference. All patients were previously instructed to take their normal BP 
medication on the day of the measurements.  
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Before taking a BP reading, the participant was seated and instructed to place his or her feet 
flat on the floor, to remove constricting clothing and to refrain from talking or moving the 
arms during the procedure[14]. A first reading (simultaneously with two automatic Omron’s 
at both arms, without a rest period) was done, to assess left to right arm BP difference. If this 
difference was >10mmHg, the patient was excluded. After this all patients rested seated for at 
least 8 min[15] with the feet flat on the floor (with the cuff in place). BP was measured at the 
left arm in all patients. After the rest period two measurements were performed in the baseline 
position (legs uncrossed with feet on the floor). Subsequently the legs were crossed at the 
ankle (lateral malleolus over the other lateral malleolus) or at the knee (popliteal fossa of one 
leg over the suprapatellar bursa of the other) (Fig. 1). This was done in a randomized order. 
After 4min in this position (to reach a steady state) BP was measured in triplicate. Then again 
the baseline position was taken and after 3 min of rest BP was measured twice. Subsequently 
the other crossing position was taken and again after 4 min the BP was measured three times. 
Finally, the baseline position was taken and the last two measurements were done after 3 min 
of rest. Statistical analyses The differences between the BP measurement in the crossed 
position and the resting position were calculated by subtracting the mean of the rest position 
(the mean of six readings in the three baseline positions with feet flat on the floor) from the 
mean of the BP measurements in the crossed two positions (average of three readings per 
position). Mean values of the crossed and uncrossed position were compared and 95% 
confidence intervals (CIs) are given. An evaluation was made how many participants had a 
systolic BP (SBP) rise of >5 and >10mmHg, and diastolic BP (DBP) rise of >5 and 
>10mmHg. 
 
Fig. 1 
 
 
 
On the left the crossing position at knee level is shown and on the right 
the crossing position at the ankles. 
 
The correlation between the difference of BP between positions and the age, BMI and 
baseline BP in the groups was calculated using the Pearson correlation coefficient (r). The 
level of significance was set at a P-value <0.05 (two-sided). Age and BMI effect were also 
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examined in stratified groups (age <35, 35–60, >60 years and BMI <30, ≥30). Significance 
was stipulated by means of student t-test and 95% CIs.  
 
Results 
The clinical characteristics of the study population are shown in Table 1.  
 
 
Table 2 demonstrates the baseline BP values during the three periods with the feet flat on the 
floor and the mean of these three readings (three times two readings of left arm). 
 
 
 
No significant time effect was found for baseline SBP or heart rate with the feet on the floor. 
Therefore, the average of all six BP readings was used for the analysis. With the legs crossed 
at knee level, we observed significantly higher SBP in all three groups versus legs uncrossed 
(Table 3).  
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DM patients and Ht showed the highest increase caused by crossing the legs at the knee, 
especially for the SBP (+7.9mmHg in the DM, and +6.7 mmHg in the Ht). The effect for the 
Nt on SBP was smaller (+2.7mmHg), but still significant. The DBP changes in the Ht and 
DM group were smaller than for SBP (Table 3), however still significant. In the Nt group no 
rise in DBP was seen. Figure 2 shows the changes in SBP and DBP for each individual in 
each group. 
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Crossing at the ankle did not induce any significant change in the BP readings of all three 
groups (Table 3). Crossing the legs at the knees resulted in a rise 5–10mmHg of SBP in 29 
participants (26%), 10–20mmHg in 25 participants (23%) and >20mmHg in six participants 
(5%). For DBP the rise was 5–10mmHg in 14 participants (13%), 10–20mmHg in three 
participants (3%) and >20mmHg in one participant (1%). Apart from one case, all rises of 
SBP or DBP >10mmHg were in DM and Ht participants.  
 
Men and women did not differ with regard to the change in BP when crossing the legs. No 
relation was found between baseline BP or age as a continuous variable and the increase of 
BP when crossing legs at knee level. No significant correlation of BMI and BP change with 
crossing the legs at the knees for the three groups was found, after correction for the other 
variables. No significant differences were found when BMI was stratified (<30, >30), or age 
was stratified (<35, 35–60, >60 years). 
 
Discussion 
This study clearly shows that crossing the legs at knee level significantly increased BP in Ht 
and DM participants. In the Nt group only the SBP showed a significant increase. The 
differences found are relevant both from an epidemiological and from a clinical point of view, 
as can be seen from the large amount of misclassifications in the study population. Further, 
this study shows that crossing the legs at the ankles has no significant influence on BP. Five 
groups have examined the effects of crossing the legs at the knees on BP measurement and 
are summarized in Table 4. 
 
 
Four studies showed a BP rise when crossing the legs; however, a broad range of BP rise was 
present. One of these five studies showed no influence of crossing the legs on BP. 
Overviewing the limited literature about this subject, most studies have some drawbacks, like 
more than one observer and one BP reading per leg position. Only one study has investigated 
the effect of different ways of crossing the legs. There was not always a proportional group of 
participants regarding sex, age or treatment status of hypertension. Some studies did not 
randomize for leg position or mention SD or 95% CIs.  
 
In our study, the protocol was performed by one single trained investigator and multiple BP 
readings were done per crossed leg position and position with the feet flat on the floor. The 
sequence of the crossing positions was randomized and all important statistical data were 
mentioned. Other strong points of our study are that we have investigated two crossing 
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positions, of which one (crossing at the ankles) is frequently practiced and unnoticed. We 
examined both treated Ht patients and Nt. In addition, DM participants participated in this 
study.  
 
Our present study, which had a rigorously standardized study protocol, supports the findings 
of most other studies and adds the fact that ankle crossing has no significant effect on BP. A 
limitation of our study is that the investigator was not blinded for leg position. However, an 
automatic device was used, thereby limiting observer bias. 
 
The rise in BP with the legs crossed might be explained by a translocation of blood from 
dependent vascular beds in the legs to the central thoracic compartment causing a higher 
stroke volume and cardiac output and thereby a rise in BP [8,10,12,16]. Another explanation 
could be that isometric exercise of the leg muscles increases peripheral vascular resistance 
and BP [9,17,18]. This possibly explains why no rise in BP is present when crossing the legs 
at the ankles. As for the relation of BMI and the increase of BP, we hypothesize that smaller 
and obese patients with more abdominal fat and with fatter upper legs could have more 
difficulty in maintaining their crossed leg position. This could cause an extra rise of BP 
caused by isometric exercise of the muscles. Unfortunately, we have not measured the exact 
upper leg circumference in our study. No clear explanation can be found for the observation 
that Nt patients have a smaller rise in BP when crossing the legs at the knee. However, it 
remains possible that differences in BMI, baseline BP and age may account the smaller effects 
in the Nt participants.  
 
In conclusion, in the Ht and DM participants, a clinically relevant increase in BP in sitting 
position with crossed knees was observed. In Nt patients there was a smaller change than in 
the Ht and DM only in the SBP, but still clinically significant. No change was found in BP 
with crossing the legs at the ankles. The results of this study argue to standardize the leg 
position during BP measurements. The position of the legs should therefore explicitly be 
defined in the guidelines about hypertension and in all publications about BP measurement. 
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Abstract 
 
Objective To determine which physiological mechanism is responsible for the blood pressure 
increase during leg crossing at knee-level in the sitting position.  
 
Methods Finger blood pressure was measured with the Finometer in 102 participants (47 
men) before and during leg crossing: 24 treated hypertensive patients, 50 diabetic individuals 
(25 with and 25 without antihypertensive medication) and 28 healthy volunteers. Mean age 
was 53 ± 15 years (range 21–82 years). All participants crossed their legs at knee-level, with 
the upper part of the popliteal fossa on the suprapatellar bursa, in the sitting position. 
Differences in mean blood pressure, cardiac output, stroke volume, heart rate and total 
peripheral resistance were assessed with legs crossed versus legs uncrossed.  
 
Results Mean blood pressure [+3.3 ± 5.5 mmHg; 95% confidence interval (CI) = 2.7–3.8], 
stroke volume (+7.6 ± 5.4 ml; 95% CI = 6.7–8.6) and cardiac output (+0.4±0.9 l/min; 95% CI 
= 0.3–0.5) were significantly higher with legs crossed than in the uncrossed position, while 
the heart rate (−1.8 ± 3.9 beats/min; 95% CI = −2.2 to −1.4) was significantly lower. Total 
peripheral resistance did not differ significantly (−0.01±0.16 AU; 95% CI = −0.03 to 0.00). 
The largest differences occurred in the hypertensive diabetic individuals, the smallest in the 
healthy volunteers. The changes were similar in men and women. There were no significant 
correlations in the total group between the differences of the hemodynamic variables and sex, 
age, body mass index or leg circumference. 
 
Conclusion The study shows that higher blood pressure with legs in the crossed position is 
due to higher cardiac output and not to a higher total peripheral resistance. 
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Introduction 
Blood pressure (BP) measurement is one of the most widely used diagnostic tests in medicine. 
 
Numerous factors can affect the outcome of a BP measurement. An erroneously measured 
high BP may lead to a false diagnosis of hypertension. This error can be caused by an arm 
position below heart level, noise, talking and movements during BP measurement and by 
smoking or caffeine use before BP measurement [1–3].  
 
Another potential interfering factor resulting in a falsely high BP is leg crossing at knee level 
in the sitting position during BP measurement. Several, but not all, studies have shown that 
BP is higher when the legs are crossed at knee level in the sitting position during BP 
measurement[4–9]. Some studies in patients with vasovagal syncope or autonomic failure 
[10–12] demonstrated that the higher BP in these patients during leg crossing in a standing 
position with active muscle tensing is due to a higher cardiac output (CO). The aim of the 
present study was to determine which physiological mechanism is responsible for the higher 
BP during leg crossing without active muscle tensing in the sitting position in healthy 
volunteers and in hypertensive and diabetic patients.  
 
Materials and methods 
 
Sample 
We included 108 participants – 28 healthy volunteers, 28 treated hypertensive patients, 52 
diabetic individuals (type I and type II, 26 with and 26 without antihypertensive medication) 
who visited the outpatient clinic at the University Medical Centre St Radboud in Nijmegen 
during a 4-week period in May–June 2006.  
 
Individuals were excluded if they were unable to cross their legs or had a history of peripheral 
vascular disease. Other exclusion criteria were pregnancy and arrhythmias. There were no 
restrictions with regard to medication.  
 
Informed consent was obtained from all participants before the start of this study. The local 
ethics committee approved the protocol. 
 
Measurement of blood pressure 
The age, height, weight, body mass index, sex, circumference of the calf (10cm below the 
patella), and circumference of the thigh (15 cm above the patella) were noted in all 
individuals.  
 
BP measurements were carried out by one trained investigator in the outpatient clinic. Beat-
to-beat systolic BP and diastolic BP were measured continuously and noninvasively by use of 
the Finometer Model 1.10 (TNO Biomedical Instrumentation, Amsterdam, The Netherlands). 
Finometer recordings accurately reflect BP changes [13–17]. The finger cuff was applied to 
the midphalanx of the left middle finger. To avoid hydrostatic level differences, the hand was 
continuously positioned at right atrial level in the midaxillary line.  
 
Patients were seated in a comfortable chair with stable head, back and arm support. The 
individual was instructed to refrain from talking or movement during the procedure. The 
investigator left the room after the patient took the uncrossed leg position with both feet flat 
on the floor. After 7 min the investigator entered the room and the BP measurement by 
Finometer was started. After 3 min in the uncrossed position, the participants had to cross 
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their legs at knee level for 4 min (the upper part of the popliteal fossa on the suprapatellar 
bursa). Subsequently there was another 4-min uncrossed period. After that, the participants 
had to cross their legs at knee level for 4 min again. Finally they took an uncrossed position 
for 4 min.  
 
The sequence of leg crossing (right/left or left/right order) was randomized.  
 
Stroke volume and total peripheral resistance computation. 
From the continuous BP measurement, the arterial pulse wave was analyzed by the pulse 
wave analysis method, which computes changes in left ventricular stoke volume (SV) from 
the pulsatile systolic area. We used the Modelflow program (described in [18]), which comes 
with the software package the manufacturer of the finometer provides with the instrument. 
Modelflow is a model-based algorithm that computes the aortic flow waveform from an 
arterial blood pressure pulsation by simulating a nonlinear, self-adaptive (three-element 
Windkessel) model of the aortic input impedance. Although Modelflow is less suitable to 
measure absolute values of SV, various studies have shown that Modelflow is a reliable 
method to assess changes in SV [19], which is the aim of our study. The CO was computed as 
the SV multiplied by the heart rate (HR). The total peripheral resistance (TPR) was calculated 
as the mean arterial pressure (MAP) divided by the CO and expressed in arbitrary units. The 
MAP was obtained as the integral of pressure over one beat divided by the corresponding 
interbeat interval.  
 
Analysis 
In the pilot phase of our study we observed that during the leg crossing itself and immediately 
thereafter the BP showed temporarily an extra increase for 1–2 min and then decreased to a 
lower steady state, but was still clearly above the BP before crossing. We therefore analyzed 
the last 2 min of each 4-min period of sitting with crossed or uncrossed legs. Changes for 
parameters are presented as the mean_SD. Reproducibility was determined by the standard 
deviation of the difference between the first and the second period of crossing the legs.  
 
For statistical analysis, we used SPSS version 14.0 for Windows (SPSS Inc., Chicago, 
Illinois, USA). The Kolmogorov–Smirnov test was used to determine the distribution of all 
hemodynamic variables.  
 
The differences in hemodynamic variables between both positions were tested by Student’s t-
test (paired). The correlations between the different variables were analyzed by Pearson’s 
linear correlation. To account for multiple testing, Bonferroni correction was used. The 
influence of age, gender, body mass index, leg circumference and the presence of 
hypertension or diabetes mellitus on the effects of the maneuvers on the hemodynamic 
variables was analyzed by univariate regression. Since diabetes mellitus and hypertension had 
a significant effect on the changes in hemodynamic parameters, we also investigated whether 
antihypertensive medication modified this response. To this end we introduced an interaction 
term of type of medication and the presence of diabetes mellitus and/or hypertension in the 
regression equation.  
 
A P value less than 0.05 was considered significant (twosided). 
 
Results 
Finally 102 participants were included in this study; six participants had to be excluded 
because of atrial flutter (n=1) or an inability to cross legs for 2 x 4 min (n=5). Patient 
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characteristics are presented in Table 1. All hypertensive individuals used antihypertensive 
medication, with a mean of 2.9 antihypertensive drugs per patient in the hypertensive group 
and 2.4 antihypertensive drugs per patient in the hypertensive diabetic group. 
 
 
All hemodynamic variables were normally distributed as demonstrated by the Kolmogorov–
Smirnov test. 
 
Leg crossing at knee level caused a significant rise in the MAP (+3.3 mmHg, +3.6%), systolic 
BP (+6.6 mmHg, +5.4%) and diastolic BP (+1.4 mmHg, +2.0%) in the total study group. This 
rise in BP was accompanied by a significant increase in SV and CO by, respectively, +7.4 ml 
(8.5%) and 0.4 l/min (6.7%). The HR decreased significantly (−1.8 beats/min, −2.4%). TPR 
did not change significantly (−0.01 AU, −1%) (Figs 1 and 2).  
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All subgroups showed the same trend in hemodynamic differences. Although the differences 
in MAP, SV, CO and HR were largest in the hypertensive diabetic individuals (+4.0 mmHg, 
+10.6 ml, +0.7 l/min and −1.0 beats/min, respectively) and lowest in the healthy volunteers 
(respectively +2.2 mmHg, +4.7 ml, +0.1 l/min and −2.9 beats/min), the differences in all 
subgroups were significant. All results are presented in Tables 2 and 3.  
 
en and women did not differ with regard to the increase in BP or any other hemodynamic 
t 
p 
 
leg circumference. By regression analysis with the difference in CO, the difference in HR or 
 
M
variables. There was no significant difference in the MAP either if the sequence was left/righ
or right/left. The difference in the MAP between the first and the second leg crossings was 
0.6±1.2 mmHg. The difference in CO between the first and the second leg crossings was 
0.02±0.6 l/min, indicating adequate reproducibility of the test. Both in the total study grou
and in the subgroups we observed a positive correlation between the difference in MAP and 
the difference in CO, varying from r=0.17 (P=0.36) in the normotensive individuals to r=0.67
(P<0.05) in the hypertensive diabetic participants. For the total study group we observed no 
correlation between the differences in CO and their baseline value, body mass index, age or 
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the difference in SV as dependent variables, we found a significant influence of the diagnosis
hypertension (for changes in CO and HR), of diabetes mellitus (for changes in CO and SV) 
and of diabetes and/or hypertension (for changes in all three variables). The use of different 
antihypertensive drugs, however, studied as an interaction term with the presence of 
hypertension, diabetes mellitus or their combination, could not explain the hemodynamic 
changes in a model that included the presence of hypertension, diabetes mellitus or th
combination (results not shown). 
 
Discussion 
 
eir 
he present study shows that, both in healthy individuals and in patients with hypertension 
 mellitus, the higher BP during leg crossing at knee level is due to a higher CO 
is 
 
the conclusions from Krediet et al. [10] and van Dijk et al. 
1] in patients with vasovagal syncope and autonomic dysfunction in the standing position 
] 
, 
hanically. Their study, 
owever, reports leg crossing with muscle tensing in a standing position. In our study, 
he 
 
hanges in hemodynamic variables were calculated based on a great number of 
 risk 
l influence of 
 
T
and diabetes
and not to a higher TPR. The rise in CO is due to an increase in the SV. An explanation of th
increase in SV and reaching a steady state is the translocation of blood to the central thoracic
compartment by continuous mechanical compression of venous capacitance vessels in the leg. 
The significant decrease in the HR is due to a baroreceptor reflex activation as a consequence 
of the increase in blood pressure. A smaller decrease in the HR is seen in the hypertensive and 
hypertensive-diabetic subgroups. 
 
Our results are in agreement with 
[1
with active muscle tensing. In these studies the BP measurement was started directly after 
performing the maneuver and took 2 min. In a previous pilot study [9] we observed that BP 
stabilized 2 min after changing leg position. For this reason, and because Wieling et al. [20
showed a blood pressure response immediately after starting dynamic leg exercise in humans
we only analyzed the BP values of the last 2 min of each position.  
 
Groothuis et al. [21] suggested that leg crossing increases TPR mec
h
participants had to cross their legs in a sitting position without muscle tensing. Comparing t
results of these studies is therefore not possible because of the study design differences.
 
Continuous beat-to-beat BP measurement is a strong point of the present study, because 
c
measurements. We examined a large number of participants with different cardiovascular
factors. The reason why we examined four subgroups is inspired by the potentia
both underlying disease and the medication on the changes in hemodynamic variables. The 
randomization of leg order is important, because when there is no randomization participants 
take their ‘preferential position’. 
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We did not consider or correct for the influence of meals, coffee, smoking and the time of 
medication intake. Possibly there is a relation between the time of meals, coffee, smoking or 
edication intake and the time of BP measurement. 
 type of the antihypertensive drug. 
urther analysis was limited by the fact that the patients were on many different combinations 
 This 
ifference cannot be attributed to different subgroup characteristics or to the use of 
 
se in 
 that is 
 
. The results of this study suggest the importance 
f standardizing the leg position during BP measurements. The position of the legs should 
rest. 
m
 
Changes in CO were related to the presence of hypertension, diabetes mellitus and their 
combination, but were not explained by the use or the
F
of antihypertensive drugs we could not adequately test for interactions of drugs. 
 
Hypertensive and/or diabetic individuals show the most pronounced hemodynamic response 
to changing leg position, whereas healthy volunteers show the smallest response.
d
antihypertensive treatments. The subgroups may have been too small, however, to rule out an
effect of antihypertensive drugs. A physiological explanation for the pronounced respon
hypertensive and/or diabetic individuals could be the decreased venous distensibility
already present in borderline hypertensive patients [22]. If crossing the legs causes 
compression of the capacitance vessels, the ensuing mobilization of blood from the legs can 
be contained to a lesser extent in the relatively stiffer venous vessels, leading to increased 
venous return and, hence, to increased CO.  
 
In conclusion, the present study shows that a higher BP during leg crossing at knee level is
due to the higher CO and not to a higher TPR
o
therefore be explicitly reported in the guidelines about hypertension and in all publications 
about BP measurement. 
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Abstract 
 
Objective The goal of this review study is to summarize 30 years of research on cut-off limits 
for the self-measured blood pressure. 
 
Methods We reviewed two meta-analyses, several prospective outcome studies in populations 
and hypertensive patients, studies in pregnant women, three clinical trials and the thresholds 
proposed in earlier and current hypertension guidelines. 
 
Results In line with existing guidelines, prospective studies support that levels of the self-
measured blood pressure at home of greater than or equal to 135mmHg systolic or greater 
than or equal to 85mmHg diastolic indicate hypertension. Circumstantial data suggest that 
levels of the self-measured blood pressure below 120/80 and 130/85mmHg are optimal and 
normal, respectively. Therapeutic targets of the self-measured blood pressure to be attained on 
antihypertensive drug treatment are currently unknown, but should logically be lower (< 
135/85mmHg) than those used to diagnose hypertension. Currently, there is no proof that 
therapeutic thresholds for the home blood pressure should be lower in high-risk compared 
with normal-risk patients. A large body of evidence, however, demonstrated that each 
millimetre of mercury of blood pressure lowering counts in the prevention of cardiovascular 
complications and that in high-risk patients even small decreases in blood pressure result in 
large absolute benefit. 
 
Conclusion The thresholds to diagnose hypertension from self-measured blood pressure 
readings at home remain unaltered since the 2000 consensus conference, but are currently 
supported by outcome data. Further studies need to establish what values of the self-measured 
blood pressure are optimal and normal in terms of cardiovascular outcome. 
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Introduction 
Already in 1971, investigators from Leuven promoted the use of blood pressure self-
measurement at home in clinical research [1]. The development of cheap and properly 
validated devices for blood pressure selfmeasurement, over the past 20 years, carried this 
technique to clinical application [2–6]. Blood pressure self-measurement offers several of the 
well-recognized advantages of the more complex approach of ambulatory monitoring [7,8]. 
The greater number of readings [5,9] and the absence of the white coat effect [10] contribute 
to a better diagnostic accuracy, compared with conventional sphygmomanometry [11,12]. If 
automated devices are used [5], self-recorded blood pressure values are free of observer bias. 
Moreover, self-measurement of blood pressure increases adherence to antihypertensive 
treatment [13,14] and allows reducing the number of clinic visits required for the diagnosis 
and treatment of hypertension [15–17].  
 
The goal of the current review study is to summarize over 30 years of research on cut-off 
limits for the selfmeasured blood pressure. We reviewed the literature in preparation of the 
second consensus meeting on the selfmeasured blood pressure, which took place in Verbania, 
Italy, on 13–14 June 2007. The European Society of Hypertension recently published its new 
guidelines, based on the second consensus conference [18].  
 
For this study, we reviewed two meta-analyses [19,20], several prospective outcome studies 
in populations [21–31] and hypertensive patients [32–36], studies in pregnant women [37–
41], children and adolescents [42–45], and three clinical trials [46–48] exploring adjustment 
of antihypertensive drug treatment guided by the self-measured blood pressure at home. We 
next reviewed the operational thresholds for the self-measured blood pressure as proposed by 
hypertension guidelines before June 2007 [49–62]. We conclude with the proposals we put 
forward for discussion at the second consensus meeting. 
 
Evidence from two meta-analyses 
In an attempt to define diagnostic thresholds for the selfmeasured blood pressure, we 
performed in collaboration with a large number of researchers two meta-analyses [19,20], 
which were respectively based on aggregate data extracted from published articles [19] and on 
individual patient data, made available to the International Database of Self-Recorded Blood 
Pressures [20]. 
 
Aggregate data extracted from published articles 
In 1998, we reviewed 17 studies [1,63–78] including a total of 5422 participants. The number 
of participants in each of the individual studies ranged from 14 [63] to 1438 [75]. Eight 
reports did not apply any selection criteria based on blood pressure values 
[1,67,68,71,73,75,76,78]. Mean age ranged from 16 [72] to 47 years [78]. The participants 
measured their blood pressure by an automatic or semiautomatic oscillometric device in five 
studies [66–68,75,78], by a semiautomatic auscultatory device in four reports [64,72,76,77], 
or by a manual sphygmomanometer in eight reports [1,63,65,69–71,73,74]. In most studies, 
participants measured their blood pressure over several days (range, 1–63 days), usually in the 
morning and evening. The number of selfrecorded blood pressures averaged for analyses 
ranged from 2 [75] to 252 [1].  
 
With weighing for the number of participants included in the various studies, the self-
recorded blood pressure averaged 115/71mmHg in normotensive participants and 
119/74mmHg in untreated participants not selected on the basis of their blood pressure [19].  
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Within each study, we computed an operational threshold for the self-measured blood 
pressure separating normotension from hypertension from the mean + 2 standard deviations or 
from the 95th percentile of the selfrecorded blood pressure in participants who were 
normotensive according to their office blood pressure (Table 1). For sake of comparability 
with the contemporary literature, we also extracted from published studies thresholds derived 
by the regression approach or the percentile method. The former consists of calculating the 
regression line between the self-recorded blood pressure and the clinic blood pressure in 
individual patients to estimate the self-recorded blood pressure that corresponds with a clinic 
blood pressure of 140mmHg systolic or 90mmHg diastolic [19]. The percentile method 
involves first the calculation of the percentile of the clinic blood pressure that corresponds to 
140mmHg systolic or 90mmHg diastolic and next the determination of the self-recorded 
blood pressure that ranks at the same percentile value [19].  
 
 
 
The reference values for the self-recorded systolic/diastolic blood pressures as derived from 
the mean + 2 standard deviations (137/89 mmHg) and the 95th percentile (135/86 mmHg) of 
the distribution in normotensive participants were concordant within 2mmHg systolic and 
3mmHg diastolic. The cut-off points derived using the regression and percentile methods 
were considerably lower, that is, 129/84 and 125/79mmHg, respectively [19]. 
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Individual patient data as available in the international database  
Thirteen research groups contributed 4668 untreated participants to the International Database 
[20], of whom 2401 were normotensive on office measurement. Participants had their office 
blood pressure measured at one (79%), two (18%) or three (3%) occasions. They were 
characterized by only one office blood pressure reading in a small minority (0.2%) or the 
average of two (39.7%), three (38.9%), four (4.4%) or six (16.7%) office blood pressure 
readings. Participants recorded their blood pressure over a median of 3 days, obtaining from 1 
to 159 readings (median, 14). The self-recorded blood pressure in the total study population 
averaged 129.9mmHg systolic and 79.8mmHg diastolic. Among 3221 participants, whose 
morning and evening blood pressures were separately available, systolic blood pressure was 
on average 1.9mmHg higher (P<0.001) in the morning with no diurnal difference in the 
diastolic blood pressure. Figure 1 illustrates the associations of the conventional and self-
measured blood pressure with age. 
 
he mean self-recorded blood pressure in 2401 normotensive participants averaged 
ded 
T
115.4mmHg systolic and 70.7mmHg diastolic. The 95th percentiles of their selfrecor
blood pressures were 136mmHg systolic and 85mmHg diastolic in the morning, 139 and 
86mmHg in the evening and 137 and 85mmHg over the whole day. 
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The database included 2267 hypertensive participants, of whom 494 participants had only a 
borderline elevation of their systolic or diastolic blood pressure (140–159/ 90–94mmHg), and 
1773 participants were definitely hypertensive (≥160 systolic or ≥95mmHg diastolic). By 
definition, there was a difference of at least 20mmHg systolic or 5mmHg diastolic between 
the office blood pressure of normotensive participants and patients with definite hypertension. 
Nevertheless, there was considerable overlap in the distributions of the self-measured blood 
pressure of normotensive and hypertensive participants (Fig. 2). 
 
f 1773 patients with definite systolic hypertension on office measurement (see above), 16% 
Hg 
ld 
 
O
had a self-measured systolic blood pressure below 137mmHg (the 95th percentile of the self-
measured systolic pressure in normotensive participants). Similarly, 25% of those with 
definite diastolic hypertension had a self-measured diastolic blood pressure below 85mm
(the 95th percentile of the self-measured diastolic pressure in normotensive participants). The 
probability that participants with definite hypertension had a self-measured blood pressure 
below these thresholds (isolated office hypertension or white-coat hypertension [79]) was 
34% (diastolic) to 62% (systolic) greater in women than in men. It was two-fold to three-fo
greater if fewer than three office blood pressure readings had been averaged to diagnose 
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hypertension, and it increased by 50 (diastolic) to 126% (systolic) if the self-measured blo
pressure had been measured on more than 3 days as opposed to fewer days (Table 2). In 
contrast, for each 10-mmHg increment in the systolic office blood pressure, the probabili
isolated office systolic hypertension decreased by 35%; for each 5-mmHg increment in the 
diastolic office blood pressure, the probability of isolated office diastolic hypertension 
diminished by 36%. Finally, the probability of isolated office systolic hypertension fell 
31% for each 10-year increment in age (Table 2). 
 
od 
ty of 
by 
 
 
vidence from prospective studies 
 in populations [21–31] or patient cohorts [32–36] 
2,34–
E
Several longitudinal studies (Table 3)
attempted to find a justification for diagnostic cut-off limits of the self-measured blood 
pressure in terms of mortality [21–23,29,30,33] or fatal and nonfatal end points [24–28,3
36]. 
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The Ohasama study 
The Japanese investigators of the Ohasama study were the first to demonstrate that the self-
measured blood pressure at home is a more precise predictor of outcome than the office blood 
pressure [21,22,25] and in consecutive publications [21–28] proposed and refined diagnostic 
thresholds for its use in clinical practice.  
 
The Ohasama researchers initially proposed 137mmHg systolic and 84mmHg diastolic as 
acceptable upper limits for home blood pressure readings on the grounds that the risk of death 
increased above these thresholds [21]. These levels were comparable with the thresholds 
previously suggested by an international research consortium (137/85mmHg [20]). Rounding 
these thresholds [20,21] to 135mmHg systolic and 85mmHg produced diagnostic limits 
similar to those in the meta-analysis of aggregate data [19] and in several guidelines 
[49,50,57,62].  
 
The Japanese investigators subsequently published a subgroup analysis of Ohasama residents 
with and without cardiovascular risk factors, including diabetes mellitus, 
hypercholesterolaemia, habitual smoking and a history of cardiovascular disease [26]. In high-
risk patients, prehypertension arbitrarily defined as a self-measured blood pressure ranging 
from greater than or equal to 115mmHg to less than 135mmHg systolic or from greater than 
or equal to 75 to less than 85mmHg diastolic, compared with normotension, carried a two-
fold higher risk of stroke. These observations suggested that the thresholds of the home blood 
pressure applicable to high-risk patients might be lower than 135/85mmHg [26]. 
 
The Ohasama investigators [27] also reported the incidence of stroke according to the level of 
the office and home blood pressures after stratification for cardiovascular risk based on the 
criteria jointly proposed by the European Society of Hypertension and the European Society 
of Cardiology [53]. The key points emerging from these analyses (Fig. 3) were that even in 
patients with low added risk both the office and self-measured blood pressures predicted 
stroke, and that across the strata of cardiovascular risk the probability of a first stroke rose 
steeper with the home than with the office blood pressure [27]. 
 
A recent Ohasama study noticed that the self-measured blood pressure predicted the risk of 
stroke, irrespective of whether it was measured in the morning or evening [28]. A level of 
135/85mmHg or higher was associated with a two-fold increase in the risk of stroke compared 
with the subgroup with levels of the home blood pressure below 135mmHg systolic and 
85mmHg diastolic in the morning and evening. The multivariate-adjusted hazard ratios 
amounted to 2.66 (95% confidence interval, 1.64–4.33) for hypertension in the morning, and 
to 2.38 (1.65–3.45) for hypertension sustained from the morning to the evening [28]. 
 
The Kahoku study 
A preliminary cross-sectional analysis of the Kahoku study considered a self-measured blood 
pressure of 135mmHg systolic and 85mmHg diastolic as the upper limit of normality, because 
these levels corresponded with the mean+1 standard deviation (79th percentile) in 708 
untreated participants aged from 25 to 64 years [80]. 
 
The first publication with outcome data from the Kahoku study [33] included 1186 residents, 
aged 65 years or older, who in 1992 measured their blood pressure at home for 5 consecutive 
days and whose mortality (134 deaths) was recorded over 4 years. Okumiya and colleagues 
[33] applied arbitrary cut-off limits to delineate four categories according to the self-measured 
systolic (≤124, 125–134, 135–144, ≥145mmHg) and diastolic (≤74, 75–79, 80–84, 
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≥85mmHg) blood pressures. In multivariate-adjusted analyses across these groups, total 
mortality showed a significant U-shaped association with the home systolic blood pressure in 
men. The lowest risk occurred at levels ranging from 125 to 134mmHg. The multivariate-
adjusted associations of mortality with the categories of systolic blood pressure in women and 
those with the diastolic subgroups in both sexes were not statistically significant. 
 
he 2005 Kahoku study included only 461 participants, who were at least 75 years old at 
d 
, 
thout large 
 
T
enrollment (mean age, 80 years) and who were followed up for 9 years [34]. Nishinaga an
colleagues [34] arbitrarily subdivided the study population in four subgroups of unequal size
depending on the level of the self-measured systolic blood pressure in the morning (<135 vs. 
≥135 mmHg) and the difference between the morning and evening systolic blood pressures 
(<15 vs. ≥15mmHg). Participants having both lower systolic blood pressure in the morning 
and less diurnal variability in systolic pressure were used as reference group. With 
adjustments for confounders applied, high blood pressure in the morning with or wi
differences between the morning and evening blood pressures predicted shorter survival and 
loss of independence. 
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The Pressioni Arteriose Monitorate e Loro Associazioni study 
ded 2051 residents of 
d 
 cross-sectional analysis of 1438 participants [75], while recruitment was still ongoing, 
 of 
ng 
80–
 
fter an average follow-up of 131 months, 186 deaths occurred, of which 56 were 
tionship 
 a subsequent analysis [30], the Pressioni Arteriose Monitorate e Loro Associazioni 
 
n on 
 of 
 
he Didima study  
es [31] followed cardiovascular morbidity and cause-specific mortality 
nd 
e 
 of six 
 categorical analyses, the Didima investigators defined office and home hypertension as 
f 
ed 
The Pressioni Arteriose Monitorate e Loro Associazioni study inclu
Monza (Italy), randomly recruited after stratification for sex and age (25–74 years). The 
participation rate was 64%. Participants obtained two readings of their self-measured bloo
pressure at home, one in the morning and one in the evening [29,30,75,81]. 
 
A
suggested that the systolic blood pressure levels at home corresponding with a clinic level
140mmHg would across the age span (25–64 years) range from 127 to 132mmHg (upper 
boundary of the 95% confidence interval, 128–134 mmHg) in men, and from 121 to 
126mmHg (125–129mmHg) in women. For diastolic blood pressure, the correspondi
thresholds varied from 75 to 81mmHg (77–83 mmHg) in men and from 77 to 81mmHg (
83 mmHg) in women. A later cross-sectional analysis of 248 normotensive and untreated 
hypertensive participants, aged 65–74 years, suggested as thresholds for the self-measured
blood pressure at home levels of 133mmHg (95% confidence interval, 131–135mmHg) 
systolic and 82mmHg (80–83 mmHg) diastolic [81].  
 
A
cardiovascular (30.1%). Office and home blood pressures showed a significant rela
with cardiovascular and all-cause mortality, but the association was not tighter for the home 
than for the office blood pressure [29].  
 
In
investigators subdivided their cohort in four groups based on the office and home blood
pressures, using as thresholds 140/90 and 135/83 mmHg, respectively. With normotensio
both types of measurement as reference, the risk of cardiovascular and total mortality 
gradually increased if the office blood pressure, the home blood pressure, or both types
blood pressure were elevated. This trend was consistent in unadjusted and sex-adjusted and
age-adjusted analyses.  
 
T
Stergiou and colleagu
over 8.2 years in 662 residents of Didima (Greece). Mean age at enrolment was 54.1 years 
and the proportion of women was 58.2%. During follow-up 78 deaths (42 cardiovascular) a
67 fatal and nonfatal events occurred. The unadjusted hazard ratios for cardiovascular events 
per 10mmHg increase in the systolic blood pressure were 1.41 (P<0.001) and 1.40 (P<0.001) 
for office and home measurements, respectively. The corresponding estimates for a 5mmHg 
increase in diastolic blood pressure were 1.20 (P<0.01) and 1.11 (P=0.07). The addition of th
home blood pressure (average of duplicate readings in the morning and evening on 3 
consecutive days) to Cox models already including the office blood pressure (average
readings; three readings at each of two clinic visits) did not significantly improve the 
prediction of cardiovascular complications.  
 
In
systolic/diastolic blood pressure levels of 140/90 and 135/85mmHg or higher, respectively 
[31]. Patients with hypertension on both types of measurements (events/patients at risk, 26 o
the 124 patients; 21.0%) and those with the white-coat phenomenon (nine of the 34 patients; 
26.5%) had significantly higher cardiovascular risk than those who had a normal blood 
pressure in the office as well as at home (24 of the 452 patients; 5.3%). In contrast, mask
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hypertension was not associated with a significantly higher risk (eight of the patients 55; 
14.5%). 
 
Patient cohorts 
The Self-measurement of blood pressure at Home in the Elderly: Assessment and Follow-up 
study [35] enrolled 4939 treated hypertensive patients aged 60 years or older. For the office 
and self-measured blood pressures, the targets to be reached on antihypertensive drug 
treatment were levels below 140/90 and 135/85mmHg, respectively. The incidence of 
cardiovascular events in patients with elevated blood pressure in the office, but not at home, 
was the same as that in patients with controlled hypertension on both measurements: 11.1 
versus 12.1 cases per 1000 patient-years, respectively. Conversely, the incidence of 
cardiovascular events in patients with elevated blood pressure at home, but not in the office, 
was high and similar to that of patients with uncontrolled hypertension on both measurements 
(30.6 vs. 25.6 cases per 1000 patient-years). In multivariate-adjusted models, using patients 
with normal office and normal selfmeasured blood pressures as the referent group, the hazard 
ratio of cardiovascular events doubled in patients with uncontrolled hypertension on both 
measurements (1.96; 95% confidence interval, 1.27–3.02) and in patients with an elevated 
blood pressure at home, but not in the office (2.06; 95% confidence interval 1.22–3.47). In 
contrast, patients with an elevated blood pressure in the office, but not at home, did not have 
an increased risk (1.18; 95% confidence interval, 0.67–2.10).  
 
Agarwal and Andersen [36] followed 217 patients with chronic kidney disease for a median 
of 3.5 years, of whom 39 patients died. Of the 178 remaining patients, 38 patients developed 
end-stage renal disease. Poor control of the self-measured blood pressure at home, defined as 
a systolic level of 130mmHg or higher, was a powerful predictor of end-stage renal disease. 
None of the patients with a self-measured blood pressure below 130mmHg systolic, even in 
the presence of an elevated office blood pressure, progressed to end-stage renal disease. 
 
Rave and coworkers [32] studied the progression of nephropathy in 71 patients with type-1 
diabetes, who were followed up for 6.2 years on average. Over this period, the office and the 
self-measured blood pressures dropped from 166/95 to 154/89mmHg and from 159/93 to 
138/83mmHg, respectively. In multivariate-adjusted analyses, the self-measured blood 
pressure at baseline was a strong and independent predictor of the subsequent loss in renal 
function. As the renal function continued to decline, Rave’s findings [32] suggest that the 
level of the self-measured blood pressure to target on antihypertensive drug treatment in 
diabetic patients might be less than 138/83 mmHg. 
 
Self-monitoring in pregnancy 
Accurate measurement of blood pressure by automated techniques is feasible in pregnant 
women [40,82]. Ambulatory blood pressure monitoring [83] and selfmeasurement of blood 
pressure at home [37], compared with office measurement, are more predictive of severe 
hypertension or proteinuria. However, there is only indirect evidence to support operational 
thresholds for the self-measured blood pressure in antenatal care. 
 
Ross-McGill and colleagues [38] randomized 80 women at 24–28 weeks of their pregnancy to 
a standard nine-visit schedule (30, 32, 34, 36–41 weeks) or to a reduced schedule (34, 38, 41 
weeks). Women with multiple pregnancies, established hypertension or a history of 
preeclampsia before 34 weeks, or pregnancy loss were not eligible. Women in the home-
monitoring group (reduced schedule group) measured their blood pressure weekly, using a 
portable sphygmomanometer. They were instructed to repeat self-measurement after 4 h, if 
 69
the blood pressure level at the first reading was between 140 and 160mmHg systolic or 
between 90 and 100mmHg diastolic and to contact their midwife if the second reading was 
higher than 140mmHg systolic or 90mmHg diastolic. If any reading was higher than 
160mmHg systolic or 100mmHg diastolic, women had to contact their midwife immediately. 
Although there were more unscheduled visits in the home monitoring group, this did not 
outweigh the reduction in scheduled visits (7.4 vs. 4.5; P<0.001) and blood pressure was 
measured during more weeks (9 vs. 7; P<0.001) in the experimental group. Most women 
expressed a preference for the reduced schedule both when the idea was first suggested, and 
after they had experienced it, and there were no significant between-group differences in 
anxiety. 
 
In a subsequent study in 72 pregnant women at high risk of preeclampsia, Waugh and 
coworkers observed that of 979 self-measurements taken only 28 (2.9%) were inaccurate [39]. 
On further questioning, two women admitted that the device had been used by other family 
members, thus making comparison with the other measurements stored in memory 
impossible. Thus, the true nonconcordance rate amongst participants was 1/72 (1.4%). The 
same investigators, based on Stergiou’s observation that on average the home blood pressure 
in nonpregnant hypertensive patients is 12/7mmHg lower than the office blood pressure [5], 
recommended to use a threshold of 135mmHg systolic and 85mmHg diastolic to monitor the 
home blood pressure in pregnant women [37]. 
 
In a study by Denolle and colleagues [40], 45 healthy pregnant women measured their blood 
pressure for 1 week before 15 weeks of gestation, between weeks 15 and 27, and after 28 
weeks for the last 3 months of gestation. The self-measured blood pressure was significantly 
lower during the second trimester and higher during the last trimester (102/59, 101/57, 105/62 
mmHg, respectively) than during other trimesters. On the basis of the mean + 2 standard 
deviations, Denolle and colleagues [40], suggested as upper limits of normality 118/73, 
117/73 and 121/80mmHg for the three trimesters of pregnancy. 
 
Self-monitoring in children and adolescents 
Self-measurement of blood pressure by children and adolescents by means of semiautomatic 
[84] or automatic [85] devices, specifically validated in this age group, is feasible [43,44]. 
Whereas in adults the self-measured blood pressure and daytime blood pressure often have 
approximately similar levels, in children and adolescents, the selfmeasured blood pressure at 
home is apparently lower than the daytime ambulatory blood pressure [42]. In 23 
normotensive children enrolled in Stergiou’s study (mean age, 12.3 years), blood pressure 
levels averaged 112.8/63.1, 106.7/67.2 and 123.9/72.0mmHg on conventional, home and 
daytime ambulatory measurement, respectively [42]. The 2004 guideline of the National 
Heart, Lung, and Blood Institute [86] defines a normal blood pressure in children and 
adolescents as systolic and diastolic levels below the 90th percentile, according to sex, age 
and height, and hypertension as systolic or diastolic levels above the 95th percentile. The 
German Working Group on Pediatric Hypertension developed similarly stratified reference 
tables from ambulatory blood pressure recordings in 949 healthy children and adolescents 
from 5 to 20 years old [87]. Stergiou and coworkers [45] recently published comparable 
reference tables for the self-measured blood pressure in 778 healthy youngsters (age range, 6–
18 years) enrolled in the Arsakeion School study. Self-monitoring of blood pressure in 
children and adolescents, although potentially useful in the follow-up of young patients 
[43,44], should not be used for the diagnosis of hypertension. The amount by which, even in 
normotensive youngsters, the self-measured blood pressure is lower than the office and 
daytime blood pressures needs further clarification[42]. Only few studies documented the 
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cross-sectional association in youngsters between early signs of targetorgan damage and the 
home blood pressure. Finally, no study evaluated to what extent the self-measured blood 
pressure in children and adolescents predicts transition to hypertension or the risk of 
cardiovascular complications in young adults or later in life. 
 
Evidence from clinical trials 
Two clinical trials compared antihypertensive drug treatment guided by the self-measured 
blood pressure as opposed to office blood pressure: the Treatment of hypertension based on 
Home or Office blood Pressure (THOP) trial [46] and the Home versus Office blood pressure 
measurements: Reduction of unnecessary treatment Study (HOMERUS [88]). The 
Hypertension Objective treatment based on Measurement by Electrical Devices of Blood 
Pressure (HOMED-BP) study [48] is still ongoing [89]. 
 
Treatment of hypertension based on Home or Office blood Pressure 
In the THOP trial [46], antihypertensive drug treatment was adjusted in a stepwise manner 
based on either the self-measured diastolic blood pressure at home (average of six 
measurements per day during 1 week; 203 patients) or the average of three sitting diastolic 
readings at the doctor’s office (197 patients). If the diastolic blood pressure guiding treatment 
was above (>89 mmHg), at (80–89 mmHg) or below (<80mmHg) target, one physician-
blinded to the patients’ randomization intensified antihypertensive treatment, left it unchanged 
or reduced it, respectively. 
 
The target blood pressure was the same in the two treatment groups. At the end of the study 
(median follow-up, 350 days; 5th–95th percentile interval, 153–586 days), more patients 
randomized to self-measurement had stopped antihypertensive drug treatment (25.6 vs. 
11.3%; P<0.001) with no significant difference in the proportions of patients progressing to 
multiple-drug treatment (38.7 vs. 45.1%; P=0.14). The final office, home and 24-h 
ambulatory blood pressures were higher (P<0.001) in patients randomized to self-
measurement than in those treated according to the office blood pressure. The baseline-
adjusted systolic/diastolic differences between these two groups averaged 6.8/3.5, 4.9/2.9 and 
4.9/2.9 mmHg, respectively. Left ventricular mass and reported symptoms were similar in the 
two groups [46]. 
 
The THOP trial [46] confirmed that the cut-off limit for the diastolic blood pressure should be 
lower on home than office measurement and suggested that one should account for both 
systolic and diastolic blood pressures to adjust antihypertensive drug treatment. 
 
Home versus Office blood pressure measurements: Reduction of unnecessary treatment 
Study.  
In the randomized HOMERUS trial [47,88], the office blood pressure and the self-measured 
blood pressure guided antihypertensive drug treatment in the control and experimental group, 
respectively. In contrast to the THOP trial [46], HOMERUS patients randomized to office 
blood pressure measurement, did not record their blood pressure at home [88]. The patients 
underwent ambulatory blood pressure monitoring at entry and at closeout. After a 
standardized treatment schedule, investigators had to reach the target blood pressure levels of 
120–139 mmHg systolic and 80–89mmHg diastolic. This goal was similar in both treatment 
groups [47]. A blinded physician at the coordinating centre took the treatment decisions. The 
stated hypothesis [88] was that at the end of the 1-year follow-up period, patients in both 
groups would have the same blood pressure, at the expense of more medication in the office 
blood pressure group. 
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The patients randomized to self-measurement (n=216) used less medication than those 
(n=214) allocated to office blood pressure measurement (1.47 vs. 2.48 drug steps; P<0.001) 
with lower costs ($3222 vs. $4420 per 100 patients per month; P<0.001), but without 
significant differences in systolic and diastolic blood pressures on office measurement 
(1.6/1.0mmHg; P=0.25/0.20), in changes in left ventricular mass index ( – 6.5 vs. – 5.6 g/m2; 
P=0.72), or in median urinary microalbumin concentration ( – 1.7 vs. –1.5mg/24h; P=0.87). 
Nevertheless, the 24-h ambulatory blood pressure was higher (125.9/77.2 vs. 
123.8/76.1mmHg; P<0.05/0.05) in the self-measurement than the office group [47]. 
 
Hypertension Objective treatment based on Measurement by Electrical Devices of Blood 
Pressure 
The primary objective of the HOMED-BP study is to determine the optimal level of the self-
measured blood pressure, to which hypertensive patients should be treated to achieve the best 
protection against cardiovascular complications [48]. A secondary objective is to investigate 
which of the newer antihypertensive drug classes (calcium-channel blockers, angiotensin-
converting enzyme inhibitors or angiotensin type-1 receptor blockers) is best suited to initiate 
blood pressure lowering treatment in Japanese [48]. The study has a 2 x 3 factorial 
randomized open design with blinded end point validation. The study will include 9000 
untreated patients with essential hypertension, aged 40–78 years, whose self-measured blood 
pressure at home is 135/85mmHg or higher. Eligible patients are randomized to one of the 
two home blood pressure target groups (125–134/80–84 vs. r125/80 mmHg), and to initial 
treatment with one of the three drug classes [48]. 
 
By the end of March 2003, a total of 1086 patients (12.1% of those planned) had been 
randomized [89]. Among 653 patients who had been followed for more than 6 months, the 
self-measured blood pressures at randomization averaged 149/89, 150/89 and 149/88mmHg in 
the calcium-channel blocker, angiotensin-converting enzyme and angiotensin II receptor 
blocker groups, respectively. After 6 months, these levels had decreased to 134/81, 135/80 
and 133/80 mmHg, respectively, with no significant between-group differences. In the 
intensive and usual treatment groups, the self-measured blood pressures at randomization and 
at 6 months were 149/88 and 150/89mmHg and 134/80 and 135/80 mmHg, respectively 
without significant between-group differences. In the less-intensive treatment group, 45% of 
the 304 patients achieved a systolic blood pressure below 135mmHg, whereas 60% achieved 
a diastolic blood pressure of less than 85 mmHg. In the intensive treatment group, 22% of the 
349 patients achieved a systolic blood pressure below 125 mmHg, and 42% reached a 
diastolic blood pressure of less than 80 mmHg. These results [89] prove that, even under the 
standardized conditions of a clinical trial, it is very difficult to control blood pressure and that 
doctors should at least strive to lower the self-measured blood pressure at home to levels 
below the commonly accepted [49,50,57,62] therapeutic target of 135/85mmHg. In the Japan 
Home versus Office blood pressure Measurement Evaluation study, only 34% of 3400 
hypertensive patients achieved these levels [90]. 
 
Current guidelines 
We reviewed the diagnostic thresholds for the selfmeasured blood pressure (Table 4) in the 
guidelines for the management of hypertension, published in 2000 at the occasion of the first 
consensus meeting on the selfmeasured blood pressure [49] or later [50–52,54,56–62]. Self-
monitoring refers to the blood pressure measured at home in all guidelines [49–52,54,56–62], 
whereas the American recommendations [56,61] leave the possibility open for self-monitoring 
at the work place. The results of our review of guidelines are summarized in Table 4.  
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Proposal for diagnostic and therapeutic thresholds 
The association between blood pressure and cardiovascular risk is continuous, without a 
threshold above which the risk suddenly increases. Clinical decisions, however, must be based 
on operational thresholds. Worldwide consensus is that the cut-off limits applicable for 
conventional sphygmomanometry cannot be extrapolated without further validation to the 
self-measured blood pressure at home, because studies in unselected populations [21–30] and 
hypertensive patients [32–36] demonstrated that the self-measured blood pressure, compared 
with the office blood pressure, is lower. 
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Diagnostic thresholds 
Definition of normality for the self-measured blood pressure at home is following the same 
path as that for defining normality of the ambulatory blood pressure [91,92]. The first 
reference values for the self-measured blood pressure started from its distributional 
characteristics in participants with a normal office blood pressure [19,20]. Subsequent cross-
sectional studies demonstrated stronger association of target-organ damage with the self-
measured than with the office blood pressure. It, however, took over 20 years to collect the 
necessary prospective data (Table 3) to define normality in terms of cardiovascular risk [21–
23,29,30,32–36]. 
 
Table 5 shows an updated proposal for diagnostic thresholds for the self-measured blood 
pressure at home. Two meta-analyses [19,20], prospective studies in populations [21–30], 
hypertensive patients [32–36] and pregnant women [37,38], as well as the consensus in 
current guidelines (Table 4, [49–54,56–62]) support the idea that hypertension on self-
monitoring at home starts at blood pressure levels of 135mmHg systolic or 85mmHg 
diastolic. 
 
 
 
The evidence for optimal and normal blood pressure levels on self-measurement is much 
weaker. In the Kahoku study [33], men with systolic levels from 125 to 134mmHg were at the 
lowest risk of death. International databases of individual-patient data demonstrated that the 
difference between automated [20,91] and conventional blood pressure readings increases 
with the level of the office blood pressure. In participants with normotension on office blood 
pressure measurement, the mean differences between the office and self-measured blood 
pressures (116.9/72.8 vs. 115.4/70.7mmHg [20]) and between the office and the daytime 
ambulatory blood pressures (119/73 vs. 122/75mmHg [91]) were only 1.5/ 2.1 [20] and 
3.0/2.0mmHg [91], respectively. Recent analyses found that levels of 120/80 and 
130/85mmHg carried similar 10-year cardiovascular risks on both office and daytime 
ambulatory measurement [93]. Until more prospective data become available, it seems 
reasonable to propose values below 120/80mmHg and below 130/85mmHg as optimal and 
normal, respectively, also for the self-measured blood pressure at home. 
 
Current diagnostic thresholds for the conventionally measured office blood pressure and 
ambulatory blood pressure are applicable irrespective of sex and age. In line with the 
recommendation of the 2000 consensus meeting [49], the thresholds in Table 5 might be used 
for adult as well as older patients and for women and men alike. 
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Therapeutic thresholds 
The target levels of the self-measured blood pressure to be attained on antihypertensive drug 
treatment are currently unknown. The HOMED-BP study is still ongoing [89]. Therapeutic 
targets for the home blood pressure (<135/85 mmHg), however, should logically be lower 
than those used to diagnose hypertension (≥135/85 mmHg). As for the office blood pressure 
[53], lower treatment targets might be advisable in high-risk patients, such as those with 
diabetes mellitus, a history of stroke, coronary heart disease or renal dysfunction. Direct 
evidence, however, supporting these lower targets is not yet available. The Japanese 
experience [89] shows how difficult it is even under the best possible conditions to lower the 
self-measured blood pressure to less than 135mmHg systolic and 85mmHg diastolic. 
 
Two considerations might be helpful in titrating antihypertensive drug treatment according to 
the self-measured blood pressure. First, in keeping with large-scale prospective observational 
studies [94,95], metaregression analyses published by us [96–98] and other research consortia 
[99–101] demonstrated that small gradients in the achieved systolic office blood pressure 
explained most of the differences in the cardiovascular outcomes, as observed in randomized 
clinical trials. This association was particularly strong for the prevention of stroke [99], the 
complication most directly associated with blood pressure [102] and weakest for heart failure 
[99]. Any reduction in the systolic conventional blood pressure by 3 mmHg will reduce the 
incidence of stroke, myocardial infarction and cardiovascular events by approximately 20, 15 
and 15%, respectively[103]. Any reduction in the conventional blood pressure will also be 
accompanied by a decrease in the self-measured blood pressure at home. As already shown 
for the daytime ambulatory blood pressure in the Systolic Hypertension in Europe trial 
(systolic daytime vs. office, 9.3 vs. 16.6 mmHg; diastolic, 4.9 vs. 7.3mmHg; systolic/diastolic 
daytime-to-office ratio, 0.59/0.67) [104], estimates of the treatment induced blood pressure 
lowering effects are smaller on automated than office measurement. In the Ambulatory blood 
Pressure monitoring and Treatment of Hypertension trial [105], this ratio was 0.64 systolic 
(14.3 vs. 22.4mmHg) and 0.70 diastolic (9.5 vs. 13.7mmHg). In the THOP trial [46], the 
home-to-office ratios in the blood pressure lowering effect were 0.73 systolic (13.5 vs. 
18.6mmHg) and 0.71 diastolic (8.7 vs. 12.2mmHg). These findings suggest that relative risk 
reductions might be approximately equivalent for any decrease in the systolic blood pressure 
by 2mmHg at home or by 3mmHg at the office. 
 
Second, in the light of the low control rates in the HOMED-BP trial [89], absolute benefit 
might override the importance of lower therapeutic goals in high-risk compared with normal-
risk patients. As suggested above, one might assume that lowering the home systolic blood 
pressure by 2mmHg would result in a 20% reduction in the incidence of stroke, independent 
of the risk at baseline. At a rate of 35.9 strokes per 1000 person-years (Fig. 3, [27]) lowering 
systolic blood pressure at home by a mere 2mmHg in 1000 patients for 1 year would 
approximately prevent seven strokes. At a rate of 6.9 strokes per 1000 person-years (Fig. 3, 
[27]), the corresponding estimate would be only one stroke. 
 
Rather than underscoring the importance of lower therapeutic thresholds in high-risk patients, 
it might be more encouraging to highlight that each millimetre of mercury counts in the 
prevention of cardiovascular complications by blood pressure lowering treatment and that 
absolute benefit and therefore the number to treat is proportional to the absolute risk. 
Nevertheless, even if every millimetres of mercury counts in prevention, opinion leaders 
should convince physicians to adopt a more aggressive approach in the control of blood 
pressure, irrespective of the way it is measured. 
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Conclusion 
The thresholds to diagnose hypertension from the selfmeasured blood pressure at home 
remain basically unaltered since the 2000 consensus conference [49], but they are currently 
supported by evidence from prospective outcome data in populations [21–30] and patients 
[32–36]. Moreover, two recently published studies [106,107] proved that the introduction of 
the self-measured blood pressure in the management of hypertensive patients reduces medical 
costs. In contrast, further studies must establish what values of the selfmeasured blood 
pressure are optimal and normal in terms of cardiovascular outcome. 
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Abstract 
 
Objective To determine the separate contribution of the physician and the hospital 
environment to differences between home and office blood pressure (BP).  
 
Methods For 3 consecutive days 65 hypertensive patients measured their blood pressure at 
home (HBP). Office BP (OBP) was determined with the same device by the physician.  A 
higher or lower OBP than HBP was regarded white coat effect (WCE) or masked effect (ME) 
respectively.  OBP was measured automatically before, during and after the presence of the 
physician. The physician’s effect (PE) was the BP rise caused by the entrance of physician.  
The WCE or ME minus the PE was regarded the hospital’s contribution to the BP differences 
(HE). A pronounced WCE, ME and PE was regarded a >10 mmHg systolic or >5 mmHg 
diastolic difference. 
 
Results A pronounced WCE was present in 20% of (13/65) the patients (mean SBP/DBP ± 
SD 11.1/7.4 ± 10.9/5.2 mm Hg). The hospital environment contributed more to the WCE 
(6.9/4.9 ± 10.9/5.3 mmHg) than the PE (4.1/2.6 ± 5.3/2.5 mmHg). A pronounced ME was 
present in 53.5% (n=35) of participants (mean 17.0/9.8 ± 12.7/8.3 mmHg). The BP difference 
induced by the hospital environment (-21.4/-13.1 ± 14.0/9.7 mmHg) was larger (P<0.001) 
than the physician induced BP difference (4.3/3.3 ± 6.2/4.1 mmHg). WCE or ME did not 
correlate with the PE. 
 
Conclusions BP differences between home and office can largely be attributed to the hospital 
environment rather than to the physician. The physician related BP effect is not related to the 
WCE or to the ME. 
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Introduction 
In 1983 Mancia and colleagues were the first reporting an immediate blood pressure (BP) 
increase when a physician entered the room to start a BP reading[1]. This phenomenon was 
labelled as the white coat effect (WCE). The term white coat hypertension (WCH) was 
introduced[2], in case the BP was only hypertensive in the presence of physician but 
normotensive in the absence. With the entrance of automatic devices for BP measurement 
outside the clinic environment at home (HBP) or in ambulatory BP monitoring (ABPM), 
office hypertensives with home normotension were additionally labelled WCH, in assumption 
that the higher BP in the office was caused solely by the physician[3]. In this context, treated 
hypertensives with higher BP in the office than at home were also regarded as having WCE. 
Although both labelled the same, office-home differences in BP are not similar to BP 
differences in the office induced by the entrance of the physician.  More recently, the term 
masked hypertension (MH) was introduced for office normotensives with hypertension at 
home[4]. In analogy with WCH and WCE the term masked effect (ME) is now customary for 
higher BP values at home than in the office in treated hypertensives. 
 
It is known that the hospital environment in itself may induce a stress reaction and that the 
entrance of the physician induces a second stress upon the first. In the intra-arterially study of 
Mancia, the entrance of the physician is the only stress whereas in most non-invasive studies 
the sum of both hospital and physician stress is used, without knowledge about the separate 
contribution of the two stress producers[1]. In a few studies looking for the relation between 
the pure physician induced BP increase and the difference between the office BP and daytime 
ABPM, the authors concluded that such a relation was not found[5-7]. As the specific 
contribution of the hospital environment on BP differences between home an office was never 
investigated before, the aim of our present study was to investigate the separate contributions 
of both the hospital environment and entrance of a physician to the WCE. We also 
investigated the association of stress by the hospital environment with stress caused by the 
physician. In order to differentiate between the different phenomena, we will use the term 
physician effect (PE) for the pure effect on BP by the physician, we will use WCE for higher 
BP in the office than at home, and we will use hospital effect (HE) for the separate 
contribution of the hospital environment on the WCE. Figure 1 shows how the different 
phenomena are related to each other. 
 
Figure 1. Schematic representation of the different blood pressure phenomena. 
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Methods 
 
Patients 
Participants were patients visiting the outpatient clinic of a university hospital routinely 
(mostly treated hypertensives).  Exclusion criteria were: diabetes mellitus, cardiac 
arrhythmias, heart failure and autonomic insufficiency.  Participants were informed and asked 
for informed consent.  They were trained by the male physician (I.A.) to perform semi-
automatic BP-measurement at home and were educated to prevent factors influencing correct 
BP-measurement (smoking, talking, exercise etc.).   
 
Blood pressure measurement 
Upper arm circumferences were measured and appropriate cuffs were used.  All participants 
measured their home BP with a validated semi-automatic oscillometric device, the Omron 
705CP (Omron Healthcare Europe B.V., Hoofddorp, The Netherlands)[8]. Triple 
measurements were made at the non-dominant arm after at least 5 min of rest, every morning 
and evening for 4 consecutive days, sitting in a comfortable chair with the back supported, 
feet flat on the floor and the arm at heart level[9, 10]. The BP values were noted by the 
patients, and the values were checked by the physician from the device memory to confirm 
the validity.  One day after the last home BP-readings, their BP was measured in the office.  
Participants were comfortably seated on a seat with arms on a support at heart level and were 
not allowed to perform activities influencing BP[11]. BP-readings were performed with both 
the Omron device at the non-dominant arm, and a fully automated oscillometric BP-
measuring device (Dinamap 1846SX, Critikon, Tampa, Florida) on the contralateral arm. The 
Dinamap was programmed to perform one BP reading automatically at 8 min, without the 
presence of a physician. After this, at exactly t=10 min, the physician (always the same male 
physician, especially trained for the study, I.A.) entered and performed two bilateral BP-
readings with both the Dinamap and the Omron device simultaneously[8]. All participants 
were familiar to the physician as they were previously carefully instructed by him about the 
measurements.  After the two simultaneous measurements with both the Omron and Dinamap 
device, the physician left the room (at about t=12 minutes).  At t=15 min the Dinamap again 
performed an automatic measurement, in the absence of the physician. No changes in 
antihypertensive treatment were made during the study period.  
 
Data and statistical analysis 
The home measurements of the first day were excluded. The mean of all remaining home BP 
readings was regarded as the HBP. The mean of the two BP-readings performed by the 
physician with the same device at t=10-12 min, was regarded as the OBP. The difference 
between office and home BP (determined by the Omron device) was regarded the WCE or 
ME.  The mean of the BP-readings at t=10-12 min, in presence of the physician, minus the 
mean of the BP-readings at t=8 and 15 min, without the physician was regarded the PE. The 
contribution of the hospital environment to the BP differences was calculated (HE = WCE – 
PE or HE = ME – PE).  The ME was defined as a higher self measure BP at home than the BP 
measured with the same device by the physician in the office. A >10mmHg systolic BP or >5 
mmHg diastolic BP higher or lower OBP than HBP was regarded as a pronounced WCE or 
ME respectively. A >10 mmHg systolic BP or >5 mmHg diastolic BP higher BP in the 
presence than the absence of the physician was regarded a pronounced PE. Magnitudes of HE 
and PE were calculated both for all participants with WCE and for participants with a 
pronounced WCE. The same was done for patients with ME and for patients with a 
pronounced ME. Differences between WCE or ME and PE were tested for significance by 
means of the Student’s t-test. Pearson’s correlation coefficients were calculated to assess the 
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association between PE and WCE or ME. We determined linear regression coefficients when 
assessing the relation of age, sex, BMI and baseline mean BP for the different BP phenomena. 
Significance was set throughout the article at a P-value of <0.05 (two-sided). 
 
Results 
 
Patient characteristics 
Our study consisted of 65 patients (33 females) of whom 57 were treated. All patients were 
familiar with the hospital environment, as they were regularly followed up for hypertension, 
vascular or metabolic disease.  Mean age ± SD was 59 ± 14 years (ranging from 29-86). Mean 
height was 172 ± 10 cm. Mean body mass index was 27.6 ± 4.6 kg/m2. Table 1 shows the 
baseline characteristics for patients with systolic WCE (n=20) or ME (n=45). No significant 
differences were present in age, height, weight or body mass index.  
 
Table 1. Baseline characteristics of participants with systolic white coat effect or masked 
effect. 
  White coat effect (n=20) Masked effect (n=45)  P-value of difference 
Females (%)   11 (55)   24 (53) n.s. 
Age (years)    55 ± 13   60 ± 15 n.s. 
Height (cm)  173 ± 10 1.72 ± 10 n.s. 
Weight (kg)    79 ± 17   82 ± 12   n.s. 
Body mass index (kg/m2)    27 ± 5   28 ± 4 n.s. 
OBP–HBP (Omron) 9/ 2/ 1 ±  8/10/7 -15/-6/0 ± 11/8/ 6 <0.01/<0.01/n.s. 
Δ BP by physician (Dinamap) 4/ 3/-1 ±  7/ 3/4    5/ 3/1  ±  6/4/ 8  n.s. 
Δ BP by hospital (calculated) 5/-2/ 2 ± 10/11/8 -20/-9/0 ± 13/9/11 <0.01/<0.01/n.s. 
All values were rounded to whole units. Data are number (%) or mean (± SD). Blood 
pressures are presented as systolic blood pressure/diastolic blood pressure/pulse rate ± SD. 
N.s., not significant; OBP, office blood pressure; HBP, home blood pressure; 
Omron/Dinamap, device used;. 
 
Blood pressure differences in the whole group 
While there were significant differences in HE between patients with WCE and ME, no 
significant differences in the magnitude of the PE were present. Table 2 shows the BP values 
at baseline for the total group and by gender. No significant differences in BP (P > 0.4) were 
present between the office measurements at t=8 (mean 136.1/77.8 mmHg) compared to t=15 
minutes (135.3/77.5 mmHg). This justified us to use the mean BP of t=8 and t=14 as the 
office BP without the presence of the physician. We omitted all home BP measurements of 
the first day. This however did not make a difference (144.2/83.1 mmHg, 64.8 bpm vs. 
144.2/83.2 mmHg, 65.0 bpm, P-values for the differences in SBP, DBP and PR >0.85). 
Surprisingly, mean HBP was higher than the mean OBP (P<0.001 for SBP and DBP). Figure 
2 shows the mean and individual BP effects for the whole group. 
Table 2. Mean blood pressures, pulse rates and blood pressure effects.  
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 All participants (n=65)  Males (n=32)    Females (n=33) 
OBP (Omron, dr.) 137/79/65  ± 20/10/10  138/82/64 ± 15/10/ 9    135/77/67 ± 24/10/11 
HBP (Omron) 144/83/65  ± 18/10/ 8  146/85/65 ± 16/9/ 8    143/82/65 ± 19/10/ 8 
    
OBP (Dinamap)  136/78/64  ± 19/10/10 138/81/63 ± 12/ 9/ 8    134/74/65 ± 24/ 9/11 
OBP (Dinamap, dr.)  140/81/63  ± 20/  9/10 141/83/64 ± 13/ 9/ 9    140/78/63 ± 26/ 9/12 
    
OBP–HBP (Omron)   -8/-4/ 0  ± 15/10/6   -8/-3/-1 ± 13/ 9/ 6     -7/-5/ 1  ± 17/10/ 6 
Δ BP by physician 
(Dinamap)    5/ 3/ 0  ±   6/ 4/ 7    3/ 2/ 1 ±  7/ 3/ 7      6/ 4/-1  ±  6/ 4/ 7 
Δ BP by hospital (calculated) -12/-7/ 0  ± 16/10/10 -11/-5/-2 ± 15/10/10   -13/-9/ 3  ± 17/11/ 9 
All values were rounded to whole units. Data are presented as systolic blood 
pressure/diastolic blood pressure/pulse rate ± SD. Omron/Dinamap, device used; dr., 
physician present; OBP, office blood pressure; HBP, home blood pressure. 
 
Figure 2. Blood pressure effects in all participants. The rectangles in the upper part of the 
figure resemble the patients with a relevant white coat effect (n=13) depicted in figure 3. The 
white coat effect is divided into a physician effect and a hospital effect.  Data is presented as 
mean with 95% CI. SBP, systolic blood pressure; DBP, diastolic blood pressure; WCE, white 
coat effect; PE, physician effect; HE, hospital effect. 
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The white coat effect 
The mean WCE in 20 patients with higher OBP than HBP was 9.0/1.7 ± 8.2/10.2 mmHg. No 
significant effect on pulse rate was present (mean 0.9 ± 6.8 bpm). A significantly higher WCE 
was present in women than in men (13.0/-0.7 ± 9.9/13.2 mmHg vs. 5.7/3.6 ± 4.8/6.9 mmHg). 
The WCE consisted of 4.6/-1.7 ± 9.9/10.9 mmHg HE and of 4.4/3.4 ± 6.6/3.3 mmHg PE. PE 
did not correlate with WCE (r=0.12, P=0.61 for SBP and r=-0.05, P=0.83 for DBP).  
 
A substantial WCE (SBP >10 or DBP >5 mmHg higher OBP than HBP) was present in 13 of 
the 65 (20%) participants. The mean WCE in these 13 participants was (SBP/DBP ± SD) 
11.1/7.4 ± 10.9/5.2 mmHg (Figure 3).  
 
Figure 3. Blood pressure effects in patients with a relevant white coat effect (n=13). The 
white coat effect is divided into a physician effect and a hospital effect.  Data is presented as 
mean with standard error of the mean. SBP, systolic blood pressure; DBP, diastolic blood 
pressure; WCE, white coat effect; PE, physician effect; HE, hospital effect. 
 
 
No significant effect on pulse rate was present (mean 0.8 ± 7.0 bpm). Of this effect 4.1/2.6 ± 
5.3/2.5 mmHg was due to the physician and 6.9/4.9 ± 10.9/5.3 mmHg due to the hospital 
environment. In regression analysis, age, baseline mean arterial pressure (at home) and BMI 
were not significantly associated with a significant WCE (all P-values >0.4). Also within this 
subgroup of patients with a substantial WCE, significantly higher systolic WCE (P=0.009) 
was present in women (20.2/7.7 ± 7.0/6.4 mm Hg) compared to men (5.4/7.3 ± 8.9/4.8 
mmHg), while they did not differ in change of pulse rate (P=0.69).  Baseline mean arterial 
pressure or age did not significantly influence the systolic or diastolic WCE (all P-values 
>0.175). The difference between the PEf and the WCE was significant for both SBP (P=0.04) 
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and DBP (P=0.006). PE correlated poorly with WCE (r=0.24, P=0.43 for SBP and r=0.22, 
P=0.47 for DBP). 
 
Masked effect  
The mean ME in 45 patients with higher HBP than OBP was 15.1/6.4 ± 11.5/8.1 mmHg. No 
significant effect on pulse rate was present (mean -0.1 ± 5.8 bpm). No significant differences 
were present in ME, HE or PE between these 21 men and 24 women. The ME consisted of a 
substantially larger HE (19.6/9.4 ± 12.7/9.5 mmHg) than PE (4.6/3.0 ± 6.4/3.9 mmHg). PE 
did not correlate with ME (r=0.08, P=0.59 for SBP and r=-0.13, P=0.39 for DBP). 
 
A substantial ME (SBP >10 or DBP >5 mmHg higher HBP than OBP) was present in 35 of 
65 participants (53.5%), with a mean effect of 17.0/9.8 ± 12.7/8.3 mmHg and -1.1 ± 6.2 bpm 
(Figure 4).  
 
Figure 4. Blood pressure effects in patients with a relevant masked effect (n=35). The masked 
effect is divided into a physician effect and a hospital effect. Data is presented as mean with 
standard error of the mean. SBP, systolic blood pressure; DBP, diastolic blood pressure; ME, 
white coat effect; PE, physician effect; HE, hospital effect. 
 
 
Also in these patients, the magnitude of the BP difference induced by the hospital 
environment (-21.4/-13.1 ± 14.0/9.7 mmHg) was larger (P<0.001) than the physician induced 
BP difference (4.3/3.3 ± 6.2/4.1 mmHg). In multivariable regression analysis, age 
significantly increased the ME (β=0.372, P=0.045). Sex, baseline mean arterial pressure and 
BMI did not have significant influence on the systolic ME (P≥0.15). Age (β=0.286, P=0.10) 
and baseline mean arterial pressure (β=0.317, P=0.07) were borderline significantly 
associated with the diastolic ME. The systolic and diastolic ME did not correlate with 
influence of the physician on BP (all P-values >0.4). 
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The physician effect 
A significantly higher rise of BP due to the physician was present in women (6.1/4.0 mmHg ± 
5.9/4.3, P=0.04 for SBP and DBP) than in men (2.8/2.2 mmHg ± 6.5/2.7). BP was 4.5/3.1 
mmHg ± 6.4/3.7 higher in the presence versus the absence of the physician in the hospital 
(P<0.001 for SBP and DBP), while pulse rate (-0.2 ± 7.0 bpm) was not altered (P =0.81). 
 
A substantial PE (SBP >10 or DBP >5 mmHg rise) was present in 30 (46%) of 65 
participants. Significantly more women (n=20) than men (n=10) had a PE (P=0.03).  The 
mean PE in these 30 subjects amounted to 7.8/5.8 mmHg ± 6.6/3.1 and -2.1 ± 7.2 bpm. In this 
group, sex, age, baseline mean arterial pressure or BMI, did not significantly influence the 
systolic or diastolic PE(all P-values >0.25). 
 
Of the 30 subjects with a substantial PE, only 4 (13%) had a substantial WCE, assessed by 
difference of home and office BP. This was because of the presence of a higher BP at home 
than in the hospital in the absence of the physician (–19.5/–13.7 ± 14.8/9.1 mmHg and 3.1 ± 
8.9 bpm) in 24 persons. This eventually resulted in a mean ME of 8.0/5.9 ± 16.7/10.0 mmHg 
and 1.4 ± 6.6 bpm. In 60% (18 of 30) of the participants with a substantial ME, also a 
substantial PE (mean 6.5/5.5 ± 6.4/3.8 mmHg and -2.9 ± 8.4 bpm) was present.  
 
Discussion 
In participants with a substantial WCE (20%), this WCE could largely be attributed to the 
hospital environment rather than to the presence of a physician. Even in patients with a 
substantial PE, often no substantial WCE, determined by office-home BP difference, was 
present. This was mostly due to the presence of a large ME. PE and the WCE or ME did not 
correlate with each other. The HE and the PE therefore, seem to be two different entities 
determining the WCE or the ME.  
 
Previous research showed that PE and WCE did not correlate well[6, 7]. Our study was 
confirmatory in this matter. These two phenomena should therefore be regarded as different 
entities, with possibly a different etiology. The PE could be caused by a stress reaction caused 
by the entrance of a physician, resulting in sympathetically mediated vasoconstriction and rise 
in blood pressure[12]. A significant rise of pulse rate observed in beat-to-beat monitoring in 
the acute moment of entrance of the physician, supports sympathetic activity as being the 
cause of the effect[13]. Moreover, plasma cortisol levels were higher in subjects with, 
compared to those without a PE[14]. In our current study, no significant rise in pulse rate was 
observed in our present investigation. The full automatic Dinamap measured BP and pulse 
rate about one minute after entrance of the physician. Due to this slight delay we could not 
measure the acute situation, where besides BP, possibly, pulse rate rises[1]. We might have 
measured the pulse rate at a time in which the baroreceptor reflex has already downregulated 
the heart rate.  The lack of a rise in pulse rate in the surrogate marker of WCE, defined as 
difference between OBP and HBP or ABPM, has been described in previous literature[6, 15, 
16]. We confirmed this lack of change in pulse rate in WCE assessed by office-home BP 
differences.   
 
We hypothesize that besides the role of physician, other factors like BP variability, 
differences in medication (difference in pharmacokinetics of the antihypertensive drugs used), 
difference between methods (different devices, environment and time of measurement) and 
difference in behavior of patients during home measurements (activity/exercise, smoking and 
diet) are important causes of the difference in BP observed between home and office.  The 
sum of these factors has been previously named ‘an idiosyncratic reaction to the hospital 
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environment[13]. In our present study we have gathered all these potential factors into the 
HE. The question if sympathetic autonomic activity has a greater role in the PE than in the 
‘surrogate’ WCE should be investigated further. Table 3 shows an outline of previously 
published articles about the (lack of) association of the classic WCE (named PE in our study) 
and the surrogate WCE.   
 
To the best of our knowledge, we are the first to specifically investigate the role of the 
hospital environment in differences of BP between home and office.  Previously, Gerin and 
colleagues successfully studied the extent to which different clinical settings influence BP 
before seeing a physician [15].  In that study different measures in the clinic (BP in the 
waiting room, examination room with and without physician) were compared to a ‘non 
clinical’ hospital setting and daytime ABPM. They concluded that WCE may not be just 
limited to the narrow window in which the patient sees the physician, but may be generalized 
to the clinical setting. In an accompanying editorial[17], Parati and Mancia claimed that any 
improvement in methods for measuring blood pressure in the clinic (for instance, in the 
absence of a physician) was unlikely to remove the confounding influence of the WCE on 
blood pressure measurements. The latter statement should be assessed with care though. More 
recent studies of Myers and colleagues provided consistent evidence that automated BP 
measurement in the office in the absence of a physician correlated strongly with and were 
similar to daytime ABPM values[18]. However, evidence that the automated BP measurement 
in the office in absence of the physician predicts cardiovascular morbidity and mortality as 
good as daytime ABPM are to be awaited. 
 
Stergiou and colleagues studied different home and clinic measurements in order to assess the 
correct term for home measurement[19]. They concluded that it did not matter whether home 
measurements were made by patients or relatives, and by patients or the physician in the 
hospital. The BP measured by the physician in the hospital was only slightly higher (1.9/1.6 ± 
6.1/4.7 mmHg) than measured by the patient 5 minutes after the physician left. The difference 
of self-measured BP in the office versus self-measured BP at home was much larger (9.3/4.9 
± 9.0/5.4 mmHg). This underscores our conclusion, namely that the hospital setting has a 
more important influence in home-office BP differences, than the presence of the physician. 
In this line, ‘isolated office hypertension’ seems to be a more correct term than white coat 
hypertension, when the data is based on home-office BP difference.   
 
In our study, remarkably, mean OBP was lower than mean HBP, despite excluding HBP 
readings of the first day. Other studies showed similar results[15, 20]. Firstly, we can 
hypothesize that the cause could be an insufficient resting period before the self measurement, 
despite the fact that we advised 10 minutes of rest before self-measurement. In contrast, 
during OBP measurement, the physician secured at least 10 minutes of rest before taking a 
BP-reading.  Secondly, the cause could be an alerting reaction or stress caused by the self 
measurement at home.  Finally, the possibility exists of an occasional large group of persons 
with ME in our population, because of selection of patients who regularly visited the hospital. 
Moreover, all patients were seen by only one well-trained physician.   
 
Our study is one of very few, assessing blood pressure differences, using the same device for 
home and office measurements.  In previous studies regarding BP differences between home 
and the office, different BP measurement techniques (mercury or aneroid spyghmomanometer 
in the office vs. ambulatory or fully automated oscillometric devices at home) were used. 
Comparison of cut-off values between different measurement techniques are often based on 
percentiles in population studies. If this comparison could be made on an individual basis for 
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the screening of WCE or ME is questionable. We made use of identical devices for evaluation 
of the PE (all measurements with Dinamap) or the WCE (all measurements with Omron).   
 
Perspectives 
The term WCE is thus largely used for two different phenomena; difference in BP between 
office and home, and BP difference caused by the entrance of the physician (or nurse).  Our 
findings show that WCE and PE have only a weak correlation, and can be in the opposite 
direction. We are the first that specifically studied the separate impacts of both the hospital 
environment and the presence of the physician on BP. We concluded that the hospital 
environment is the largest factor that influences BP differences between home and office BP 
(e.g. WCE and ME). 
 
Disclosures 
None. 
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Table 3. Previous literature regarding (dis)agreement between the true WCE and the ‘surrogate’ WCE. 
Publication Population Method  Main findings 
Parati et al.[6] 28 hypertensives • Finger BP recorded before and during the visit 
of the physician 
• BP measured during visit with mercury 
sphygmomanometer was compared to daytime 
ABPM 
 
 • No relation between physician-dependent peak BP 
increase and office-daytime ABPM-difference 
     
Lantelme et 
al.[7] 
88 hypertensives • Classic WCE determined by finger BP  
• The surrogate WCE was assessed by 
difference between office BP (by a physician) 
and 24-hour ABPM 
 • The estimated WCE relates poorly to the classic 
WCE  
 
     
Palatini et al.[5]  64 hypertensives  
and 33 normotensives 
• Responses to BP measurement by a physician 
were assessed with beat-to-beat finger BP 
recording 
• Difference between office BP and daytime 
ABPM was used as a surrogate measure of 
WCE 
 • The surrogate WCE was unrelated to the BP 
response in the office by the physician 
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; WCE, white coat effect.
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Abstract ⎯ In march 2006, a consortium of researchers introduced a new marker of arterial 
stiffness, the ‘Ambulatory Arterial Stiffness Index’ (AASI). AASI was defined unity minus 
the regression slope of diastolic blood pressure on systolic blood pressure in 24-hour 
ambulatory blood pressure recordings. The stiffer the arterial tree, the closer the regression 
slope is to 0 and the AASI is to 1. AASI has proven to predict total cardiovascular mortality, 
fatal and non-fatal stroke and target organ damage, over and beyond classical risk factors. 
This review highlights and discusses (a) the physiologic principles of the AASI, its 
determinants and association with other markers of arterial stiffness (b) cross-sectional studies 
focusing on the relationship of AASI with hypertensive target organ damage (c) prospective 
studies in which AASI predicted cardiovascular morbidity and mortality. Finally we 
summarized perspectives and future challenges regarding the AASI. 
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Introduction  
Cardiovascular disease is the major cause of morbidity and mortality in the ageing 
populations of the world in developing and developed regions alike. Scientists and policy 
makers increasingly recognize the role of prevention, which is the continuum of knowledge of 
the cause, subsequently coming to a diagnosis, and finally initiating treatment.  Arterial 
stiffness is a marker of arterial ageing and predicts future cardiovascular morbidity and 
mortality over and beyond traditional risk factors[1-4].  It is an appealing measure as it can be 
determined automatically and non-invasively.  
 
In march 2006, a consortium of researchers introduced a new indirect marker of arterial 
stiffness, the Ambulatory Arterial Stiffness Index (AASI)[5].  This method is based on 
physiological insights, already reviewed in 1914[6]. In elastic arteries any increase in systolic 
blood pressure (SBP) will be accompanied by a similar rise in diastolic blood pressure (DBP), 
whereas in stiff arteries, DBP will increase less or even fall with higher SBP. AASI was 
therefore defined as 1 minus the regression slope (Figure 1) of DBP on SBP in 24 hour 
ambulatory blood pressure recordings (ABPM).[7] The regression line was not forced through 
the origin, because during diastole when flow drops to zero, such a phenomenon does not 
occur for blood pressure[8]. The stiffer the arterial tree, the closer the regression slope to 0 
and AASI to 1, respectively. AASI can be easily computed from ordinary 24 hour ABPM and 
therefore does not necessitate any extra equipment or observer training. 
 
Figure 1. Derivation of the ambulatory arterial stiffness index (AASI) from a 24-hour 
ambulatory blood pressure recording in one participant, whose 24-hour blood pressure was 
129 mm Hg for systolic blood pressure and 95 mm Hg for diastolic blood pressure. 
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This review of the recent literature highlights (a) the physiologic principles of the AASI, its 
determinants and association with other markers of arterial stiffness (b) cross-sectional studies 
focusing on the relationship of AASI with hypertensive target organ damage (c) prospective 
studies in which AASI predicted cardiovascular morbidity and mortality. Finally, we will 
summarize perspectives and future challenges regarding this promising new marker of arterial 
stiffness. 
 
Comparison with other markers of arterial stiffness  
Markers of arterial stiffness include aortic pulse wave velocity (PWV) and the augmentation 
Index (AIx). At a constant resting blood pressure level PWV reflects stiffness of the arterial 
wall because blood flow is faster in a more rigid than in an elastic artery. AIx rests on the 
principle that in stiffer arteries reflected waves travel faster and augment SBP. Both measures 
of arterial stiffness predict cardiovascular disease[9, 10]. These techniques however require 
the use of expensive devices and the involvement of highly trained observers, which renders 
them unsuitable for use in routine clinical practice. Moreover they should be performed apart 
from the standard screening procedure of the Framingham or SCORE risk models, whereas 
AASI could be determined from a 24-h ABPM[11, 12]. The QKD (QRS to Korotkoff Delay) 
interval is derived from the time between the QRS-wave on the electrocardiogram and the 
detection of the last Korotkoff sound during deflation of the cuff in 24-h BP monitoring[13]. 
From multiple linear regression of QKD according to SBP and heart rate, the theoretical value 
of the QKD for a SBP of 100 mm Hg and a heart rate of 60 beats/min is determined[14].  
 
Li and colleagues assessed the correlation of AASI with carotid-femoral PWV in a group of 
166 healthy Chinese volunteers[15]. A close relation was present between PWV and AASI 
(r=0.51, P<0.0001). Another study found a significant (r=0.28, P<0.001), albeit weaker 
(P=0.004, calculated by Fisher’s R-to-Z transform), correlation between PWV and AASI in 
346 untreated hypertensive patients.[16] In 348 participants AASI correlated with the central 
and peripheral AIx and the 24 hour PP[15, 17]. AASI in comparison with the 24 hour PP, 
correlated more closely with the central (r=0.48 vs. 0.34, P<0.001) and the peripheral AIx 
(r=0.50 vs. 0.36, P<0.001). In subjects <40 years, the correlation between AASI and both 
central and peripheral AIx remained significant (r=0.18 and 0.19, P<0.05), unlike the 
correlation between PP and the central or peripheral AIx (r=0.00 and –0.02, both non-
significant).  In 469 hypertensive patients[14], AASI was significantly inversely correlated 
with the QKD (r=–0.29, P<0.001).  The correlation coefficient between the AASI, PWV and 
AIx measures the strength of relation between variables, not the agreement between them. 
Therefore one study[18] examined the inter-correlations in 622 (391 untreated, 231 treated) 
hypertensive patients, adjusting for confounders like age and sex. Furthermore they used 
Bland-Altman analysis to determine the 95% confidence intervals for the AASI to predict 
PWV or the AIx. AASI was significantly correlated with PWV (r=0.28, P<0.001) and AIx 
(r=0.24, P<0.001), however when adjusted for age and gender, the significance was lost 
(r=0.07, P=0.08 for PWV and r=0.04, P=0.22 for AIx). These results were similar in treated 
and in untreated subjects. The 95% confidence interval for the AASI to predict PWV and AIx 
was ±4.18 m/s and ±25.4% respectively.  These studies proved that AASI had a substantial 
correlation with other commonly used markers of arterial stiffness.  The AASI nevertheless is 
not interchangeable with the other measures, but rather mutually exclusive measures.  
 
As PWV is the golden standard, we chose to compare this index, with the more easily 
determined AASI.  Table 1 gives an overview of prognostic power of PWV and AASI in 
terms of cardiovascular risk stratification, in hypertensive patients or general populations. In 
the section ‘prospective studies’ later in this review we will focus in more detail on the 
prospective value of the AASI. Compared to the AASI, PWV seems to have best prognostic 
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value for cardiac mortality and events[5, 19-23].  For total cardiovascular mortality, 
cerebrovascular mortality and stroke, PWV and AASI have similar prognostic strength[5, 20, 
22-25]. AIx does not independently predict cardiovascular disease in general populations or 
hypertensive patients[26]. In models including both measures of arterial stiffness, AASI was a 
better predictor of stroke than PWV, whereas PWV performed better in the prediction of a 
composite cardiovascular endpoint. These findings support that both indexes of arterial 
stiffness provide complementary information in cardiovascular risk stratification[27]. 
 
Determinants of the AASI  
After multivariate correction, AASI showed to rise with female sex, higher age, higher mean 
arterial pressure and to diminish with higher 24-hour pulse rate and body height[15].  In the 
International Database of Ambulatory blood pressure in relation to Cardiovascular Outcomes 
(n=7604)[28], it was confirmed in multivariate analyses, that AASI associated positively with 
age and 24-h mean arterial pressure and negatively with height and 24-h heart rate, in 
different sex and ethnicities.  This study proved that a higher goodness of fit (r²) of the AASI 
regression line in individual subjects strengthens the association with its known determinants 
and enhances the statistical power of analyses involving AASI as marker of arterial stiffness. 
Therefore, the authors suggested that future reports of research on AASI might include a 
sensitivity analysis, excluding subjects with the r² value for the goodness of fit of the AASI 
regression line set at a threshold of 0.36, or higher. However, primary analyses should always 
include all subjects, because a very low r², e.g. uncoupling of SBP and DBP, might also 
reflect cardiovascular dysregulation.  
 
Schillaci and colleagues stated that other factors than arterial stiffness may affect the 
regression slope of AASI and confound results[16].  AASI was significantly higher in non-
dippers than dippers (0.44 vs. 0.29, P<0.001), and the correlation between relative nighttime 
BP reduction and AASI was significant both for DBP as SBP (0.46 and 0.28, both P-values 
<0.001).  No significantly higher PWV was found in non-dippers, excluding arterial stiffness 
as the cause. Therefore they stated that nocturnal BP dipping is a possible confounder for 
AASI determination. It was confirmed in a Flemish population that AASI inversely correlated 
with the nocturnal BP fall, especially in ambulatory recordings with a disproportionately large 
number of nighttime readings[29]. It was proposed therefore to standardize the number of 
nighttime and daytime readings and to use regression weighted for the time interval between 
successive readings to remove the effect of the night-to-day ratio of the number of BP 
readings computing AASI. Strikingly, in contrary to Schillaci’s findings[16], nighttime 
dipping similarly influenced PWV and AASI measured within 24 hours (r=0.54 and 0.49 for 
systolic and r=0.56 and 0.57 for diastolic dipping, P-value of the difference = 0.54) in 166 
Chinese volunteers[29]. 
 
Another group stated that the magnitude of nocturnal BP fall and thus AASI was associated 
with the correlation between SBP and DBP (r²)[30]. The Sym_AASI was created, calculated 
by 1 minus a so called symmetrical regression slope of SBP on DBP.  This variant of AASI 
was less (but now significantly positive) associated with nocturnal dipping and not affected by 
the goodness of fit (r²) of the regression slope.  Little evidence was presented for Sym_AASI 
in reflecting arterial stiffening or cardiovascular risk.  These concerns proved justified in a 
Belgian cohort (n=1127)[31]. AASI was similarly associated with classical risk factors and 
stronger correlated than Sym_AASI with PP (r=0.50 vs. r=0.17, P<0.001)[32]. 
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Table 1. Prospective studies on cardiovascular outcome for AASI and PWV.  
Authors Participants N Age (years) 
Follow-
up 
(years) 
Outcome Groups events Risk* 
AASI         
Dolan et al.[5]  Hypertensives 11291 54.6±14.6 5.3 CV mortality G1: 1 SD increase 566 CV deaths; 151 fatal strokes 
G1: CV deaths: 
1.08 (0.98-1.19)  
G1: Stroke deaths  
 1.21 (1.01-1.45)  
Kikuya et 
al.[22] 
General 
population 1542 61.7±10.7 13.3 CV mortality 
G1:<0.39 U  
G2:0.39-0.45  
G3:0.45-0.51  
G4:>0.51 
126 CV deaths; 
63 fatal strokes 
G1: 1.41 (1.01-1.96)  
G2: 0.85 (0.61-1.20)  
G3: 0.65 (0.46-0.91)  
G4: 1.29 (0.97-1.70)  
Hansen et 
al.[23] 
General  
population 1829 55.5±10.7 9.4 CV events 
G1: 1 SD increase 
(0.14 U) 
212 CV events;  
40 strokes 
G1: CV events  
 1.06 (0.91-1.23)  
G1: Stroke events  
 1.62 (1.14-2.28)  
Gosse et 
al.[14]  Hypertensives 440 54 ± 13 5.8±3.2 CV events 
G1: Tertile 1 vs. 2 
G2: Tertile 1 vs. 3 
Composite of 
unspecified CV 
events, CV death 
and non-CV 
death: 62 
G1: Composite  
 1.5 (0.7-3.3)  
G2: Composite  
 2.8 (1.3-5.8) 
PWV         
Laurent et 
al.[57] Hypertensives 1980 50±13 9.3±4.4 
CV mortality  
All-cause 
mortality 
G1: +5 m/s increase 107 fatal events; 46 CV deaths 
G1: CV mortality:  
 1.51 (1.08-2.11)  
G2: All cause:  
 1.34 (1.04-1.74) 
Hansen et 
al.[20] 
General  
population 1678 40-70 9.4 
CV mortality  
CHD 
G1: 1 SD increase 
(3.4 m/s) 
62 CV deaths; 
101 CHD 
G1: CV mortality:  
 1.20 (1.01-1.41)  
G2 CHD:  
 1.16 (1.00-1.35) 
Mattace-Raso 
et al.[58] 
General  
population 945 71.7±6.7 4.1±0.8 CV events 
Tertiles of PWV  
G1: Reference   
G2  
G3 
156 CV events; 
63 strokes 
CV events:  
 G2: 1.37 (0.83-2.29)  
 G3: 1.93 (1.16-3.21)  
Stroke events:  
 G2: 1.20 (0.56-2.75)  
G3: 1.96 (0.94-4.29) 
CV, cardiovascular; CHD, coronary heart disease; AASI, Ambulatory Arterial Stiffness Index; PWV, Pulse Wave Velocity. *All studies used Hazard Ratios 
(HR) to calculate risk except for Laurent et al. who used Odds Ratios (OR).  
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Reproducibility and heritability of AASI  
In the Ohasama study population[22], a mean number of 46 readings were available per 
recording for the calculation of AASI.  AASI seemed less reproducible when the number of 
readings in ambulatory blood pressure decreased, but this did not affect the predictive 
accuracy of AASI for cardiovascular mortality, until the median number of readings per ABP 
recording was less than ~35. This number should be regarded as the minimum of readings 
performed in 24-h ABPM to determine AASI. Further, it should be prevented to have a 
disproportional number of daytime or nighttime readings, as this could influence the 
AASI[33]. 
 
In a study consisting of 145 isolated systolic hypertensives from the Syst-Eur trial[34] and 
152 patients with systolic and/or diastolic hypertension, referred to an outpatient clinic 
(Radboud University Medical Centre Nijmegen), the repeatability of AASI and 24-h PP 
within a period of 3 months was investigated. Mean age was 46.2 and 71.0 years and the 
median interval between measurements was 8 and 31 days for the Nijmegen and Syst-Eur 
populations, respectively. In the Nijmegen patients, the repeatability coefficients (RC) of 
AASI and 24-h PP, expressed as twice the SD of the within-subject differences between 
repeat recordings as a percentage of 4 times the SD of the mean of the paired measurements, 
were ~50%.  In Syst-Eur patients, the corresponding values of the RC were ~60% for AASI 
and ~40% for PP.  Sensitivity analyses stratified for type of hypertension, or dipping status 
did not significantly change RC’s for AASI, as they were in the 50%–60% range.  The 
authors concluded AASI was modestly reproducible.  
 
A French group investigated the reproducibility of AASI and QKD in 38 volunteers within 2 
weeks[14]. QKD showed better reproducibility (r = 0.79, SD of differences [SDD] = 9 msec, 
coefficient of variation [CV] = 4%) than AASI (r = 0.21, SDD = 0.15, CV = 25%).  
Unfortunately, no statistical test and associated P-value was presented for the comparison of 
the reproducibility.  Moreover, the CV does not account for the possible range of biological 
variation. Had the SDD been expressed as a percentage of near maximal variation in a 
measurement, as given by four times the SD[35], the conclusion of reproducibility might have 
been quite different[36]. 
 
One study investigated the heritability of AASI in 260 siblings from 118 families in 
Sweden[37]. Before adjustment for significant covariates the heritability of AASI was 41% 
(P=0.009), which decreased to 28% (P=0.05) after adjustment for age, 24-h PP and 24-h pulse 
rate. After adjustment of 24-h PP for AASI, age sex and BMI, the heritability decreased from 
63 to 55% (P=0.002). This study showed that AASI is partially heritable and confirms that 
arterial stiffness is under genetic control[38, 39]. The authors stated that AASI and 24-h PP 
might reflect partially different aspects of arterial stiffness and that the power of genetic 
studies aiming at finding genes of importance for arterial stiffness would be significantly 
increased by including both of the two surrogate markers as phenotypes. 
 
Cross-sectional studies 
An Italian study investigated if AASI relates to the asymptomatic and potentially reversible 
early phase of cardiovascular disease[40]. Leoncini and colleagues recruited 188 previously 
untreated primary hypertensives and explored the association of AASI with 
microalbuminuria, left ventricular hypertrophy and carotid atherosclerosis[41]. They 
measured albuminuria as the albumin to creatinine ratio (ACR), left ventricular mass index 
(LVMI) by echocardiography and carotid abnormalities by ultrasonography. AASI was 
significantly related to early signs of target organ damage (TOD), such as urinary albumin 
excretion (ρ=0.234; P=0.002) and carotid intima-media-thickness (r=0.196; P=0.016), 
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whereas the correlation between AASI and LVMI, did not reach statistical significance 
(r=0.133; P=0.086). Schillaci and colleagues also investigated the relation between AASI and 
LVMI and demonstrated a significant correlation between AASI and LVMI (r=0.17, 
P<0.001)[16]. 
 
As the global burden of cardiovascular risk runs in parallel with abnormalities in renal 
function[42, 43], Ratto and colleagues[40] focussed on (early) signs of renal damage, namely 
albuminuria, as measured by ACR, creatinine clearance, estimated using the Cockgroft-Gault 
formula (eGFR), and the interlobar resistive index, evaluated by renal ultrasound and Doppler 
examination. They related these measures to AASI in 168 untreated patients with sustained 
primary hypertension. AASI correlated positively to urinary albumin excretion (r=0.212; 
P=0.0074) and resistive index (r=0.176; P=0.0377), and was negatively associated with eGFR 
(ρ=0.253; P=0.0018) and with the renal volume to the resistive index ratio (r=0.203; 
P=0.0184), a marker of nephroangiosclerosis. Even after adjustment for confounding factors, 
patients with target organ involvement had a higher AASI than those who did not, and each 
SD increase in AASI roughly doubled the risk of having subclinical organ damage.  
 
Palmas and colleagues compared the value of PP and AASI in predicting deterioration of 
renal function, as measured by ACR[44], in a multiethnic cohort of 1180 type-2 diabetic 
subjects. The main finding of this study was that, in the fourth quartile of the population, 
AASI was associated with a higher ACR at follow-up after adjustment for several covariates, 
including office PP (P=0.024). However, this association weakened to a non-significant level 
after replacing office PP with 24-hour PP (P=0.38), whereas 24-hour PP retained its status as 
independent predictor after full adjustment (P=0.001). In this high risk (overweight, mean 
BMI 31.5 and advanced age, mean ≈ 70 years) population, AASI was only modestly 
associated with progression of albuminuria, as compared to 24-hour PP.   
 
Others evaluated the relationship between AASI and glomerular filtration rate (GFR), in 143 
untreated hypertensive patients without CV complications and without severe renal 
insufficiency[45].  Mean (± SD) GFR (assessed by a radioisotopic technique) was 110.5 ± 
33.4 ml/min/1.73 m². A significant inverse correlation between AASI and GFR was found (r 
= −0.30; P<0.001). This association was also observed in a multiple regression model with 
parameters age, gender, HDL cholesterol, body mass index, 24-h PP, and day-night diastolic 
(or systolic) reduction in BP. In this model, only AASI maintained a statistically significant 
(P = 0.02) association with GFR. The authors hypothesized that this finding may in part help 
to explain the increased risk for CV morbidity and mortality documented in subjects with 
mild-to-moderate renal dysfunction.  
 
The relationship between AASI and the metabolic syndrome (MS) was investigated in 156 
untreated non diabetic hypertensives[46]. The prevalence of MS was 23% (n=36). After 
adjustment, AASI was significantly higher in MS (0.53 vs. 0.48, P=0.03). Each SD (0.16 
units) increase in AASI entailed an almost twofold risk of having MS (OR 1.73, 95% CI 1.07-
2.79). The prevalence of MS resulted in a more than twofold risk (OR 2.63, 95% CI 1.22-
5.71) for an increased AASI (>0.55 units).  
 
Comprehensively, these findings underscore that AASI holds the ability to predict TOD, 
although it was not always superior to 24-h PP.  This suggests that this new marker might be 
an appropriate instrument for detecting patients at an early stage of the disease process in 
order to prevent cardiovascular events.  
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Prospective studies  
The first prospective study regarding AASI included 11291 untreated subjects from Ireland 
and monitored cardiovascular mortality, from 1980 to 2002.[5] Mean follow-up time was 5.3 
years and 566 cardiovascular deaths occurred. Baseline AASI and pulse pressure (PP) 
significantly predicted cardiovascular mortality, after multivariate correction for other risk 
factors (hazard ratio (HR) of 1 SD increase with 95% CI, 1.14 (1.04-1.24), P<0.01).  In 
adjusted analyses dichotomized as normal/abnormal values (under/above 95th percentile) of 
AASI and PP, AASI independently predicted cardiovascular (HR with 95% CI, 1.71 (1.33-
2.19), P<0.001), cardiac (1.44 (1.03-2.00), P<0.05) and stroke mortality (2.49 (1.64-3.80), 
P<0.001). PP only predicted cardiac mortality (1.34 (1.05-1.71), P<0.05). When PP and AASI 
were additionally corrected for each other, only AASI remained significantly predictive for 
total cardiovascular and stroke mortality, whereas PP lost significance. Moreover, AASI 
significantly predicted cardiovascular and stroke mortality in both hypertensives and 
normotensives, whereas PP only predicted cardiac mortality in hypertensives. This study 
demonstrated the ability of AASI to predict various forms of cardiovascular mortality for the 
first time. AASI could be extra useful in low risk populations, as it was especially predictive 
in normotensives.  
 
In a second prospective study AASI was evaluated in terms of fatal and non-fatal 
cardiovascular complications in a cohort with 1829 randomly selected participants from the 
Copenhagen County (Denmark)[23]. Median follow-up was 9.4 years and included 60 
cardiovascular deaths, 128 coronary events, and 24 strokes. While after full adjustment, AASI 
remained independently and significantly predictive for fatal and non-fatal stroke (HR of 1 
SD increase with 95% CI, 1.62 (1.14-2.28), P<0.01), PP lost its value for all three outcome 
measures. This study validated AASI in terms of cardiovascular mortality and extended the 
prognostic value of AASI in terms of cardiovascular events.  In 1678 Danes (mean age 54.8 
years) from the same cohort PWV, which is regarded as the golden standard for the non-
invasive measurement of arterial stiffness, was measured within 24 hours and directly 
compared to AASI.  In multivariate-adjusted Cox regression models including both indexes, 
AASI (standardized hazard ratio, 1.68; P=0.01) but not PWV (0.91; P=0.62) predicted stroke, 
whereas the opposite was true for the composite of all cardiovascular events (PWV, 1.15; 
P=0.03 and AASI, 1.04; P=0.68).  This study was the first that included both AASI and PWV 
in the same Cox model and provided evidence for the independent contributions of both 
measures of arterial stiffness to cardiovascular risk stratification.  
 
Although AASI might ameliorate risk stratification based on ambulatory blood pressure 
measurements, its use cannot be recommended before the outcome results are replicated in 
population cohorts of different ethnic extraction.  Therefore a comparable study was initiated 
in a population cohort of Asian ethnicity[22].  AASI and PP were related to mortality in 1542 
randomly recruited Ohasama residents (Japan). Almost half of the patients had ambulatory 
hypertension, of whom 62% used antihypertensives. Median follow-up was 13.3 years and 
126 cardiovascular (63 stroke, 59 cardiac) deaths occurred. The sex- and age-standardized 
incidence rates of cardiovascular and stroke mortality across quartiles were U-shaped for 
AASI and J-shaped for PP. Across quartiles, the multivariate-adjusted HR for cardiovascular 
and stroke mortality were significant and U-shaped for AASI, whereas for PP significance 
was lost. The hazard ratios for cardiovascular mortality (versus overall risk in the whole 
population) across ascending AASI quartiles were 1.41 (P=0.04), 0.85 (P=0.25), 0.65 
(P=0.01), and 1.29 (P=0.03). That study[22] confirmed the results of previous studies[5, 23] 
analysing the predictive capabilities of AASI on cardiovascular outcome and extended the 
validation to a general population of Asian extraction. Striking were the U-shaped incidence 
rates of cardiovascular and stroke mortality across quartiles, which were confirmatory even 
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after exclusion of several subgroups. One could speculate that other risk factors, like physical 
activity, nutrition and psychosocial factors, for which no adjustments could be made, may 
have contributed to this distribution[47, 48]. Further, use of antihypertensives or genetic 
differences could account for the differences in this population.  
 
A French group investigated AASI in terms of a composite endpoint (unspecified 
cardiovascular death, non-cardiovascular death, and cardiovascular events) in 440 
hypertensive patients without a history of cardiovascular disease, referred to a clinic for 
antihypertensive treatment.  Mean follow-up was 70 ± 39 months and a composite of 62 
events were recorded.  AASI was directly compared to the QKD interval[13], which is 
derived from the time between the QRS-wave on the electrocardiogram and the detection of 
the last Korotkoff sound during deflation of the cuff in 24-h BP monitoring.  This value is 
inversely related to arterial stiffness.  In age adjusted analysis, participants in the highest 
tertile vs. the lowest tertile of AASI had a RR of 2.8 (95%CI 1.3-5.8, P=0.01). For the QKD 
the RR was 6.9 (95% CI 2-23) in the lowest vs. the highest tertile.  When age and 24-h PP 
were included in the model, only QKD remained significantly (RR 4.7, 95%CI 1.4-16, 
P=0.04) linked to the composite endpoint.  Regrettably, no continuous analysis was present 
for the risk estimations, no sensitivity analyses were made for cardiovascular disease and no 
statistical test was provided to compare the QKD to the AASI. 
 
Viewpoints and future of AASI  
O’Brien stressed in an editorial that AASI extends the usefulness of ABPM[49]. Besides 
providing prognostic information through circadian blood pressure variation, assessment of 
white coat and masked hypertension, additionally arterial stiffness could be determined in 
assessing cardiovascular risk. 
 
A lively debate was initiated whether the AASI purely reflected arterial stiffness or 
additionally other entities[16, 32, 33, 50-53]. Physiological assumptions were used to rewrite 
AASI in a complex formula (AASI=1-(3-T/τ) / (3+2T/τ) = (T/ τ) / (1+2T/3τ)[53], with T as R-
R interval of the heart and τ as aortic decay time in diastole. The conclusion of this 
mathematical approach, was that AASI was not only a measure of arterial stiffness, but also 
dependent on systemic peripheral resistance, heart period and blood pressure. Therefore the 
authors stated that AASI was a ventriculo-arterial coupling factor, rather than an exclusive 
measure of arterial stiffness.  Benetos and Lacolley considered the fact that peripheral 
resistance varies over the day[54], hereby influencing AASI and diminishing its ability to 
determine arterial stiffness. Mean arterial pressure, a rough marker of small artery resistance, 
predicts stroke better than PP, which predicts cardiac events better. In this line of thinking the 
authors hypothesised that the possible influence of small artery resistance on AASI is the 
reason why it is more predictive for stroke than cardiac events.  
 
Possible future work on AASI might include the assessment of other confounders in the 
determination of AASI. An overview of the literature depicts important differences in mean 
AASI, which can not be entirely attributed to determinants like age, sex, cardiovascular 
history, hypertensive and diabetic status and arterial pressure[55]. Other factors, like study 
set-up and methods for determining AASI, could possibly account for these differences.  
Therefore, AASI determination should be standardized. After doing so, cut-off values for 
AASI should be created in different sex, ethnicity and age.  AASI should be tested 
prospectively, with sensitivity analyses using cut-off values for the goodness of fit of the 
regression line (r²), or other modifications.  These developments could further refine AASI’s 
prognostic quality.  Further, it should be investigated if AASI has additional value in clinical 
decision making, in different populations and patients and different disease conditions.  
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Finally, it should be investigated, if the AASI is influenced by treatment, and if this is in 
accordance with improved (cardiovascular) outcome.  Only in this way, AASI could develop 
into a stable, firmly rooted marker of cardiovascular risk. 
Perspectives  
Recently, AASI was introduced as a new indirect marker of arterial stiffness[5], which can 
easily be computed from 24 hour ABPM and does not necessitate any extra equipment or 
observer training.  In prospective and cross-sectional studies, AASI proved to predict total 
cardiovascular mortality, fatal and non-fatal stroke and target organ damage, over and beyond 
classical risk factors[5, 22, 23, 27, 40, 41, 56].  AASI proved to be significantly related to 
other measures of arterial stiffness, and complementary to the other measures in providing 
cardiovascular risk[5, 27]. Further standardization and refinement could extend the AASI into 
an important marker in cardiovascular risk estimation.  
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Abstract 
 
Background We studied the repeatability of the ambulatory arterial stiffness index (AASI), 
which can be computed from 24-h blood pressure (BP) recordings as unity minus the 
regression slope of diastolic on systolic BP. 
 
Methods One hundred and fifty-two hypertensive outpatients recruited in Nijmegen (mean 
ageU46.2 years; 76.3% with systolic and diastolic hypertension) and 145 patients enrolled in 
the Systolic Hypertension in Europe (Syst-Eur) trial (71.0 years) underwent 24-h BP 
monitoring at a median interval of 8 and 31 days, respectively. We used the repeatability 
coefficient, which is twice the SD of the within-participant differences between repeat 
recordings, and expressed it as a percentage of four times the SD of the mean of the paired 
measurements. 
 
Results Mean AASI (crude or derived by time-weighted or robust regression) and 24-h pulse 
pressure (PP) were similar on repeat recordings in both cohorts. In Nijmegen patients, 
repeatability coefficients of AASI and PP were ≈50%. In Syst-Eur trial patients, repeatability 
coefficient was ≈60% for AASI and ≈40% for PP. For comparison, repeatability coefficients 
for 24-h systolic and diastolic BP were ≈30%. Differences in AASI between paired recordings 
were correlated with differences in the goodness of fit (r2) of the AASI regression line as well 
as with differences in the night-to-day BP ratio. However, in sensitivity analyses stratified for 
type of hypertension, r2, or dipping status, repeatability coefficients for AASI did not widely 
depart from 50 to 60% range. 
 
Conclusion Estimates of mean AASI were not different between repeat recordings, and 
repeatability coefficients were within the 50–60%range. 
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Introduction 
Increased arterial stiffness of the large arteries predicts cardiovascular complications over and 
beyond blood pressure (BP) and classical cardiovascular risk factors [1]. Nevertheless, risk 
stratification based on arterial stiffness remains underused in clinical practice because most 
techniques to measure arterial properties require expensive equipment and highly trained 
observers. We recently proposed the ambulatory arterial stiffness index (AASI) as a measure 
reflecting arterial stiffness [2,3]. This novel index, defined as one minus the regression slope 
of diastolic on systolic BP in individual subjects, can be determined from 24-h ambulatory BP 
recordings [2,3]. To date, several cross-sectional studies [4,5] and at least three prospective 
cohort studies [3,6,7] demonstrated an association of AASI either with signs of target organ 
damage in never-treated hypertensive patients [4] or with the incidence of cardiovascular 
mortality and morbidity[3,6,7]. When adjusted for pulse pressure (PP) [3,6,7] or aortic pulse 
wave velocity [8], AASI remained predictive, in particular of stroke. 
 
To our knowledge, no previous publication has addressed the reproducibility of AASI as 
determined from repeat ambulatory BP recordings. We investigated the reproducibility of 
AASI in patients with systolic and/or diastolic hypertension recruited in Nijmegen and in 
older patients with isolated systolic hypertension enrolled in a substudy to the Systolic 
Hypertension in Europe (Syst-Eur) trial.  
 
Methods 
 
Study population 
Patients referred to the outpatient clinic of the University Medical Centre St Radboud, 
Nijmegen, the Netherlands[9], and patients enrolled in the substudy on ambulatory BP 
measurement to the Syst-Eur trial [10] qualified for the present analysis, if they had 
undergone repeat 24-h ambulatory recordings within 2 months, while being untreated [9,10] 
or minimally treated [9] with no change in treatment status between the first and repeat 
recording. 
 
Nijmegen cohort 
At the Nijmegen outpatient clinic, doctors discontinued BP-lowering drugs in newly referred 
patients, except when there was a compelling indication, such as the use of b-blockers in 
patients with angina pectoris (‘minimal treatment’). The office BP was then reassessed by 
obtaining three consecutive measurements at two to three follow-up visits. Of 1325 
consecutive patients attending the Nijmegen clinic, 275 underwent repeat ambulatory BP 
measurement within 2 months. Of those, we excluded 33 (12.0%) from analysis because their 
treatment status changed between the first and repeat recording, and 56 (20.4%) because over 
the whole day the mean interval between the ambulatory BP readings was shorter than 15 min 
or longer than 45 min. 
 
The Systolic Hypertension in Europe trial cohort 
Previous publications describe the protocol of the Syst-Eur trial in detail [10]. Eligible 
patients were aged 60 years or older. They had a sitting BP ranging from 160 to 219mmHg 
systolic and less than 95mmHg diastolic. The standing systolic BP had to be at least 
140mmHg. Of 837 patients [10] enrolled in the substudy on ambulatory BP monitoring, 153 
(18.3%) had repeat recordings within 2 months, while taking placebo. 
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Blood pressure measurement 
Trained observers measured the patients’ office BP at repeated visits. To describe the 
patients’ conventional BP, we used the average of six to nine readings (three readings at two 
to three visits) in the Nijmegen cohort [9] and the average of six readings (two readings at 
three visits) in Syst-Eur trial patients [10]. For the definition of hypertension in the sensitivity 
analyses, we applied current guidelines [11]. Isolated systolic hypertension was a BP of 
140mmHg systolic or higher with diastolic BP below 90mmHg. 
 
For analysis,weconsideredambulatoryBPrecordings with the interval between successive 
readings programmed at intervals from 15 to 30 min during daytime and from 30 to 60 min 
during nighttime. We only analysed recordings with at least five readings between midnight 
and 06:00 h. In addition, we required that the recordings included at least 15 daytime 
readings. On the basis of these quality criteria, we excluded 34 patients from the Nijmegen 
cohort (12.4%) and eight Syst-Eur trial patients (5.2%). Thus, the number of patients analysed 
totalled 297, that is 152 patients from Nijmegen and 145 Syst-Eur trial patients. 
 
The validated monitors used in Nijmegen were the auscultatory Oxford Medilog (Oxford 
Medical Systems Ltd, Oxford, UK [12]) in 54 patients (35.5%), the oscillometric Mobil O 
Graph (I.E.M., Stolberg, Germany [13]) in 43 patients (28.3%), and the oscillometric 
SpaceLabs 90207 (SpaceLabs Inc., Redmond, Washington, USA [14]) in 55 patients (36.2%). 
The monitors fitted to Syst-Eur trial patients were the oscillometric SpaceLabs 90202 [14] or 
90207 [15] in 49 patients (35.5%) and 78 patients (56.5%), respectively, and the auscultatory 
TakedaTM2420 (A&D, Tokyo, Japan [16]) in 11 patients (3.7%). 
 
The same SAS macro processed all ambulatory recordings, which stayed unedited. For the 
sensitivity analysis involving dipping status, we defined daytime and nighttime in both 
cohorts as the intervals ranging from 10:00 to 20:00 h and from midnight to 06:00 h, 
respectively [17,18]. We weighted the individual means of the ambulatory BP by the interval 
between readings. 
 
From individual 24-h recordings, we computed the regression slope of diastolic on systolic 
BP. We defined the AASI as one minus the regression slope (crude AASI). We used the 
coefficient of determination (r2) as a measure of the goodness of fit of the AASI regression 
line. We also computed AASI, using time-weighted or robust regression (least trimmed 
squares). 
 
Statistical methods 
For database management and statistical analysis, we used SAS software (version 9.1.3; SAS 
Institute, Cary, North Carolina, USA). For comparison of means, we applied the Student’s t-
test for paired or unpaired observations, as appropriate. For comparison of proportions 
between groups, we applied the x2-statistic. Statistical significance was an a-level of 0.05 on 
two-sided tests. 
 
We assessed the agreement between paired ambulatory recordings by Bland and Altman’s 
approach [19,20]. For the evaluation of reproducibility, we used the repeatability coefficient, 
which is twice the SD of the withinparticipant differences between repeat recordings (repeat 
minus first) [21]. This measure is specifically designed to evaluate within-participant 
reproducibility. To take into consideration the normal biological variation of a measure, we 
expressed the repeatability coefficient as a percentage of close to maximal variation (four 
times the SD of the mean of the duplicate measurements). By this, a reasonable comparison of 
the repeatability of different measures can be undertaken. 
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We also applied single and multiple regression analysis. In stepwise regression, we set the P-
value for independent variables to enter and to stay into models at 0.15. We studied the 
coincidence of regression lines by analysis of covariance, as described by Kleinbaum et 
al.[22]. 
 
Results 
 
Patient characteristics 
Table 1 lists the main clinical characteristics of the two study cohorts. Both groups of patients 
included nearly 60% of women. Compared with Syst-Eur trial patients, the Nijmegen patients 
were younger (46.2 versus 71.0 years), taller (170 versus 162 cm), heavier (77.9 versus 69.4 
kg), but had similar body mass index (26.8 versus 26.4 kg/m2). 
 
 
 
In line with the recruitment criteria based on office BP, Syst-Eur compared with Nijmegen 
patients (Table 1) had higher systolic BP (178.4 versus 168.6mmHg) on conventional 
measurement, but lower diastolic BP (85.4 versus 101.2mmHg). A history of cardiovascular 
disease was more prevalent among the older Syst-Eur trial patients (30.3 versus 14.5%). Table 
2 shows that Syst-Eur trial patients on average had higher AASI than Nijmegen patients, 
irrespective of the way AASI was computed (all P<0.008). 
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Repeatability of ambulatory measurements 
Figure 1 provides Bland and Altman plots for the crude AASI in Nijmegen and Syst-Eur trial 
patients, respectively. Detailed repeatability statistics appear in Table 2. 
 
ijmegen cohort 
l between the first and repeat ambulatory recording was 8 days [range=4–
 
nd 
d 
 
 
N
The median interva
60 days; interquartile range (IQR)=7–15 days]. AASI, time-weighted AASI, robust AASI and
24-h PP were similar on first and repeat measurement (P≥0.10; Table 2). The 24-h diastolic 
BP was significantly lower on repeat than first recording (−1.43mmHg; P=0.009) with a 
similar trend for the 24-h systolic BP (−1.51mmHg; P=0.09). The repeatability of AASI a
24-h PP expressed as a percentage of the near maximal variation in these measurements (the 
interval corresponding with _2SD around the mean of the repeat recordings) ranged from 
approximately 45 to 55%. The corresponding repeatability estimate for the 24-h systolic an
diastolic BP was around 30% (Table 2). 
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In Nijmegen patients, the differences between repeat minus first crude AASI correlated 
; 
ut 
, 
he Systolic Hypertension in Europe trial patients 
atory recording was 31 days (range=2–
to 
 Syst-Eur trial patients, the differences between repeat minus first crude AASI correlated 
). 
s 
omparison of repeatability between Nijmegen and the Systolic Hypertension in Europe 
ferences in the estimates of repeatability among paired recordings between 
 
ensitivity analyses 
ity analyses, according to the type of hypertension, dipping status, and 
we 
iscussion 
ing of our study was that AASI as determined from ambulatory BP recordings 
 
tter 
inversely with the differences in the goodness of fit of the AASI regression line (r=−0.77
P<0.0001) and the changes in the night-to-day ratios of diastolic BP (r=−0.29; P=0.0003), b
not systolic BP (r=−0.12; P=0.14). In multiple regression analyses, with mutual adjustments 
for these covariates, the corresponding partial correlation coefficients were −0.76 (P<0.0001)
−0.25 (P=0.003), and −0.25 (P=0.002), respectively. 
 
T
The median interval between the first and repeat ambul
57 days; IQR=28–35 days). AASI, time-weighted AASI, robust AASI, 24-h PP and 24-h 
systolic and diastolic BP were similar on first and repeat measurement (P≥0.09; Table 2). 
Estimates of repeatability expressed as a percentage of near maximal variation were close 
60% for AASI, around 40% for the 24-h PP, and approximately 30% for 24-h systolic and 
diastolic BP (Table 2). 
 
In
inversely with the differences in the goodness of fit of the AASI regression line (r=−0.57; 
P<0.0001) and those in the night-to-day ratios of diastolic BP (r=−0.25; P=0.003) with a 
similar trend for the differences in the night-to-day ratio of systolic BP (r¼_0.15; P¼0.07
The corresponding partial correlation coefficients with mutual adjustment for these covariate
were −0.55 (P<0.0001), −0.30 (P=0.001), and −0.23 (P=0.006), respectively. 
 
C
trial patients 
None of the dif
Nijmegen and Syst-Eur trial patients reached significance for any of the variables listed in 
Table 2 (P≥0.10). For the sensitivity analyses, we therefore pooled Nijmegen and Syst-Eur 
trial patients. The regression lines for the differences among the paired recordings in crude 
AASI versus those in the goodness of fit of the AASI regression lines were not coincident in
Nijmegen and Syst-Eur trial patients because the slope was steeper in the Nijmegen patients 
(P=0.008; Fig. 2). In contrast, the regression lines for the differences among the paired 
recordings in crude AASI versus those in the night-to-day BP ratio were coincident (P≥0.70; 
Fig. 3). 
 
S
Table 3 shows sensitiv
the r2 of the AASI regression line. In these analyses, we defined nondipping as a diastolic 
night-to-day BP ratio higher than 0.90. For the goodness of fit of the AASI regression line, 
used 0.36 as the cut-off threshold, because the association of AASI with four determinants of 
arterial stiffness increased curvilinearly with r2, with most of the improvement in the 
association occurring above a value of r2 of 0.36. 
 
D
The key find
repeated within an interval of 2 months had moderate reproducibility. Mean values of AASI
were similar in paired recordings. The repeatability coefficient, which is a measure for 
reproducibility within individual participants, was within the 50–60% range, which is be
than for other parameters derived from the diurnal BP profile[23]. 
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For comparison, the repeatability coefficients of the 24-h systolic and diastolic BPs in the 
current study were close to 30%, but diastolic BP in the Nijmegen cohort showed significant 
regression to the mean with lower values of the 24-h diastolic BP on repeat recording. PP, the 
QRS-Korotkoff-delay (QKD) index standardized to a systolic BP of 100 mmHg and a heart 
rate of 60 beats per minute (QKD100–60), the systolic augmentation index and pulse wave 
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velocity are other non-invasive measures of arterial stiffness. Stergiou et al. [24] investigated 
the reproducibility of 24-h PP from repeat ambulatory BP recordings in 133 untreated 
hypertensive patients. The SD of the paired differences was 4mmHg compared with 7 and 
9mmHg in our Nijmegen and Syst-Eur trial patients, respectively. In Stergiou’s study, the 24-
h PP averaged (±SD) 47.5±7.4 and 46.4±7.9mmHg on first and repeat measurement. The 
nonreported P-value for the difference (−1.1mmHg) was therefore 0.0015 [1.1/(4/1330.5)]. We 
estimated that in Stergiou’s study the repeatability coefficient expressed as a percentage of 
near maximal variation was approximately 27% [24], which at first sight seems somewhat 
smaller than in our Syst-Eur trial patients (37%). However, in 16 of Stergiou’s patient who 
were older than 60 years, the SD of the paired differences in the 24-h PP was 5mmHg [24], 
which would have yielded a repeatability estimate almost identical to that in our Syst-Eur trial 
cohort. 
 
osse et al. [25] evaluated the reproducibility of QKD100–60 and AASI in 38 volunteers, 
 ms; 
tion 
s 
 
atsui et al. [26] studied the reproducibility of the brachial-ankle pulse wave velocity 
 
 
ere 
 
 
G
who were selected from a cohort of 469 patients and who underwent repeat ambulatory 
recordings within 2 weeks. According to the French group [25], QKD100–60 (mean=224
coefficient of variation=4%) had a better reproducibility than AASI (mean=0.60; coefficient 
of variation=25%). Coefficient of variation is the SD of the differences between paired 
measurements (SDD) divided by the mean of all measurements. The coefficient of varia
does not account for the possible range of biological variation in the two ambulatory measure
of arterial stiffness. We, therefore, expressed repeatability (twice SDD) as a percentage of 
near maximal variation in the measurements as given by four times the SD. Had the French
investigators [25] expressed reproducibility in this way with the application of a proper test 
statistic, their results and conclusions could possibly have been different. 
 
M
(baPWV) and the carotid augmentation index (cAIX) in 103 hypertensive patients. The
interval between the repeat measurements was 4 weeks. They measured baPWV, using a
volumeplethysmographic device with four cuffs fitted with oscillometric sensors, which w
wrapped around the upper arms and ankles and automatically and simultaneously inflated. 
The measurement of cAIX was done by multielement applanation tonometry. The Japanese
investigators used the correlation between paired measurements as index of agreement [26]. 
The correlation coefficients were 0.89 for abPWV and 0.87 for cAIX. In our study, the 
correlation coefficients for AASI ranged from 0.52 to 0.61. In the absence of statistics 
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specifically designed to assess repeatability [26], the Japanese results are difficult to int
Moreover, the Japanese study was done under highly standardized laboratory conditions, 
using a fully automated technique, whereas we measured AASI over 24 h during the usual
daily activities of our patients. 
 
erpret. 
 
 our current study, we found that the differences between repeat minus first AASI correlated 
d 
ents. 
d 
ur 
P 
 
 the present analysis, differences in the goodness of fit of the AASI regression line had an 
I 
f 
, 
he results of our study have to be interpreted in the context of its potential limitations. First, 
als 
ory 
pute 
 conclusion, estimates of group mean AASI were not different between repeat recordings. 
s were 
 
In
inversely with the differences in the night-to-day ratios of diastolic BP. Two recent reports 
already reported on AASI’s dependency on the nocturnal BP fall [27,28]. We also confirme
the inverse association between AASI and the night-to-day BP ratio in 1325 hypertensive 
patients referred to the Nijmegen clinic for ambulatory BP monitoring [29]. Several 
investigators demonstrated poor reproducibility of dipping status in hypertensive pati
Hernandez-del Rey [30] performed repeat ambulatory monitoring on 2 consecutive days an
noticed that of 611 patients 147 (24.1%) participants switched from a nighttime dipper to 
nondipper or vice versa. Other studies [31] reported similar findings. When we stratified o
study sample according to the consistency of dipping status, the repeatability coefficients 
expressed as a percentage of maximal variation were not substantially different. Thus, 
although there is a significant inverse association between AASI and the night-to-day B
ratio, this relation does not affect intra-individual repeatability of AASI to a large extent in
stratified analyses. 
 
In
impact on the repeatability of AASI. Similar to recent observations by Gavish et al. [32], we 
demonstrated in 7604 participants enrolled in the International Database on Ambulatory BP 
monitoring in relation to Cardiovascular Outcomes (IDACO [33]) that the association of 
AASI with four main determinants of arterial stiffness (age, height, 24-h mean arterial 
pressure and 24-h heart rate) increased curvilinearly with the goodness of fit of the AAS
regression line with most of the improvement in these associations occurring when the r2 o
the AASI regression line was 0.36 or higher. In line with these still unpublished observations
the repeatability of AASI was 68% and 44% in patients who in repeat recordings consistently 
had an r2, respectively, below or above this 0.36 threshold. 
 
T
the Nijmegen cohort included 11.8% who were on antihypertensive medications. However, 
treatment remained unchanged between the first and repeat recording. Second, we did not 
standardize the ambulatory BP recordings across centres in terms of device type and interv
between readings. However, within patients, we used the same monitor and intervals in the 
first and repeat recordings. Moreover, we did not find any significant differences in 
repeatability between the five device types or between oscillometric versus auscultat
machines. To minimize heterogeneity, we additionally used the same programme to com
BP means and used time-weighted and robust regression. 
 
In
Within individual participants, the repeatability coefficients of AASI expressed as a 
percentage of near maximum variation were within the 50–60% range. These finding
consistent in older patients with isolated systolic hypertension and in a younger patient group
with predominantly mixed hypertension. To our knowledge, this study is the first to report on 
the repeatability of AASI in hypertensive patients. 
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Putting a spin on the ambulatory arterial stiffness index 
 
We defined the ambulatory arterial stiffness index (AASI) as unity minus the slope of 
diastolic on systolic blood pressure [1,2]. When determined from 24-h ambulatory blood 
pressure recordings, AASI reflects the dynamic relation between diastolic and systolic blood 
pressure throughout the day [1]. According to physiological concepts already proposed in 
1914 [3], the stiffer the arterial tree, the closer the regression slope and AASI are to zero and 
one, respectively.  
 
Since our original publications [1,2], several investigators have published on AASI. In the 
February issue of the Journal of Hypertension two articles [4,5] and one editorial comment [6] 
addressed the merits and limitations of AASI as a simple surrogate measure of arterial 
stiffness. Gavish and colleagues [4] proposed the use of the so-called symmetrical regression 
instead of ordinary regression to compute AASI. Baumann and colleagues [5] misread our 
publications [1,2] and computed AASI from the regression slope of systolic on diastolic blood 
pressure.  
 
The study by Gavish et al. [4] included a selected group of 140 referred hypertensive patients, 
of whom 76 (54.3%) were on antihypertensive drug treatment. The study by Baumann et al. 
[5] included 106 potential kidney donors, of whom 31 were hypertensive (29.2%), and 22 
(20.8%) were treated. The small sample size, selection, and the use of antihypertensive drugs 
make a reasonable interpretation of the results impossible. Our original publications derived 
conclusions from a considerably larger sample size and included a randomly selected Chinese 
population (n=348 [1]) and untreated hypertensive patients (n=11291 [2]).  
 
Both publications [4,5] also built part of their argument on the correlation of AASI with pulse 
pressure. These associations are spurious because the dependent and independent variables 
are both calculated from the same systolic and diastolic blood pressure readings. 
Nevertheless, while keeping this potential flaw in mind, in our Belgian cohort (n=552 [7]), the 
correlation with pulse pressure was stronger for AASI than for symmetrical AASI (0.50 vs 
0.17; P<0.001). Moreover, the correlation between AASI and pulse pressure was almost 
identical in 428 diastolic dippers and 124 diastolic nondippers (0.44 vs. 0.44; P¼0.98). 
Baumann and co-workers [5] only had about 19 nondippers to investigate these associations.  
 
The studies by Gavish et al. [4] and Baumann et al. [5] spin an issue first raised by Schillaci 
and co-workers [8], and subsequently confirmed by us [9], that AASI is inversely correlated 
with night-time dipping. According to the experts [10], aortic pulse wave velocity (PWV) is 
the gold standard for measuring arterial stiffness. In 166 Chinese volunteers [1], in whom we 
measured AASI and PWV within 24 h, the correlation coefficients with the percentage fall in 
nocturnal blood pressure were similar for PWV and AASI [MTEST statement in the PROC 
REG procedure of the SAS package, version 9.1.3 (SAS Institute Inc., Cary, North Carolina, 
USA); P>0.54], amounting to –0.54 and –0.49 for systolic dipping and to –0.56 and –0.57 for 
diastolic dipping. Moreover, AASI was consistently and significantly related to PWV in 99 
diastolic dippers (r=0.27; P=0.007) as well as in 67 diastolic nondippers (r=0.41; P=0.0005).  
 
We concur with our colleagues [6,10] that AASI is an indirect measure of arterial stiffness 
and must be under the influence of other haemodynamic factors such as heart rate and the 
velocity of left ventricular ejection. However, we strongly believe that with regard to AASI, 
researchers should now leave the circular argumentation and the mathematical hair-splitting. 
What clinically counts at the end of the line is that AASI improves the risk stratification based 
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on ambulatory blood pressure monitoring. To date, several cross-sectional studies [11,12] and 
at least three prospective cohort studies [2,13,14] have demonstrated the association of AASI 
with either the signs of target organ damage in never-treated hypertensive patients [11] or the 
incidence of cardiovascular mortality and morbidity [2,13,14]. When adjusted for pulse 
pressure [2,13,14] or PWV [15], AASI remained predictive, in particular of stroke. 
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Reply 
 
Marcus Baumann 
Liu Dan  
Jens Nürnberger 
Uwe Heemann 
Olier Witzke 
 
The authors point in their comment to the fact that we computed ambulatory arterial stiffness 
index (AASI) based on the regression slope of systolic–diastolic blood pressure. If we 
computed our data according to the original work of Li et al. [1] and Dolan et al. [2], the 
correlation between diastolic dipping and AASI remained significant (r=−0.28; P=0.006). 
Moreover, the difference between nondipper and dipper with respect to AASI remained 
significant (mean±SD; nondipper, 0.36±0.14; dipper, 0.29±0.11; P=0.01).  
 
Another point made by the authors was the heterogeneity of our group including 
normotensive and hypertensive subjects. Therefore, we computed our data according to the 
original work of Li et al. [1] and Dolan et al. [2], excluding our 31 hypertensive individuals. 
Again, the correlation between diastolic dipping and AASI remained significant; however, to 
a lesser extent (r=−0.23; P=0.03). Moreover, the difference between nondipper and dipper 
with respect to AASI remained significant for the normotensive cohort (mean±SD; nondipper, 
0.35±0.15; dipper, 0.29±0.11; P=0.04). Therefore, our data are in line with the work of 
several groups including the authors [3].  
 
Schillaci et al. [4] pointed out hemodynamic factors potentially influencing AASI. Similarly, 
our discussion focused on the potential role of autonomic nerve function as a cause of dipping 
[5] and thus as factor influencing AASI. We believe that understanding factors influencing 
AASI, such as the autonomic nerve function, may be useful for the further interpretation of 
AASI, as we fully agree with the authors that AASI improves the risk stratification based on 
ambulatory blood pressure monitoring. 
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Reply 
 
Giuseppe Schillaci 
Gianfranco Parati 
 
We concur with Adiyaman et al. [1] that the ultimate testing ground for ambulatory arterial 
stiffness index (AASI), as for any newly proposed index of target organ damage, is 
represented by its ability to predict cardiovascular complications over and above the 
prognostic power of established risk factors and markers of organ damage. In this regard, 
several of the authors of the study by Adiyaman et al. should be commended for their 
tremendous amount of work aimed at elucidating the prognostic contribution of AASI as well 
as its limitations [2–5]. Overall, in different clinical settings, AASI was found to be an 
independent predictor of stroke [2–4] and cardiovascular mortality [2,3] but not of 
cardiovascular events [5] and coronary heart disease [3,5].  
 
On the contrary, we are certain that Adiyaman et al. will agree with our view that the actual 
physiological significance of AASI is far from being clarified [6]. Recently published data [7] 
confirm our finding [8] that, at least in hypertensive individuals, AASI may not be considered 
as a surrogate marker of arterial stiffness. In 515 volunteers examined by us [8,9] and in 824 
individuals observed by Jerrard-Dunne et al. [7], the positive correlation between AASI and 
carotid-femoral pulse-wave velocity, which is considered as a direct measure of aortic 
stiffness, was considerably weaker than that reported earlier in a smaller cohort of 166 
predominantly normotensive Chinese individuals [10] and was lost following adjustment for 
age [7–9]. Overall, AASI was found to be a poor predictor of aortic pulse-wave velocity, with 
95% prediction limits for the AASI to predict pulse-wave velocity as wide as ±4.18 m/s [7].  
 
We had previously shown that this lack of association between AASI and established, though 
indirect, measures of arterial stiffness might be in part related to the strong, spurious inverse 
association between AASI and day–night diastolic, and consequently systolic, blood pressure 
(BP) reduction [8]. It has been suggested that such a strong relation may be due to the fact that 
nocturnal BP fall might be in itself a correlate of arterial stiffness [1]. However, the absence 
of a significant relationship between nocturnal BP fall and aortic pulse-wave velocity in two 
large, independent studies on hypertensive individuals [7,8] makes this hypothesis unlikely. 
The paper by Gavish et al. [11] is a first attempt to eliminate the limitations characterizing 
such artefactual relationship by using a symmetrical regression model.  
 
In conclusion, the development of AASI [2,10] unquestionably represents a theoretically 
attractive means of easily exploring arterial stiffness without the use of dedicated, operator-
dependent equipment. However, given the present uncertainties regarding the meaning and 
the clinical importance of AASI, we believe that any contribution toward a better 
understanding of AASI should not be considered as a pedant hair-splitting exercise but as an 
attempt to more deeply appreciate the mechanisms and the clinical significance of the 
dynamic features characterizing the relation between systolic and diastolic BPs. 
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The possibility that the observed linear relationship between repeatedly measured systolic and 
diastolic blood pressures can provide parameters that express mechanical properties of arteries 
and have clinical significance is exciting. Schillaci and Parati [1] expressed the increasing 
interest in this phenomenon by devoting an editorial to two articles on this topic [2,3]. This 
correspondence is a response to the letter by Staessen and colleagues, who addressed these 
publications [1–3]. We raise basic questions related to definition, determination and 
physiological origins of selected parameters in an attempt to widen the interest in this newly 
emerging topic, beyond arterial stiffness index (AASI) and arterial stiffness. 
 
Parameter definition and determination 
The linear relationship between variations in systolic and diastolic pressures over time is 
known for office measurements with follow-up over years in the Framingham study [4]; 24-h 
ambulatory measurements [5–7] and can be clearly demonstrated in home measurements over 
months and in beat-by-beat measurements within few minutes. Therefore, this phenomenon is 
not limited to ambulatory blood pressure measurements, suggesting that the dipping status 
may be important mainly as a generator of variability range, as already pointed out by 
Schillaci et al. [8]. The relevant parameter is the slope of the regression line associated with 
either systolic versus diastolic plot (‘S–D slope’) or with diastolic versus systolic plot (‘D–S 
slope’), where AASI is defined by 1_[D–S slope]. The S–D and D–S slopes are reciprocal to 
each other when calculated by symmetric regression (but not with standard regression) [2] and 
can be referred collectively as ‘slope’. The importance of using appropriate regression 
procedure for ‘slope’ determination cannot be underestimated when correlations with clinical 
and demographic variables are found to depend strongly on the regression method applied.  
 
‘Slope’ determination 
by standard regression, as commonly used, leads to flattening of a strong dependence on age 
and generates a negative correlation between AASI and systolic dipping, as observed by 
Schillaci et al. [8] and Bauman et al. [3]. This correlation turns weak and positive upon using 
symmetric regression [2]. The underlying intriguing phenomenon is the observed relationship 
between systolic–diastolic correlation coefficient r and systolic or diastolic dipping [2]. In 
fact, neither AASI nor S–D slope were found to depend on r when determined by symmetric 
regression [2].  
 
Underlying physiological principles 
Real arteries cannot be described as simple elastic tubes characterized by a single value of 
arterial stiffness. Instead, arterial stiffness increases for greater pressure. This ‘arterial-
stiffening’ property that sharply increases after age 50–60 years reflects the nonlinear 
pressure–diameter (or volume) relationship [9]. As a result, arterial stiffness, as well as pulse-
wave velocity, may undergo large variations between systolic and diastolic pressures during 
the cardiac cycle [10,11] and both are expected to decrease with nocturnal blood pressure fall. 
In contrast, ‘slope’ is by definition a parameter that is independent of pressure over the entire 
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pressure range. The fact that ‘slope’ measured by 24-h ambulatory blood pressure monitoring 
displayed independence of mean arterial pressure in a tested population of 140 patients [2] 
casts further doubts about the justification of associating AASI with arterial stiffness, in spite 
of its observed correlation with pulse-wave velocity [6,8]. 
 
The possibility that the ‘slope’ expresses the arterial stiffening during the cardiac cycle and 
not arterial stiffness is challenging. Support for this view comes from a theoretical derivation 
by Gavish [12] showing that S–D slope expresses quantitatively the relative increase of 
arterial stiffness during the systole that appears independent of pressure [2], as well as from 
important work by Conway and Smith [13] and Abboud and Huston [14] that attempted to 
characterize arterial stiffening by a parameter called ‘arterial rigidity index’. These 
researchers measured beat-to-beat intra-arterial pressure in response to inhalation of amyl 
nitrite. This parameter increased with age and showed good potential as an index for arterial 
aging and degenerative vascular disease. Arterial stiffening was found to reflect increased 
loading of the collagen tissue in the vascular wall [15]. Increased collagen/elastin ratio that 
characterizes vascular aging and pathology may lead to increase in both stiffness and 
stiffening. This pressure-independent structural aspect may explain why AASI positively 
correlates with pulse wave velocity and expresses arterial stiffening but not stiffness. The 
present view is consistent with the finding of Dolan et al. [7] that AASI is a predictor of 
cardiovascular mortality in hypertensive patients. 
 
In conclusion, in searching for the clinical significance and the physiological origin of the 
linear relationship between systolic and diastolic pressures, it is necessary to expand the view 
beyond ambulatory blood pressure measurements and arterial stiffness. The possibility of 
characterizing the nonlinear mechanical properties of arteries using pressure-independent 
parameters derived from blood pressure measurements is stimulating. 
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Dipping Deeper Into the Ambulatory Arterial Stiffness Index 
 
To the Editor: 
Methodologic and conceptual issues seriously weaken the conclusions of Schillaci et al1 on 
the ambulatory arterial stiffness index (AASI), as published in the May 2007 issue of 
Hypertension. 
 
Schillaci et al1 reported that, in 515 untreated patients, AASI depended on the nocturnal 
blood pressure fall. We confirmed this observation in our Flemish population study2. The 
correlation coefficients were similar to those in the report by Schillaci et al1: −0.24 versus 
−0.28 for systolic blood pressure (2-sided P value computed by Fisher’s Z transformation, 
0.42), and −0.39 versus −0.46 for diastolic blood pressure (P=0.11). However, the ambulatory 
recording of 1 of the representative patients of Schillaci et al1 included ≈25 
nighttime and ≈35 daytime readings. The night:day ratio of the number of blood pressure 
readings was therefore 0.71, whereas in our studies,2,3 it was ≈0.30. As shown in the 
Figure, this ratio influences estimates of AASI. Furthermore, in our 166 Chinese volunteers,3 
in whom we measured AASI and pulse wave velocity (PWV) within 24 hours, the correlation 
coefficients with the percentage fall in nocturnal blood pressure were similar for PWV and 
AASI (MTEST statement in the PROC REG procedure of the SAS package, version 9.1.3; 
P>0.54), amounting to −0.54 and −0.49 for systolic dipping and to −0.56 and −0.57 for 
diastolic dipping. 
 
Schillaci et al1 did not seek survival of AASI in the multivariate-adjusted association with left 
ventricular mass index. In Table 3 of their report,1 they introduced not independent but highly 
intercorrelated predictors, bound to remove AASI from the model. The correlation between 
the daytime systolic pressure and the nocturnal fall in systolic blood pressure is close, because 
computation of the latter requires use of the former. Schillaci et al1 did not report the t-to-
enter for AASI and the variable, probably the daytime systolic blood pressure, that excluded 
AASI to remain in the model. More importantly, Schillaci et al1 failed to demonstrate that, 
with similar adjustments applied as for AASI, the association between left ventricular mass 
index and PWV remained significant. 
 
In line with our first report on AASI,3 Schillaci et al1 found significant (P<0.001) association 
between PWV and AASI, although the correlation coefficient was lower (0.28 versus 0.51; 
P=0.0039). Schillaci et al1 must be aware of Bland and Altman’s4 recommendations for 
assessing concordance between 2 measurements and our analyses complying with these 
recommendations.5 Nevertheless, the Italian investigators did not go beyond reporting a 
correlation coefficient as measure of agreement. Moreover, it is conceptually wrong in the 
assessment of concordance between measurements to adjust for common determinants 
underlying the measured trait. In our Chinese volunteers,3 mean arterial pressure removed the 
association between PWV and AASI. That accounting for common determinants weakens the 
correlation between PWV and AASI actually corroborates that these 2 measurements reflect 
arterial stiffness. 
 
In conclusion, we confirmed that AASI is inversely correlated with the nocturnal fall in blood 
pressure, especially in ambulatory recordings with a disproportionately large number of 
nighttime readings. We concur with the idea that AASI is an indirect measure of arterial 
stiffness.3,5 However, we disagree with inappropriate or unnecessary adjustment in 
regression models,1 and we regret that the information on the correlations of left ventricular 
mass index with AASI and PWV was incomplete.1 
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Although we regret that Adiyaman et al1 misinterpreted some of our results, we are glad to 
see that they agree with the main findings of our study,2 in which we described a strong and 
previously undetected inverse association between ambulatory arterial stiffness index (AASI) 
and day-night blood pressure (BP) fall. Indeed, they were able to replicate our findings in 2 
different cohorts.3,4  
 
Adiyaman et al1 argue that the estimate of AASI may be influenced by the night:day ratio of 
the number of BP readings. However, to support their view, they rely on ambulatory BP 
recordings performed with a very low frequency of nocturnal BP readings. In fact, the 
night:day ratio of the number of BP readings in their study was only ≈0.30 with 26 to 30 
measurements during the day and 8 to 9 measurements at night (see the figure in the letter by 
Adiyaman et al1) because of a longer nocturnal interval between automated measurements. In 
our representative patients (Figure 3 of our article),2 the number of valid BP measurements 
was 34 during nighttime and 57 during daytime (and not ≈25 and ≈35, as erroneously 
indicated by Adiyaman et al1). Such a distribution, rather than including a “disproportionally 
large” number of nocturnal readings, is the desirable result of having BP evenly measured 
every 15 minutes throughout the 24 hours. By avoiding an artificially lower BP sampling 
frequency at night than during the day, in our article the night:day ratio in the number of BP 
readings simply mirrors the physiologically different duration of the nighttime and daytime 
subperiods.  
 
Our demonstration that day-night BP reduction is a major determinant of AASI provides a 
rational explanation for the dependency of AASI on the number of diurnal and nocturnal 
readings. Given that nocturnal diastolic and systolic BP reductions are strongly related to each 
other, the physiological nocturnal BP fall generates a number of nocturnal systolic and 
diastolic BP values, which are considerably lower than the corresponding daytime values. 
This, in turn, increases the regression coefficient of diastolic BP on systolic BP (B) and 
reduces AASI. If the number of nocturnal readings is artificially reduced by adopting longer 
betweenmeasurement intervals at night, this reduces B and increases AASI. As a matter of 
fact, in our cohort, AASI calculated on the basis of daytime readings, thus excluding the 
nocturnal values, was much higher than 24-hour AASI (0.48±0.26 versus 0.31±0.17). In other 
words, we postulate that a low number of nocturnal readings artificially increases AASI, 
irrespective of any association with an increase in arterial stiffness. 
 
Another point raised by Adiyaman et al1 is the high intercorrelation between daytime systolic 
BP and nocturnal fall in systolic BP, which should prevent these variables from being include 
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simultaneously in a multivariate model. This observation is incorrectly made with reference to 
our study, however, in which we included in the same model daytime BP and percentage of 
nocturnal BP fall. In our population, there was indeed no significant correlation between the 2 
variables (r=0.07; P=0.08), and the examined model was found to be free from collinearity 
using standard diagnostic techniques (tolerance: 0.89 to 0.99). 
 
Moreover, Adiyaman et al1 argue that information on the correlation between left ventricular 
mass and pulse wave velocity was incomplete in our article. Indeed, it was completely absent. 
We did not address the association between pulse wave velocity and left ventricular mass 
index simply because this was not the aim of our study. Our observations focused on what 
was the primary target of our study, ie, the actual meaning of AASI. The important result of 
our article was that the previously reported5 association with a common index of organ 
damage, such as left ventricular mass, depends on the shared association with the degree of 
nocturnal BP reduction. 
 
We agree that Bland-Altman plots may give a different and complementary view of the 
concordance between 2 measures, in particular when comparing 2 estimates of the same 
parameter. Conversely, we disagree that a Bland-Altman plot could be helpful to assess 
concordance between AASI and aortic pulse wave velocity. These 2 parameters measure quite 
different biological traits, which are distributed over different numerical ranges. Because data 
of different kind cannot be averaged or subtracted, absolute values of means, differences, and 
coefficients of variation cannot be given in such nondimensional graphs (see Figure 3, panel 
3, in the article by Li et al6). 
 
Finally, we do not agree with Adiyaman et al1 that adjustment for common determinants is 
inappropriate when assessing concordance between a newly proposed and an established trait. 
At least, the confounding effect of age should be taken into account when assessing the 
clinical value of any new surrogate marker of atherosclerosis. In our population, the bivariate 
relation between AASI and aortic pulse wave velocity (r=0.28; P<0.001) lost its significance 
when the effect of age was taken into account (partial r=0.05; P=0.39), not even considering 
the impact of mean arterial pressure and other variables. Although the actual physiological 
significance of AASI needs to be elucidated further, these data confirm our view that, at least 
in untreated hypertensive subjects, AASI may not be considered as a surrogate marker of 
arterial stiffness tout court. 
 
Disclosures 
None. 
 
 
References 
1. Adiyaman A, Boggia J, Li Y, Wang J-G, O’Brien E, Richart T, Thijs L, Staessen JA. 
Dipping deeper into the ambulatory arterial stiffness index. Hypertension. 2007;50:e59–e60. 
2. Schillaci G, Parati G, Pirro M, Pucci G, Mannarino MR, Sperandini L, Mannarino E. 
Ambulatory arterial stiffness index is not a specific marker of reduced arterial compliance. 
Hypertension. 2007;49:986–991. 
 153
3. Staessen JA, Bieniaszewski L, O’Brien ET, Imai Y, Fagard R. An epidemiological 
approach to ambulatory blood pressure monitoring: the Belgian population study. Blood Press 
Monit. 1996;1:13–26. 
4. Li Y, Wang JG, Dolan E, Gao PJ, Guo HF, Nawrot T, Stanton AV, Zhu DL, O’Brien E, 
Staessen JA. Ambulatory arterial stiffness index derived from 24-hour ambulatory blood 
pressure monitoring. Hypertension. 2006; 47:359 –364. 
5. Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi A, Falqui V, Conti N, Tomolillo C, 
Deferrari G, Pontremoli R. Increased ambulatory arterial stiffness index is associated with 
target organ damage in primary hypertension. Hypertension. 2006;48:397– 403. 
6. Li Y, Dolan E, Wang JG, Thijs L, Zhu DL, Staessen JA, O’Brien E, Stanton A. 
Ambulatory arterial stiffness index: determinants and outcome. Blood Press Monit. 
2006;11:107–110. 
 
 154
Part 3   
 
Procession of blood pressure: The Ambulatory Arterial Stiffness Index  
 
Chapter 4.4 
 
Determinants of the Ambulatory Arterial Stiffness Index in 7604 
Subjects From 6 Populations. 
 
Ahmet Adiyaman 
Dirk G. Dechering 
José Boggia 
Yan Li 
Tine W. Hansen 
Masahiro Kikuya 
Kristina Björklund-Bodegård 
Tom Richart 
Lutgarde Thijs 
Christian Torp-Pedersen 
Takayoshi Ohkubo 
Eamon Dolan 
Yutaka Imai 
Edgardo Sandoya 
Hans Ibsen 
Jiguang Wang 
Lars Lind 
Eoin O'Brien 
Theo Thien 
Jan A. Staessen  
 
and on behalf of the International Database on Ambulatory Blood Pressure Monitoring in 
Relation to Cardiovascular Outcomes Investigators 
 
Hypertension 2008; 52(6):1038-1044 
 155
Abstract—The ambulatory arterial stiffness index (AASI) is derived from 24-hour ambulatory 
blood pressure recordings. We investigated whether the goodness-of-fit of the AASI regression 
line in individual subjects (r2) impacts on the association of AASI with established determinants 
of the relation between diastolic and systolic blood pressures. We constructed the International 
Database on the Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (7604 
participants from 6 countries). AASI was unity minus the regression slope of diastolic on systolic 
blood pressure in individual 24-hour ambulatory recordings. AASI correlated positively with age 
and 24-hour mean arterial pressure and negatively with body height and 24-hour heart rate. The 
single correlation coefficients and the mutually adjusted partial regression coefficients of AASI 
with age, height, 24-hour mean pressure, and 24-hour heart rate increased from the lowest to the 
highest quartile of r2. These findings were consistent in dippers and nondippers (night:day ratio 
of systolic pressure ≥0.90), women and men, and in Europeans, Asians, and South Americans. 
The cumulative z score for the association of AASI with these determinants of the relation 
between diastolic and systolic blood pressures increased curvilinearly with r2, with most of the 
improvement in the association occurring above the 20th percentile of r2 (0.36). In conclusion, a 
better fit of the AASI regression line enhances the statistical power of analyses involving AASI 
as marker of arterial stiffness. An r2 value of 0.36 might be a threshold in sensitivity analyses to 
improve the stratification of cardiovascular risk. 
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In 1914, MacWilliam and Melvin1 already noticed that loss of elasticity in the arterial system 
impacted on the relation of diastolic with systolic pressure. We recently defined the ambulatory 
arterial stiffness index (AASI) as unity minus the regression slope of diastolic on systolic blood 
pressure in individual 24-hour ambulatory blood pressure recordings.2,3 The stiffer the arterial 
tree, the closer the regression slope and AASI are to 0 and 1, respectively. We validated AASI 
against other markers of arterial stiffness, such as the systolic augmentation index and aortic 
pulse wave velocity.2 In spite of the prognostic accuracy of AASI over and beyond classical risk 
factors, including pulse pressure3–5 and pulse wave velocity,6 some researchers criticized AASI. 
It would be a surrogate marker of arterial stiffness not different from pulse pressure.7 Schillaci et 
al8 reported that AASI decreased with less nocturnal dipping in blood pressure. Gavish et al9 
suggested that symmetrical regression might provide a better estimate of AASI less affected by 
the nocturnal blood pressure fall and the goodness-of-fit of the regression slope, as expressed by 
the coefficient of determination (r2). To clarify these issues, we analyzed the International 
Database on the Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular 
Outcomes.10 We investigated whether r2 affects the association of AASI with established 
determinants of the relation between diastolic and systolic blood pressures, including age, body 
height, heart rate, and mean arterial pressure.2 We evaluated the consistency of the determinants 
of AASI in dippers and nondippers, women and men, and across different ethnic groups. 
 
Methods 
 
Study Population 
Previous publications (for details, see the expanded Methods in the online data supplement, 
available at http://hyper.ahajournals.org) described the construction of the International Database 
on the Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes.10,11 All 
of the included studies received ethical approval.12–17 The current analysis incorporates the 
baseline data of 2138 residents from Copenhagen, Denmark14; 1127 subjects from 
Noorderkempen, Belgium12; 1100 older men from Uppsala, Sweden15; 1520 inhabitants from 
Ohasama, Japan13; 349 villagers from the JingNing county, China16; and 1370 subjects from 
Montevideo, Uruguay.17 All 7604 subjects were ≥18 years old, gave informed written consent, 
and had ≥30 daytime and ≥5 nighttime blood pressure readings. 
 
Blood Pressure Measurement 
We programmed portable monitors to obtain ambulatory blood pressure readings at 30-minute 
intervals throughout the whole day,13 or at intervals ranging from 1514 to 3015 minutes during 
daytime and from 30 [14] to 60 [15] minutes at night. The devices implemented an auscultatory 
algorithm (Accutracker II) in Uppsala15 or an oscillometric technique (SpaceLabs 90202 and 
90207, Nippon Colin, and ABPM-630) in the other cohorts.12–14,16,17 We used linear 
regression, weighted by the time interval between successive readings, to determine the 
regression slope of diastolic on systolic blood pressure in individual recordings. AASI was unity 
minus the regression slope. Pulse pressure was systolic minus diastolic blood pressure. Because 
the oscillometrically measured mean arterial pressure was not available in all of the cohorts, we 
computed mean arterial pressure as diastolic blood pressure plus one third of pulse pressure. We 
studied the concordance between the computed and the oscillometrically measured mean arterial 
pressures in 1144 Belgian12 and 349 Chinese2 participants. Ambulatory hypertension was a 24-
hour blood pressure of 130 mm Hg systolic or 80 mm Hg diastolic18 or higher or the use of 
antihypertensive drugs. While accounting for the daily pattern of activities of the participants, we 
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defined daytime as the interval from 10 AM to 8 PM in Europeans12,14,15 and South 
Americans17 and from 8 AM to 6 PM in Asians.13,16 The corresponding nighttime intervals 
ranged from midnight to 6 AM12,14,15,17 and from 10 PM to 4 AM,13,16 respectively. In 
dichotomous analyses, we defined nondipping as a night:day ratio of systolic blood pressure of 
≥0.90 [19]. 
 
 
Other Measurements 
We used the questionnaires originally administered in each cohort12– 
17 to obtain information on each subject’s medical history and smoking and drinking habits. 
Body mass index was body weight in kilograms divided by height in meters squared. We 
measured serum cholesterol and blood glucose by automated enzymatic methods. Diabetes 
mellitus was a self-reported diagnosis, a fasting or random blood glucose level of ≥7.0 mmol/L 
(126 mg/dL) or ≥11.1 mmol/L (200 mg/dL),20 respectively, or the use of antidiabetic drugs. 
 
Statistical Analyses 
For database management and statistical analyses, we used SAS 9.1.3 (SAS Institute) and its JMP 
add-on, version 6.0. We checked that the assumption of normality was applicable to the variables 
under study by normal probability plots. We compared means and proportions by the large 
sample z test and by the χ2 statistic, respectively. Statistical significance was a 2-sided P value of 
0.05. In single and multiple regression analyses, the established determinants of the relation of 
diastolic on systolic blood pressure were age, body height, 24-hour mean arterial pressure, and 
24-hour heart rate.2 In single regression analysis, we also considered the night:day ratio of 
systolic blood pressure8,21 and 24-hour pulse pressure.22 Multivariable-adjusted models 
included as covariables cohort and/or sex, as appropriate, and age, body height, 24-hour mean 
arterial pressure, and 24-hour heart rate. In sensitivity analyses, we additionally adjusted for 
serum cholesterol, smoking, antihypertensive drug treatment, diabetes mellitus, and a history of 
cardiovascular disease. We used the coefficient of determination (r2) as a measure of the 
goodness-of-fit (Figure 1) of the regression line of diastolic on systolic blood pressure in 
individual ambulatory recordings. We subdivided the study population in cohort and sex-specific 
quartiles of r2. We compared Pearson’s correlation coefficients and partial regression coefficients 
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of AASI with its determinants, using Fisher’s z transform and interaction terms with binary 
variables coding for the quartiles of r2, respectively. In the last step of the analyses, we computed 
a cumulative z score for the single correlation coefficients of AASI with age, body height, 24-
hour mean arterial pressure, and 24-hour heart rate. We plotted the average cumulative z score 
against the goodness-of-fit of the AASI regression line, going from r2=0 to r2=0.80 (≈90th 
percentile of r2) by steps of 0.01.  
 
Results 
 
Characteristics of Participants 
The 7604 participants included 4365 Europeans (57.4%), 1869 Asians (24.6%), and 1370 South 
Americans (18.0%). Of the 7604 participants, 3472 were women (45.7%), 1703 (22.4%) were 
taking blood pressure–lowering drugs, and 946 (12.4%) had ambulatory hypertension. Mean±SD 
age was 56.9±13.9 years. At enrollment, 2203 participants (29.0%) were current smokers, and 
3535 (46.5%) reported intake of alcohol. In the whole study population, the 24-hour blood 
pressure averaged 124.8±14.4 mm Hg systolic and 73.9±9.2 mm Hg diastolic. The systolic and 
diastolic daytime levels averaged 131.2±15.5 mm Hg and 78.9±9.3 mm Hg, and the nighttime 
blood pressures were 113.2±15.5 mm Hg and 65.0±9.2 mm Hg. The night:day ratio of systolic 
blood pressure was 0.87±0.08.  
 
The 24-hour mean arterial pressure averaged 90.0±9.7 mm Hg. In 1493 subjects with available 
data, the computed compared with the measured mean arterial pressure (SD) was 0.71±2.50 mm 
Hg higher (88.3±9.1 versus 87.6±9.4 mm Hg; P<0.0001). The slope (P=0.87) and the intercept 
(P=0.54) of the regression line of the measured on the computed mean arterial pressure (r=0.98; 
P<0.0001) did not differ from the parameters of the line of identity (Figure S1). 
 
In all of the subjects, AASI averaged 0.46±0.18 and 24-hour pulse pressure 50.9±10.1 mm Hg. 
Mean r2 in 7604 individual recordings was 0.54±0.20. r2 was lower in the auscultatory 
recordings in 1100 older Swedish men than in the oscillometric registrations in 6504 other 
subjects (0.42±0.20 versus 0.56±0.19; P<0.001). Table 1 shows the characteristics of the 
participants by quartiles of r2. All of the P values for the differences between quartiles were 
significant (P≤0.01), with the exception of diastolic blood pressure (P=0.09). 
 
Unadjusted Analyses 
In all of the subjects combined, in single regression analysis, AASI correlated positively with age 
and 24-hour mean arterial pressure and negatively with height and 24-hour heart rate (Table 2). 
As shown in Table 2 and Figure 2, the correlation coefficients of AASI with age, height, 24-hour 
mean arterial pressure, and 24-hour heart rate were significantly tighter in the highest compared 
with the lowest quartile of r2. Figure 3 shows the plot of cumulative z scores of the 
aforementioned 4 covariables against the goodness-of-fit of the AASI regression line in steps of 
0.01 of r2, going from 0 to 0.80. The first, fifth, 10th, 20th, 50th, 75th, and 90th percentile values 
of r2 were 0.05, 0.17, 0.25, 0.36, 0.56, 0.69, and 0.79, respectively.  
 
The association between AASI and 24-hour pulse pressure increased across the quartiles of r2 
and was 0.49 (P<0.0001) in the whole study population. The correlation between AASI and 
serum cholesterol did not increase with r2. In all of the subjects combined, the correlation 
coefficient between AASI and the night:day ratio in systolic blood pressure was 0.15 (P<0.001). 
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This association was inconsistent across the quartiles of r2 (Table 2). The positive correlation 
between AASI and the systolic night:day ratio was larger in 1100 auscultatory recordings than in 
6504 oscillometric registrations (0.28 versus 0.15; P<0.0001). Furthermore, of 7604 participants, 
5361 were dippers (70.5%) and 2243 were 
nondippers (29.5%). The associations of AASI with age, body height, and 24-hour heart rate and 
mean arterial pressure were similar in dippers and nondippers (Figure 2). 
 
Multivariable Analyses 
In all 7604 of the subjects combined, AASI increased independently with age and 24-hour mean 
arterial pressure and decreased with height and 24-hour heart rate (Table 3). The multivariable-
adjusted associations of AASI with age, 24-hour mean arterial pressure, and 24-hour heart rate 
were significantly closer in the highest compared with the lowest quartile (Table 3). In multiple 
regression, the variance of AASI explained (R2) by age, height, 24-hour mean arterial pressure, 
and 24-hour heart rate increased from 0.04 to 0.37 from the lowest to the highest quartile of r2. 
 
Sensitivity Analyses 
The aforementioned unadjusted (Table S1) and multivariableadjusted (Table S2) findings were 
consistent in women and men and in Europeans, Asians, and Americans (see online 
Data Supplement). Analyses, from which we excluded the 1100 auscultatory recordings, also 
produced consistent results (Tables S3 and S4 and Figure S2). Our findings also remained 
consistent after the additional adjustment of the results in Table 3 for serum cholesterol, smoking, 
antihypertensive drug treatment, diabetes mellitus, and a history of cardiovascular disease (data 
not shown). 
 
Discussion 
We investigated whether r2 affects the association of AASI with established determinants of the 
relation between diastolic and systolic blood pressures.2 We confirmed that the strength of the 
relation of AASI with age, body height, 24-hour mean arterial pressure, and 24-hour heart rate 
increased with the goodness-of-fit of the AASI regression line. In fact, in the lowest quartile of 
the fit, the correlations of AASI with these determinants were weak and at times inconsistent with 
the expected direction of the associations.  
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For our current analyses, we used established determinants of AASI.2 In 348 randomly recruited 
Chinese subjects, AASI significantly and independently increased with age and mean arterial 
pressure, decreased with body height, and was higher in women than in men.2 Most other studies 
reported differences of these characteristics across quantiles of the distribution of AASI. They 
showed more advanced age,3,4,23 a higher proportion of women,3,4,23 and elevated blood 
pressure in higher AASI quantiles.3,23 In keeping with several other studies, in our hands, AASI 
did not or only weakly correlated with serum cholesterol,2,5,23,24 body mass index,3 and 
smoking. 2,4,5,23 AASI was negatively correlated with heart rate. Although heart rate is not a 
determinant of static arterial stiffness (pulse wave velocity), it is a determinant of dynamic 
measures of arterial stiffness, such as AASI or the augmentation index. A faster heart rate reduces 
the time required for the reflected pressure wave to reach the central arteries and leads to 
augmentation of systolic blood pressure.25 As reported by others, there was a positive correlation 
between AASI and pulse pressure, which increased with r2. Using 24-hour ambulatory pulse 
pressure as an index of arterial stiffness assumes that the difference between diastolic and systolic 
blood pressure is constant throughout the day.9,22 In contrast, AASI accounts for the dynamic 
relation between diastolic and systolic blood pressures in individual 24-hour ambulatory 
recordings. Furthermore, in hypertensive patients3 and representative population samples,4–6 
AASI predicted cardiovascular mortality and fatal and nonfatal stroke, over and beyond classic 
risk factors, including pulse pressure3–5 and even aortic pulse wave velocity.6 These prospective 
studies support the use of AASI for risk stratification.  
 
Schillaci et al8 reported that, in 515 untreated patients, AASI depended on the nocturnal blood 
pressure fall. We confirmed this observation in our Flemish population study.12,26 The 
correlation coefficients were similar to those in the report by Schillaci et al8: Flemish population 
versus Italian patients, −0.24 versus −0.28 for systolic blood pressure (2-sided P value for 
difference computed by Fisher’s z transformation: 0.42) and −0.39 versus −0.46 for diastolic 
blood pressure (P=0.11). In our current study, the correlation coefficient between AASI and the 
night:day ratio of systolic blood pressure (n=7604) was significantly weaker (P=0.0013) than in 
the hypertensive patients in the study by Schillaci et al.8 This association was not significant in 
the bottom and top quartiles of r2. At variance with the report by Schillaci et al,8 we noticed that 
the associations of AASI with its major determinants across quartiles of r2 were similar in 
dippers and nondippers. 
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Li et al2 measured AASI and aortic pulse wave velocity on the same day in 166 Chinese 
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volunteers. They found a close relation between these indices of arterial stiffness, which w
consistent in women (r=0.58; P<0.0001) and men (r=0.38; P=0.002) and in young (<40 years
r=0.26; P=0.02) and older adults (r=0.25; P=0.02). AASI was also significantly related to aortic
pulse wave velocity in 99 diastolic dippers (r=0.27; P=0.007), as well as in 67 diastolic 
nondippers (r=0.41; P=0.0005). Schillaci et al8 also measured both indices on the same d
346 untreated hypertensive patients, they reported a direct correlation between AASI and aortic 
pulse wave velocity of 0.28 (P<0.001). In 1678 subjects randomly recruited from the population 
of Copenhagen, the correlation coefficient between AASI and aortic pulse wave velocity was 
only 0.02 (P=0.47). In view of our current results, we computed the correlation coefficients 
between the 2 indices in the lowest and highest quartiles of the distribution of the goodness-o
of the AASI regression line in the Danish cohort.14 These correlation coefficients were −0.007 
(P=0.89) and 0.22 (P<0.0001), respectively (P value for the difference: <0.0001). These 
unpublished observations, along with the present findings, suggest that a better fit of the A
regression line in individual subjects might enhance the accuracy of AASI as a measure of 
arterial stiffness. 
 
T
anthropometric characteristics and lifestyle. However, the correlations of AASI with
determinants of the association between diastolic and systolic blood pressures were adjus
one another at the level of individual subjects. Sensitivity analyses showed that our findings were
consistent in dippers and nondippers, in women and men, in various ethnic groups, and with 
extensive multivariable adjustments applied. Second, ambulatory blood pressure monitoring w
not standardized across the 6 contributing studies in terms of device type and intervals between 
readings. However, across cohorts, we used the same SAS program to compute blood pressure– 
derived variables that were time weighted. Sensitivity analyses from which we excluded the 
auscultatory recordings were also confirmatory. Third, as suggested by experts in the field,7 
AASI is an indirect measure of arterial stiffness and is under the influence of other hemodyna
factors, such as wave reflections originating from peripheral sites, stroke volume, and peripheral 
resistance. The range of diastolic and systolic blood pressure values, which itself depends on the 
duration of the awake and asleep periods and on the intensity of physical activity during daytime,
might additionally influence AASI. Nevertheless, in collaboration with the Ohasama 
investigators, 5 we demonstrated recently that random exclusion of readings from ambulato
recordings with measurements programmed at 30-minute intervals did not significantly change
the average value of AASI until >7 readings were disregarded. Finally, we chose to use the 
calculated instead of the measured mean arterial pressure, because in most patients the meas
mean arterial pressure was unavailable for analysis. However, the concordance between 
computed and measured mean arterial pressures was high in 1493 participants with availa
data. 
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Perspectives 
A higher goodness-of-fit of the AASI regression line in individual subjects strengthens the 
association with its known determinants and likely enhances the statistical power of analyses 
involving AASI as a marker of arterial stiffness. Our findings have implications for clinical 
practice and research. The z score for the association of AASI with the 4 determinants of arterial 
stiffness combined (age, height, mean arterial pressure, and heart rate) increased curvilinearly 
with r2, with most of the increase occurring above the 20th percentile of r2 (0.36). One might use 
this threshold in clinical practice as the minimum value of r2, when AASI is applied for the risk 
stratification of individual patients. On the other hand, in clinical research, it is not good practice 
to exclude subjects from statistical analyses based on an arbitrary threshold. We would suggest 
that future reports of research on AASI might include a sensitivity analysis, excluding subjects 
with the r2 value set at a threshold of 0.36. However, primary analyses should always include all 
of the subjects, because a low r2 might also reflect disconnection of diastolic from systolic blood 
pressure because of cardiovascular disease. 
 
Acknowledgments 
We gratefully acknowledge the secretarial assistance of Sandra Covens and Ya Zhu (Studies 
Coordinating Centre, University of Leuven, Leuven, Belgium). 
 
Sources of Funding 
The European Union (grants IC15-CT98-0329-EPOGH, LSHM-CT-2006-037093 InGenious 
HyperCare, and HEALTH-F4-2007-201550 HyperGenes); the Fonds voor Wetenschappelijk 
Onderzoek Vlaanderen, Ministry of the Flemish Community, Brussels, Belgium (grants 
G.0453.05 and G.0575.06); and the University of Leuven (OT/00/25 and OT/05/49) gave support 
to the Studies Coordinating Centre. The Dutch Heart Foundation (Dr E. Dekker grant), Den 
Haag, The Netherlands, supported the fellowships of A.A. and D.G.D. in Leuven. 
 
Disclosures 
None. 
 
 165
References 
1. MacWilliam JA, Melvin GS. Systolic and diastolic blood pressure estimation with special 
reference to the auditory method. BMJ. 1914;1: 693–697. 
2. Li Y, Wang JG, Dolan E, Gao PJ, Guo HF, Nawrot T, Stanton AV, Zhu DL, O’Brien E, 
Staessen JA. Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure 
monitoring. Hypertension. 2006; 47:359 –364. 
3. Dolan E, Thijs L, Li Y, Atkins N, McCormack P, McClory S, O’Brien E, Staessen JA, Stanton 
AV. Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin 
Outcome Study. Hypertension. 2006;47:365–370. 
4. Hansen TW, Staessen JA, Torp-Pedersen C, Rasmussen S, Li Y, Dolan E, Thijs L, Wang JG, 
O’Brien E, Ibsen H, Jeppesen J. Ambulatory arterial stiffness index predicts stroke in a general 
population. J Hypertens. 2006;24:2247–2253. 
5. Kikuya M, Staessen JA, Ohkubo T, Thijs L, Metoki H, Asayama K, Obara T, Inoue R, Li Y, 
Dolan E, Hoshi H, Hashimoto J, Totsune K, Satoh H, Wang JG, O’Brien E, Imai Y. Ambulatory 
arterial stiffness index and 24-hour ambulatory pulse pressure as predictors of mortality in 
Ohasama, Japan. Stroke. 2007;38:1161–1166. 
6. Hansen TW, Li Y, Staessen JA, Jeppesen J, Rasmussen S, Wang JG, Thijs L, Ibsen H, Safar 
ME, Torp-Pedersen C. Independent prognostic value of the ambulatory arterial stiffness index 
and aortic pulse wave velocity in a general population. J Hum Hypertens. 2008;22:214–216. 
7. Laurent S. Surrogate measures of arterial stiffness: do they have additive predictive value or 
are they only surrogates of a surrogate? Hypertension. 2006;47:325–326. 
8. Schillaci G, Parati G, Pirro M, Pucci G, Mannarino MR, Sperandini L, Mannarino E. 
Ambulatory arterial stiffness index is not a specific marker of reduced arterial compliance. 
Hypertension. 2007;49:986 –991. 
9. Gavish B, Ben-Dov IZ, Bursztyn M. Linear relationship between systolic and diastolic blood 
pressure monitored over 24 h: assessment and correlates. J Hypertens. 2008;26:199 –209. 
10. Thijs L, Hansen TW, Kikuya M, Bjo¨rklund-Bodegård K, Li Y, Dolan E, Tikhonoff V, 
Sleidlerova´ J, Kuznetsova T, Stolarz K, Bianchi M, Richart T, Casiglia E, Malyutina S, 
Filipovsky´ J, Kawecka-Jaszcz K, Nikitin Y, Ohkubo T, Sandoya E, Wang JG, Torp-Pedersen C, 
Lind L, Ibsen H, Imai Y, Staessen JA, on behalf of the IDACO Investigators. The International 
 166
Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO): 
protocol and research perspectives. Blood Press Monit. 2007;12:255–262. 
11. Kikuya M, Hansen TW, Thijs L, Bjo¨rklund-Bodegård K, Kuznetsova T, Ohkubo T, Richart 
T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Staessen JA, on behalf of the IDACO 
Investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year 
cardiovascular risk. Circulation. 2006;115:2145–2152. 
12. Ga˛sowski J, Li Y, Kuznetsova T, Richart T, Thijs L, Grodzicki T, Clarke T, Staessen JA. Is 
“usual” blood pressure a proxy for 24-hour ambulatory blood pressure in predicting 
cardiovascular outcomes? Am J Hypertens. 2008;21:994 –1000. 
13. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, 
Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. Prognostic significance of 
the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: 
the Ohasama Study. J Hypertens. 2002;20:2183–2189. 
14. Hansen TW, Jeppesen J, Rasmussen F, Ibsen H, Torp-Pedersen C. Ambulatory blood 
pressure monitoring and mortality: a population-based study. Hypertension. 2005;45:499 –504. 
15. Ingelsson E, Bjo¨rklund K, Lind L, A¨ rnlo¨v J, Sundstro¨m J. Diurnal blood pressure pattern 
and risk of congestive heart failure. JAMA. 2006;295: 2859–2866. 
16. Li Y, Wang JG, Gao HF, Nawrot T, Wang GL, Qian YS, Staessen JA, Zhu DL. Are 
published characteristics of the ambulatory blood pressure generalizable to rural Chinese? The 
JingNing Population Study. Blood Press Monit. 2005;10:125–134. 
17. Schettini C, Bianchi M, Nieto F, Sandoya E, Senra H; the Hypertension Working Group. 
Ambulatory blood pressure. Normality and comparison with other measurements. Hypertension. 
1999;34(part 2):818–825. 
18. O’Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, Myers M, Padfield P, Palatini 
P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P, on behalf of the 
European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice 
guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure 
measurement. J Hypertens. 2005;23:697–701. 
19. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bjo¨rklund-Bodegård K, Richart T, Ohkubo 
T, Kuznetsova T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Wang JG, Sandoya E, O’Brien E, 
Staessen JA, on behalf of the International Database on Ambulatory blood pressure monitoring in 
 167
relation to Cardiovascular Outcomes (IDACO) investigators. Prognostic accuracy of day versus 
night ambulatory blood pressure: a cohort study. Lancet. 2007;370:1219 –1229. 
20. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the 
expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 
2003;26(suppl 1):S5–S20. 
21. Schillaci G, Parati G. Ambulatory arterial stiffness index: merits and limitations of a simple 
surrogate measure of arterial compliance. J Hypertens. 2008;26:182–185. 
22. Baumann M, Liu D, Nu¨rnberger J, Heemann U, Witzke O. Association of ambulatory 
arterial stiffness index and brachial pulse pressure is restricted to dippers. J Hypertens. 
2008;26:210 –214. 
23. Palmas W, Pickering T, Eimicke JP, Moran A, Teresi J, Schwartz JE, Field L, Weinstock RS, 
Shea S. Value of the ambulatory arterial stiffness index and 24-h pulse pressure to predict 
progression of albuminuria in elderly people with diabetes mellitus. Am J Hypertens. 
2007;20:493–500. 
24. Gosse P, Papaioanou G, Coulon P, Reuter S, Lemetayer P, Safar M. Can ambulatory blood-
pressure monitoring provide reliable indices of arterial stiffness? Am J Hypertens. 2007;20:831– 
838. 
25. Albaladejo P, Copie X, Boutouyrie P, Laloux B, Descorps Declere A, Smulyan H, Benetos A. 
Heart rate, arterial stiffness, and wave reflections in paced patients. Hypertension. 2001;38:949 –
952. 
26. Adiyaman A, Boggia J, Li Y, Wang JG, O’Brien E, Richart T, Thijs L, Staessen JA. Dipping 
deeper into the ambulatory arterial stiffness index. Hypertension. 2007;50:e59–e60. 
 168
DATA SUPPLEMENT  
Determinants of the Ambulatory Arterial Stiffness Index  
in 7604 Subjects from 6 Populations 
Short title: Ambulatory Arterial Stiffness Index   
Ahmet Adiyaman, Dirk G. Dechering, José Boggia, Yan Li, Tine W. Hansen, 
Masahiro Kikuya, Kristina Björklund-Bodegård, Tom Richart, Lutgarde Thijs, 
Christian Torp-Pedersen, Takayoshi Ohkubo, Eamon Dolan, Yutaka Imai,  
Edgardo Sandoya, Hans Ibsen, Jiguang Wang, Lars Lind, Eoin O’Brien, Theo Thien,  
Jan A. Staessen, on behalf of the International Database on Ambulatory blood pressure 
monitoring in relation to Cardiovascular Outcomes (IDACO) Investigators   
Word Counts: manuscript 3351  
Number: Tables 4, Figures 2  
Correspondence to:  
Jan A. Staessen, MD, PhD, FESC, FAHA,  
Studies Coordinating Centre,  
Laboratory of Hypertension,  
University of Leuven,  
Campus Gasthuisberg,  
Herestraat 49, Box 702,  
B-3000 Leuven, Belgium  
 
Telephone:+32-16-34-7104 (office)  
 +32-15-41-1747 (home)  
 +32-47-632-4928 (mobile)  
Facsimile: +32-16-34-7106 (office)  
 +32-15-41-4542 (home)  
email:  jan.staessen@med.kuleuven.be   
  ja.staessen@epid.unimas.nl   
voicemail:  jan.staessen@proximus .be   
 169
Ambulatory Arterial Stiffness Index - 170 - 
Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, 
Department of Cardiovascular Diseases, University of Leuven, Belgium (A.A., D.G.D., L.T., 
J.A.S.); University Medical Centre Sint Radboud, Department of General Internal Medicine, 
Radboud University, Nijmegen, the Netherlands (A.A., D.G.D., T.T.); Departamento de 
Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay 
(J.B.); Center for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai 
Jiaotong University School of Medicine, Shanghai, China (Y.L., J.W.); Research Center for 
Prevention and Health, Copenhagen, Denmark (T.W.H.); Tohoku University Graduate School 
of Pharmaceutical Sciences and Medicine, Sendai, Japan (M.K., T.O., Y.I.); Section of 
Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, 
Sweden (K.B.B., L.L.); Department of Epidemiology, Maastricht University, Maastricht, the 
Netherlands (T.R., J.A.S.); Copenhagen University Hospital, Copenhagen, Denmark (T.W.H., 
C.T.P., H.I.); Cambridge University Hospitals, Addenbrook’s Hospital, Cambridge, United 
Kingdom (E.D.); Asociación Española Primera de Socorros Mutuos, Montevideo, Uruguay 
(E.S.); and the Conway Institute of Biomolecular and Biomedical Research, University 
College Dublin, Dublin, Ireland (E.O.B.).   
Correspondence to Jan A. Staessen, Studies Coordinating Centre, Division of Hypertension 
and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of 
Leuven, Campus Gasthuisberg, Herestraat 49, Box 702, B-3000 Leuven, Belgium. E-mail: 
jan.staessen@med.kuleuven.be.  
 - 170 - 
Ambulatory Arterial Stiffness Index 171 
Expanded Methods  
Study Population  
Previous publications described the construction of the IDACO database.1,2  After an 
electronic search of the literature, we included studies if they involved a random population 
sample.  All studies3-8 included in the IDACO database received ethical approval and have 
been reported in peer-reviewed publications.  For the current analysis, we considered the 
baseline data of 2311 residents from Copenhagen, Denmark;5 2542 subjects from 
Noorderkempen, Belgium;3 1221 older men from Uppsala, Sweden;6 1535 inhabitants from 
Ohasama, Japan;4 360 villagers from the JingNing county, China;7 and 1859 subjects from 
Montevideo, Uruguay.8  All participants gave informed written consent.  Of the 9828 
subjects, we excluded 2224 participants (22.6%), because they were less than 18 years old at 
enrolment (n=17), or because their 24-h ambulatory recording included less than 30 readings 
in total (n=563), or less than 5 nighttime readings (n=1644).   The number of participants 
statistically analyzed amounted to 2138 from Copenhagen;5 1127 from Noorderkempen;3 
1100 from Uppsala;6 1520 from Ohasama; 4 349 from JingNing;7 and 1370 from 
Montevideo.8   
Blood Pressure Measurement  
We programmed blood pressure monitors to obtain ambulatory readings at 30-minute 
intervals throughout the whole day,4 or at intervals ranging from 155 to 306 minutes during 
daytime and from 305 to 606 minutes at night. The devices implemented an auscultatory 
algorithm (Accutracker II, Suntech Medical Instruments Inc., Morrisville, NC9) in Uppsala6 
or an oscillometric technique (SpaceLabs 90202 and 90207, SpaceLabs Inc., Redmond, 
WA10) in Noorderkempen,3 Montevideo8 and JingNing.8  The Takeda TM-2421 recorders 
(A&D, Tokyo, Japan11) and the ABPM-630 devices (Nippon Colin, Komaki, Japan12), used 
in Copenhagen5 and Ohasama,4 respectively, implemented both techniques, but we only 
analyzed the oscillometric readings.  The Ohasama recordings were edited sparsely according 
to previously published criteria,13 but all other recordings remained unedited.  
We used linear regression, weighted by the time-interval between successive readings, to 
determine the regression slope of diastolic on systolic pressure in individual recordings.  We 
did not force the regression slope through the origin, because during diastole when blood flow 
drops to zero, such a phenomenon does not occur for blood pressure.14  We defined AASI as 
unity minus the regression slope.  Pulse pressure was systolic minus diastolic blood pressure.   
Mean arterial pressure was diastolic blood pressure plus one third of pulse pressure.  Because 
the oscillometrically measured mean arterial pressure was not available in all cohorts, we 
computed mean arterial pressure as diastolic blood pressure plus one third of pulse pressure.  
We studied the concordance between the computed and the oscillometrically measured mean 
arterial pressure in 1144 Belgian3 and 349 Chinese15 participants.  Ambulatory hypertension 
was a 24-h blood pressure of 130 mm Hg systolic or 80 mm Hg diastolic,16 or higher, or the 
use of antihypertensive drugs.   
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While accounting for the daily pattern of activities of the participants, we defined daytime as 
the interval ranging from 10 AM to 8 PM in Europeans3,5,6 and South Americans,8 and from 8 
AM to 6 PM in Asians.4,7  The corresponding nighttime intervals ranged from midnight to 6 
AM3,5,6,8 and from 10 PM to 4 AM,4,7 respectively.  These fixed intervals eliminate the 
transition periods in the morning and evening when blood pressure changes rapidly, resulting 
in daytime and night-time blood pressure levels that are within 1–2 mm Hg of the awake and 
asleep levels.7,17  In dichotomous analyses, we defined nondipping as a night-to-day ratio of 
systolic blood pressure of 0.90 or higher.18   
Other Measurements  
We used the questionnaires originally administered in each cohort3-8 to obtain information on 
each subject’s medical history, and smoking and drinking habits.  Body mass index was body 
weight in kilograms divided by height in meters squared.  We measured serum cholesterol 
and blood glucose by automated enzymatic methods.  Diabetes mellitus was a self-reported 
diagnosis, a fasting or random blood glucose level of at least 7.0 mmol/L (126 mg/dL) or 11.1 
mmol/L (200 mg/dL),19 respectively, or the use of anti-diabetic drugs.  
Statistical Analyses  
For database management and statistical analyses, we used SAS software, version 9.1.3 (SAS 
Institute, Cary, NC) and its JMP add-on, version 6.0.  We checked that the assumption of 
normality was applicable to the variables under study by normal probability plots.  We 
compared means and proportions by the large sample z-test and by the χ2 statistic, 
respectively. Statistical significance was a two-sided P-value of 0.05.  
In single and multiple regression analyses, the established determinants of the relation of 
diastolic on systolic blood pressure were age, body height, 24-h mean arterial pressure, and 
24-h heart rate.15  In single regression analysis, we also considered the night-to-day ratio of 
systolic blood pressure20,21 and 24-h pulse pressure.22  Multivariable-adjusted models 
included as covariables cohort and/or sex, as appropriate, and age, body height, 24-h mean 
arterial pressure, and 24-h heart rate.  In sensitivity analyses, we additionally adjusted for 
serum total cholesterol, smoking, antihypertensive drug treatment, diabetes mellitus and a 
history of cardiovascular disease.   
We subdivided the study population in cohort and sex-specific quartiles of the goodness of fit 
of the slope of diastolic on systolic blood pressure.  We used the coefficient of determination 
(r2) as a measure of the goodness of fit.  We compared Pearson’s correlation coefficients 
across quartiles, using Fisher’s z-transform.  In multivariable-adjusted analyses, we compared 
the partial regression coefficients across quartiles, using appropriate interaction terms with 3 
design variables coding for the quartiles of r2. In the last step of the analyses, we computed a 
cumulative z-score for the single correlation coefficients of AASI with age, body height, 24-h 
mean arterial pressure, and 24-h heart rate.  For each subject, we then computed a cumulative 
z-score as the sum of the unsigned z-values for the 4 single correlation coefficients of AASI.  
We plotted the average cumulative z-score against the goodness of fit of the AASI regression 
line, going from r2=0 to r2=0.80 (approximate 90th percentile of r2) by steps of 0.01.  
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Appendix   
 
IDACO Centers and Investigators  
Belgium (Noorderkempen): R Fagard, T Kuznetsova, T Richart, JA Staessen, L Thijs; China 
(JingNing): Y Li, J Wang; the Czech Republic (Pilsen): J Filipovský, J Seidlerová, M Tichá; 
Denmark (Copenhagen): TW Hansen, H Ibsen, J Jeppesen, S Rasmussen, C Torp-Pedersen; 
Italy (Padua): E Casiglia, A Pizzioli, V Tikhonoff; Ireland (Dublin): E Dolan, E O’Brien; 
Japan (Ohasama): K Asayama, J Hashimoto, H Hoshi, Y Imai, R Inoue, M Kikuya, H 
Metoki, T Obara, T Ohkubo, H Satoh, K Totsune; Poland (Cracow): A Adamkiewicz-Piejko, 
M Cwynar, J Gąsowski, T Grodzicki, K Kawecka-Jaszcz, W Lubaszewski, A Olszanecka, K 
Stolarz, B Wizner, W Wojciechowska, J Zyczkowska; the Russian Federation (Novosibirsk): 
T Kuznetsova, S Malyutina, Y Nikitin, E Pello, G Simonova, M Voevoda; Sweden (Uppsala): 
B Andrén, L Berglund, K Björklund, L Lind, B Zethelius; Uruguay (Montevideo): M Bianchi, 
J Boggia, V Moreira, E Sandoya, C Schettini, E Schwedt, H Senra.  
Database Management and Coordination  
J Boggia, TW Hansen, M Kikuya, Y Li, JA Staessen (project coordinator), and L Thijs 
(supervisor database management) constructed the IDACO database at the Studies 
Coordinating Centre in Leuven, Belgium.  
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Table S1.   Correlates of AASI in the Whole Study Population and in the lowest and highest quartiles of the 
Goodness of Fit of AASI by Sex and Ethnicity   
  All subjects  Low   High  P   
Women (n = 3472)      
Age  0.35‡  0.16‡  0.57‡  <0.001  
Body height  –0.06‡  –0.04  –0.49‡  <0.001  
24-h mean pressure  0.12‡  0.04  0.24‡  <0.001  
24-h heart rate  –0.18‡  –0.15‡  –0.36‡  <0.001  
Men (n = 4132)      
Age  0.37‡  0..21‡  0.52‡  <0.001  
Body height  –0.05‡  –0.02   –0.24‡  <0.001  
24-h mean pressure  0.12‡  0.05   0.14‡    0.003  
24-h heart rate  –0.13‡  –0.04   –0.22‡  <0.001  
Europeans (n = 4365)      
Age  0.37‡  0.12‡  0.49‡  <0.001  
Body height  –0.06‡  –0.02   –0.13‡    0.020  
24-h mean pressure  0.15‡  0.03   0.27‡  <0.001  
24-h heart rate  –0.13‡  –0.02   –0.14‡    0.003  
Asians (n = 1869)      
Age  0.47‡  0.31‡  0.58‡  <0.001  
Body height  –0.24‡  –0.18‡  –0.22‡    0.53  
24-h mean pressure  0.05*  0.02   0.21‡    0.002  
24-h heart rate  –0.12‡  –0.05   –0.24‡    0.002  
South Americans (n = 1370)      
Age  0.22‡  0.12*  0.33‡    0.002 
Body height  –0.06†  –0.03   –0.09    0.44  
24-h mean pressure  0.11‡  0.03   0.21‡    0.009  
24-h heart rate  –0.17‡  –0.07   –0.23‡    0.016  
AASI is the ambulatory arterial stiffness index.  The P-values are for the differences in the correlation coefficients 
between the lowest and highest quartiles of the goodness of fit of AASI.   
Significance of the correlation coefficients: * P ≤ 0.05; † P < 0.01; ‡ P < 0.001.  
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Table S2.   Adjusted Regression Coefficients in the Whole Study Population and in the Lowest and Highest 
Quartiles of the Goodness of Fit of AASI by Sex and by Ethnicity  
  All subjects  Low   High  P   
Women (n = 3472)      
Age (+10 years)  32.1±2.4 ‡ 11.4±4.2 † 27.7±3.4 ‡   0.003 
Body height (+10 cm)  –8.9±4.3* –15.2±7.4 * –13.8±5.7 *   0.88 
24-h mean pressure (+10 mmHg)  –1.4±2.9  –0.5±4.9 14.1±3.8 ‡   0.019 
24-h heart rate (+10 bpm)  –12.8±3.2 ‡ –8.2±5.5 –16.3±4.4 ‡   0.250 
Men (n = 4132)      
Age (+10 years)  18.4±2.4 ‡ 10.9±4.7 * 28.1±3.1 ‡   0.002 
Body height (+10 cm)  –11.1±3.8 †  –3.2±7.4 –13.8±5.2 †   0.24 
24-h mean pressure (+10 mmHg)  4.4±2.6  –2.1±4.6 11.7±3.9  †   0.022 
24-h heart rate (+10 bpm)  –11.5±2.7 ‡ 0.1±4.8  –11.3±3.9  †   0.065 
Europeans (n = 4365)      
Age (+10 years)  23.6±2.5 ‡ 9.3±4.7 * 26.2±3.4 ‡ <0.001 
Body height (+10 cm)  –5.9±3.8  –0.8±6.6  –12.4±5.5 *   0.18 
24-h mean pressure (+10 mmHg)  0.2±2.7  –2.8±4.3 9.7±4.3 *   0.026 
24-h heart rate (+10 bpm)  –12.1±2.7 ‡ –2.7±4.4  –7.6±4.2    0.420 
Asians (n = 1869)      
Age (+10 years)  34.5±2.6 ‡ 20.3±5.2 ‡ 24.3±3.6 ‡ <0.001 
Body height (+10 cm)  –7.4±4.5 ‡ –10.1±9.0  –7.8±5.5    0.82 
24-h mean pressure (+10 mmHg)  4.2±2.8  10.9±4.7 * 14.3±3.7 ‡   0.57 
24-h heart rate (+10 bpm)  –1.6±3.4  –3.0±6.2  –12.7±4.4 †   0.20 
South Americans (n = 1370)      
Age (+10 years)  18.0±3.8 ‡ 10.4±6.4    24.8±6.7 ‡ <0.001 
Body height (+10 cm)  –23.6±7.8 †  –9.9±14.2  –19.2±12.0    0.62 
24-h mean pressure (+10 mmHg)  5.1±5.3  –3.8±8.6 –20.7±9.1 *   0.18 
24-h heart rate (+10 bpm)  –25.7±5.8 ‡ –6.1±9.9  –33.0±9.0 ‡   0.039 
AASI is the ambulatory arterial stiffness index.  All regression coefficients were mutually adjusted and in addition 
accounted for cohort (except in South Americans).  The associations in different ethnic groups were also adjusted for sex.  
The partial regression coefficients were multiplied by 103 to remove leading zeros.  The P-values are for the differences in 
the regression coefficients between the lowest and highest quartiles.   
Significance of associations: * P ≤0.05; † P<0.01; ‡ P<0.001.  
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 Legends to Figures  
Figure S1.  Scatterplot of the measured on the computed mean arterial pressure (MAP) in 
1493 subjects.  The slope (P=0.87) and the intercept (P=0.54) of the regression line (blue; 
r=0.98; P<0.0001) did not differ from the parameters of the line of identity (black).  The dotted 
lines delineate a 5 mm Hg interval above and below the regression line.   
Figure S2.   Plot of the average cumulative z-score against the goodness of fit of the AASI 
regression line, going from r2=0 to r2=0.80 (approximate 90th percentile of r2) by steps of 
0.01.  The cumulative z-score is the sum of the unsigned Fisher z-transforms of the single 
correlations of AASI with age, body height, 24-h mean arterial pressure, and 24-h heart rate.  
Vertical lines denote percentiles of the distribution of the goodness of fit (r2).  This sensitivity 
analysis excludes 1100 auscultatory recordings.   
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General discussion and summary 
 
A large body of evidence supports the notion that cardiovascular disease is for the most 
preventable by interventions like exercise, modified diets, statins and antihypertensive 
therapy[1]. Hypertension is an established and well known risk factor both for 
cerebrovascular and cardiac disease.  
 
Systolic BP increases with age until the eighth or ninth decade of life[2]. In contrast, diastolic 
BP rises only until middle age and then either levels off or decreases slightly. With increasing 
age, there is a gradual shift from diastolic BP to systolic BP as main predictor of 
cardiovascular risk[3]. From 60 years of age onward, coronary heart disease risk is positively 
correlated with systolic BP but is inversely related to diastolic BP.[4] Reduction of systolic 
BP is beneficial over the whole range of systolic blood pressures. Reducing diastolic BP is 
also beneficial, but too much reduction could be harmful (because of reduced perfusion of the 
coronary arteries)[5]. Whether or not the J-curve phenomenon for diastolic BP is attributable 
to antihypertensive treatment has been debated over the past decades. In general, one could 
opt to reduce systolic BP in patients with high cardiovascular risk according to the guidelines 
(office BP <140/90 or <130/80 in patients with a history of cardiovascular, renal disease or 
diabetes mellitus)[6]. For diastolic BP, given the results of the above cited literature, one 
should adapt a prudent approach in patients with concomitant coronary heart disease, in 
whom diastolic BP should probably not be lowered to less than 70 mm Hg, whereas the lower 
border could be at least 55 mmHg for others.[5]  
 
The choice of which antihypertensive drugs are started to reduce BP is of minor importance, 
as a large body of evidence has shown that the BP reduction itself is what matters in term of 
cardiovascular risk reduction[7, 8]. Effects beyond BP reduction (antihypertensive class 
effects) account for only 10-15%. The only exception could be monotherapy with beta-
blockers. Beta-blockers are nowadays not recommended as monotherapy for hypertension, 
because of their weak ability to reduce stroke incidence, compared to other antihypertensives, 
like calcium channel blockers, thiazide diuretics, ace-inhibitors or angiotensin II receptor 
antagonists[9]. This could be because of their "pseudo-antihypertensive" efficacy (failure to 
lower central aortic pressure)[10]. Of course, for other indications (such as during or after 
cardiac ischaemia, in heart failure, certain types of arrhythmia and hypertrophic obstructive 
cardiomyopathy), monotherapy with a beta-blocker could still be a good choice[9, 11]. 
Otherwise, combining beta-blockers with vasodilating antihypertensives could be advised. 
 
Blood pressure measurement; the procedure 
 
The biological variability of BP is high[12], and many factors influence BP itself or the BP 
measurement[13-17]. The procedure of BP measurement in the office should therefore be 
highly standardized. Some reminders for adequate performance of sitting BP measurement 
are: Instruct patients not to drink coffee or eat meals hours before the measurement. Let the 
patient rest for at least 5 minutes, if possible, 10 minutes. Although bare arm is ideal, there is 
discussion about the fact if BP should not be measured with the cuff placed over clothing. The 
patient should not talk or perform other activity while BP is measured.  
 
We have shown in this thesis (chapter 2.1) that the arm should be supported at heart level, as 
the BP could be 0.49 mmHg systolic and 0.47 mmHg diastolic BP higher for every cm of the 
cuff under the level of the right atrium. In our hands, this represented 9.3/9.4 mmHg 
overestimation of BP when the arm was placed on a chair support (67.5 cm high), and 6.1/5.7 
 186
mmHg overestimation when the arm was placed on the desk (77.0 cm high). A systolic BP 
difference of these magnitudes represents a 10-15% risk difference in coronary heart disease, 
18-27% difference in stroke, 12-18% difference in total cardiovascular mortality, and 6-9% 
difference in all-cause mortality rates[18]. Use a chair that supports the back. Make sure that 
the legs are uncrossed and feet flat on the floor. In this thesis (chapter 2.2), we proved that 
leg crossing at the level of the knees raised the mean BP up to 7.9/2.3 mmHg for 
systolic/diastolic BP, with higher values especially in hypertensives and diabetics. This 
systolic BP difference represents an overestimation of cardiovascular risk by approximately 
12, 23 and 15% for coronary heart disease, stroke, and total cardiovascular mortality 
respectively. We additionally proved (chapter 2.3) that a higher stroke volume was the reason 
of the rise of BP when crossing the legs at the level of the knee. Therefore, both in BP studies 
and in future guidelines, arm and leg position during BP measurement should explicitly be 
mentioned. 
 
Blood pressure measurement; progress 
 
Differences in the office versus at home 
 
Home BP has revealed that significant differences can exist between office and home[19]. 
These differences are largely determined by other factors than the presence of a doctor. It 
appears that the hospital environment has a more important contribution. In our hands for 
example (chapter 3.2), approximately 2/3 of the systolic BP differences were caused by the 
hospital environment and only 1/3 by the entrance of the doctor. Diastolic BP differences 
were explained for approximately 75% by the hospital environment and for 25% by the 
entrance of the doctor.  
 
The clinical significance of “white coat” hypertension (WCH), a condition in which BP is 
slightly elevated  in the clinic environment but normal in daily life, is controversial[20-22]. 
Although in general there seems no substantial higher cardiovascular risk compared to 
normotensives in trials with relatively short follow-up[23, 24], some studies with longer 
follow-up have shown a higher cardiovascular risk in WCH compared to normotensives[21, 
22, 25]. Masked hypertension (MH), a condition in which BP is normal in the clinic 
environment but elevated in daily life, has a similar prevalence in the population as WCH (10-
20%)[26]. For MH, in which hypertension is hidden from the doctor and therefore not 
adequately treated, there is consistent evidence in those patients that the cardiovascular risk is 
higher than in normotensives, and almost as high as in hypertensives[27-29]. This indicates 
that it is essential to include out of office BP measurement (self measured BP at home or 24-
hour ambulatory BP monitoring) in cardiovascular risk stratification.  
 
Self blood pressure measurement 
 
Self measured BP is increasingly being used with the introduction of fully automated and 
cheap devices[30]. Is has proven to have a better reproducibility than conventional office 
measurement and it provides more accurate estimates of the daily BP, resulting in higher 
predictive value for cardiovascular disease[6, 31]. Because of the different environmental 
setting in which BP is measured and because of the difference in measurement technique 
(auscultatory versus oscillometric)[32], different cut-offs are present for hypertension. A 
review of 30 years of research (chapter 3.1 of this thesis), regarding cut-off limits results in 
the following limits for diagnosis and treatment[33]: 
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Table 1. Thresholds for optimal, normal and high BP for home BP measurement.  
 
 Systolic (mmHg) Diastolic (mmHg) 
Optimal home BP <120 <80 
Normal home BP <130 <85 
High home BP ≥135 ≥85 
 
Treatment should probably be started if home BP is equal to or higher than 135/85 mmHg. 
Currently, there is no proof that therapeutic thresholds for the home BP should be lower in 
high-risk compared with normal-risk patients. This should be investigated further in the 
future. A large body of evidence, however, demonstrated that each millimetre of mercury of 
BP lowering counts in the prevention of cardiovascular complications and that in high-risk 
patients even small decreases in BP result in large absolute benefit[7].  
 
Ambulatory blood pressure monitoring 
 
Ambulatory blood pressure monitoring (ABPM) helps to make therapeutic decisions in patients 
who exhibit discordance between clinic and ambulatory BP values (WCH, resistant hypertension 
and MH)[34]. It has also augmented our understanding of BP circadian rhythm (24-hour 
period and night-day patterns) and has become an efficacious instrument aiding therapeutic 
decisions in hypertensive patients and other subjects at risk for cardiovascular disease[35]. 
ABPM is more strongly correlated with target-organ damage than office BP and offers more 
accurate prognostic information of cardiovascular outcomes[6, 36].  
 
Each 5% attenuation in the decline in nocturnal systolic/diastolic BP confers approximately a 
20% rise in the risk of cardiovascular mortality[37]. Subjects with a less than 10% nighttime 
BP decrease (non-dippers), or even an increase in BP during the night were those to exhibit a 
worse cardiovascular prognosis[38]. The dipping phenomenon is however poorly 
reproducible and should therefore be interpreted carefully[37]. Independent of the nocturnal 
dipping, high nocturnal BP is an additional determinant of an unfavourable prognosis. 
Nocturnal BP seems to correlate better with signs of target organ damage and cardiovascular 
morbidity than daytime BP[36, 39]. Both nondipping and high nighttime BP share common 
determinants such as sympathetic overactivity, sleep apnoea, pressure-dependent natriuresis 
and underlying organ damage. It could therefore be that non-dipping and high nighttime BP 
are a consequence of hypertensive target organ damage and tend to occur when target organ 
damage is present. Therefore it is hypothesized that these phenomena indicate reverse 
causality[37]. For diagnostic uses therefore, these parameters are useful, however for 
treatment purposes, it is debatable if these parameters themselves should be targeted 
(chronotherapy)[40]. It may be more logical to vigorously treat the underlying disease or risk 
factors. For thresholds of the measures determined by 24-hour ABPM, we refer to table 2 and 
to the guidelines[6]. 
 
Table 2. Diagnostic thresholds for conventional and ambulatory hypertension. 
 
 Systolic (mmHg) Diastolic (mmHg) 
Conventional BP 140 90 
24-h ambulatory BP 125-130 80 
24-h daytime BP 130-135 85 
24-h nighttime BP 120 70 
 
 188
Blood pressure measurement; process 
 
Arterial stiffness processed from ambulatory blood pressure 
 
Ageing and atherosclerosis contribute to stiffening of the arteries. The properties of the walls 
of large arteries change and eventually result in plaque formation and ischaemic events (heart 
attack, stroke etc.)[41, 42]. New indexes are increasingly being implemented in 
cardiovascular risk stratification, beyond the classic Framingham risk score (cholesterol, age, 
sex, BP, smoking etc). Indexes like intima media thickness (highly standardized measurement 
of arterial vessel wall thickness by ultrasonography), coronary calcium score (CT indexed 
evaluation of calcium deposits in the coronary vasculature), and indexes of arterial stiffness, 
like pulse wave velocity (measurement of blood flow velocity over the large arteries by 
special equipment) have shown to have additional predictive value beyond the classical risk 
stratification[42-44]. They are however difficult to measure, because of the need for special 
devices and highly trained technicians, and therefore they are costly.  
 
The ambulatory arterial stiffness index (AASI) is a novel marker of arterial stiffness that can 
be easily determined from 24-hour BP monitoring[45]. It predicts cardiovascular events 
(especially stroke) and mortality, above and beyond the classical cardiovascular risk factors, 
after additional correction for 24-hour pulse pressure and even pulse wave velocity[46]. 
Furthermore, it is closely related to other measures of arterial stiffness, like the pulse wave 
velocity and the aortic augmentation index[45]. It predicts target organ damage, e.g. renal 
insufficiency, (micro)albuminuria and intima media thickness[47, 48]. In chapter 4.1 of this 
thesis we have compiled nearly all present literature in a review. The AASI appears to be 
modestly reproducible (chapter 4.2 of this thesis), however it was better reproducible than 
other ambulatory indices of cardiovascular risk, like dipping status[49]. When quality criteria 
were set, the AASI had comparable reproducibility as 24-hour pulse pressure, together with 
an approximately similar reproducibility as the 24-hour systolic BP or diastolic BP in various 
hypertensive populations. One of these quality criteria is the goodness of fit (r²) of the AASI 
regression line, which determines the AASI as explained in Figure 1[50]. 
 
Figure 1. Three patients with the same ambulatory arterial stiffness index (0.50), 
approximately the same number of blood pressure readings (49-56), however a different 
goodness of fit of the regression line (r² of 0.23 up to 0.86) determining the ambulatory 
arterial stiffness index. 
 
 
 
The higher the scatter around the fitline, the lower the goodness of fit (left in figure 1, 
r²=0.23) and conversely, the better the correlation of the scatter with the AASI regression line, 
the better the goodness of fit (right in figure 1, r²=0.86). We have proven in chapter 4.4 that 
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the higher the r², the better AASI was associated with determinants of arterial stiffness. This 
was especially the case when a cut-off value of r²=0.36 was chosen. After this the association 
of the AASI with established determinants of arterial stiffness rose exponentially[50]. 
Therefore, in future analyses of AASI, sensitivity analyses should be made excluding data 
with a r² lower than 0.36. The r² could count as a quality criterion for AASI.  
 
Additionally, the novel AASI index created substantial discussion (chapter 4.3)[51-57]. 
Some authors were very positive naming AASI one of the gems of the 24-hour ABPM, 
whereas others criticized it as being an indirect measure of arterial stiffness. 
Comprehensively, a large body of evidence regarding the AASI exists that it predicts 
cardiovascular target organ damage, cardiovascular events and mortality. The AASI is 
reproducible and, with the quality criteria that are set, it is ready for the implementation in 
clinical practice. One of the manufacturers of 24-hour BP measuring devices (Spacelabs), has 
already implemented the automatical calculation of the AASI in their devices (personal 
communication prof.dr. J.A. Staessen). Future challenges are to standardize the measurement 
of AASI further, and to set reference values for different ethnicities and patient groups. 
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Samenvatting 
 
Cardiovasculaire ziekten, zoals beroertes, hartinfarcten en hartfalen, zijn grotendeels te 
voorkomen door adequate interventies, zoals verlaging van een verhoogde bloeddruk, 
lichaamsbeweging, dieet en cholesterolverlaging)[1]. Daarom dient men een hoge systolische 
bloeddruk bij patienten met een hoog risico op hart- en vaatziekten te verlagen volgens de 
richtlijnen (<140/90 mmHg of <130/80 mmHg voor mensen met een verleden van hart- en 
vaatziekten, nierziekten of diabetes mellitus)[2]. Welk bloeddrukverlagend medicijn wordt 
gestart, is van ondergeschikt belang. Voordat men echter tot behandeling kan overgaan, dient 
men een nauwkeurige en betrouwbare bloeddruk te verkrijgen. In dit proefschrift zijn wij 
verder ingegaan op verschillende aspecten die invloed hebben op de meting. Daarnaast zijn 
wij ingegaan op nieuwe ontwikkeling in risicovoorspelling door middel van bloeddrukmeting, 
zoals thuisbloeddrukmeting en 24-uurs ambulatoire bloeddrukmeting.  
 
Bloeddrukmeting: de procedure 
 
Bloeddruk is van nature zeer variabel [3], en vele factoren beinvloeden de bloeddruk zelf, of 
de meting ervan [4-8]. De bloeddrukmeting in de artsenpraktijk moet daarom zoveel als 
mogelijk gestandaardiseerd zijn. Dat het belangrijk is dat men de arm op harthoogte dient te 
houden, hebben wij in in dit proefschrift (hoofdstuk 2.1) aangetoond. Het blijkt dat elke 
centimeter onder hartniveau leidt tot een overschatting van de daadwerkelijke bloeddruk. Er 
was een gemiddelde overschatting van 9,3/9,4 mmHg systolische en diastolische bloeddruk 
bij het plaatsen van de arm op een armleuning van een stoel. Er was een gemiddelde 
overschatting van 6,1/5,7 mmHg toen de arm op een bureau werd geplaatst. Het plaatsen van 
de arm op bureau respectievelijk op de armleuning van een stoel, iets wat frequent wordt 
gedaan, overschat het risico op hartziekten met 10-15%, het risico op beroertes met 18-27%, 
de totale cardiovasculaire sterfte met 12-18% en de totale mortaliteit met 6-9%[9]. Er dient 
vermeden te worden dat de patient de benen of knieën kruist. In dit proefschrift toonden wij 
aan (hoofdstuk 2.2) dat het kruisen van de benen ter hoogte van de knieen de bloeddruk 
gemiddeld tot wel 7,9/2,3 mmHg verhoogt, vooral bij patienten met hypertensie en/of diabetes 
mellitus. Een systolische bloeddruk van deze orde overschat het risico met 12, 23 en 15% op 
respectievelijk hartziekten, beroertes en totale cardiovasculaire sterfte. Daarnaast toonden wij 
aan (hoofdstuk 2.3) dat deze bloeddrukstijging werd veroorzaakt door een verhoging van het 
slagvolume. In toekomstige richtlijnen dient daarom aandacht geschonken te worden aan arm- 
en beenpositie tijdens bloeddrukmeting. Voor gedetailleerde informatie betreffende een 
correcte bloeddrukmeting, verwijzen we u naar de richtlijnen[10].  
  
Bloeddrukmeting; progressie  
 
Verschillen tussen de artsenpraktijk en thuis 
 
De thuismeting van bloeddruk heeft ons geleerd dat er significante verschillen van bloeddruk 
tussen de artsenpraktijk en thuis aanwezig kunnen zijn[11]. Tot nu toe werd aangenomen dat 
de hogere bloeddruk in het ziekenhuis werd veroorzaakt door de arts. Later bedacht men dat 
ook de ziekenhuisomgeving zelf invloed zou kunnen hebben op de bloeddruk. Wij hebben 
voor het eerst de afzonderlijke invloeden van de ziekenhuisomgeving en de arts op de 
bloeddruk onderzocht (hoofdstuk 3.2). Verschillen van bloeddruk tussen thuis en het 
ziekenhuis blijken grotendeels verklaard te worden door andere factoren dan de binnenkomst 
van de arts. Wij toonden aan dat de ziekenhuisomgeving zelf een belangrijke bijdrage aan 
deze verschillen levert. In ons onderzoek bleek bijvoorbeeld dat de verschillen in systolische 
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bloeddruk thuis ten opzichte van het ziekenhuis voor 2/3 werden verklaard door de 
ziekenhuisomgeving en voor 1/3 door binnenkomst van de arts. Voor het diastolisch 
bloeddrukverschil was dit 75% door de ziekenhuisomgeving en 25% door de binnenkomst 
van de arts.  
 
Zelfbloeddrukmeting  
 
De zelfmeting van bloeddruk thuis wordt steeds vaker gebruikt, nu goedkope volautomatische 
apparaten op de markt zijn gekomen[12]. De thuismeting blijkt een betere risicoschatting op 
hart- en vaatziekten te geven dan de conventionele spreekuurmeting. Aangezien de bloeddruk 
op een andere plaats wordt gemeten dan in de spreekkamer of op de polikliniek, en omdat de 
techniek van de meting anders is, zijn de referentiewaarden ook anders dan die van de 
praktijkmeting[13]. In hoofdstuk 3.1 analyseerden wij de aanwezige literatuur van de laatste 
30 jaar om afkappunten te formuleren voor optimale, normale en te hoge bloeddruk. Tabel 1 
toont de waarden die uit onze analyse kwam[14]:  
 
Tabel 1. Afkappunten voor optimale, normale en hoge bloeddruk voor de zelfmeting van 
bloeddruk thuis.  
 
 Systolisch (mmHg) Diastolisch (mmHg) 
Optimale thuisbloeddruk <120 <80 
Normale thuisbloeddruk <130 <85 
Hypertensie ≥135 ≥85 
 
Dit betekent dat behandeling van de bloeddruk met medicatie dus gestart zou moeten worden 
als de thuisbloeddruk gelijk of hoger is dan 135/85 mmHg.  
 
Bloeddrukmeting; processie 
 
Arteriestijfheid en 24-uurs ambulatoire bloeddrukmeting  
 
Ambulatoire bloeddruk monitoring (ABPM) helpt om therapeutische beslissingen te nemen bij 
personen wiens bloeddruk thuis en in het ziekenhuis verschillend is (witte jas hypertensie en 
gemaskeerde hypertensie)[15]. Ambulatoire bloeddrukmeting geeft een betere schatting van de 
kans op cardiovasculaire complicaties dan de conventioneel gemeten bloeddruk[2, 16]. De 
afkappunten voor de verschillende 24-uurs bloeddrukken zijn samengevat in de onderstaande 
tabel[2]. 
 
Tabel 2. Diagnostische afkappunten voor conventionele en ambulatoire hypertensie. 
 
 Systolisch (mmHg) Diastolisch (mmHg) 
Conventionele bloeddruk 140 90 
24-uurs ambulatoire bloeddruk 125-130 80 
24-uurs dagbloeddruk  130-135 85 
24-uurs nachtelijke bloeddruk 120 70 
 
Veroudering en atherosclerose dragen bij aan het stijver worden van de vaten. De 
samenstelling en functie van de wanden van de slagaders veranderen en uiteindelijk onstaan 
er vernauwingen in de vaten, die voor beroertes en hartinfarcten kunnen zorgen[17, 18]. De 
ambulatory arterial stiffness index (AASI) is een nieuwe methode om arteriestijfheid te meten 
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en kan makkelijk worden bepaald uit een simpele 24-uurs bloeddrukmeting[19]. In hoofdstuk 
4.1 hebben wij samengevat hoe men deze index bepaalt, wat de achterliggende fysiologische 
mechanismen zijn en welke literatuur er over aanwezig is. De AASI heeft in prospectieve 
studies bewezen dat het cardiovasculaire aandoeningen (met name beroertes) voorspelt, 
bovenop de klassieke risicoscreening, 24-uurs polsdruk en zelfs pulse wave velocity (de 
gouden standaard van de bepaling van arteriestijfheid)[20]. Er is aangetoond dat de AASI 
nauw gerelateerd is aan andere methoden om arteriestijfheid te meten, zoals pulse wave 
velocity en de augmentatie index[19]. AASI voorspelt hypertensieve eindorgaanschade, zoals 
nierinsufficientie, eiwitverlies in de urine en intima media dikte[21, 22]. Daarnaast hebben wij 
in hoofdstuk 4.2 onderzocht hoe de reproduceerbaarheid is van deze nieuwe index. De AASI 
is bescheiden reproduceerbaar gebleken, maar was beter reproduceerbaar dan andere 
ambulatoire waarden die cardiovasculair risico voorspellen, zoals de mate van nachtelijke 
bloeddrukdaling[23]. Als kwaliteitscriteria worden gesteld, heeft AASI een vergelijkbare 
reproduceerbaarheid als 24-uurs polsdruk, niet veel slechter dan 24-uurs systolische en 
diastolische bloeddruk. Deze nieuwe AASI heeft veel discussie losgemaakt[24-30]. 
Sommigen waren erg positief en noemden de AASI een van de verborgen schatten van 24-
uurs ABPM. Anderen bekritiseerden het, aangezien zijn van mening zijn dat het een indirecte 
maat is voor arteriestijfheid. In hoofdstuk 4.3 hebben wij enkele discussiepunten over de 
AASI weergegeven die wij zelf hebben ingebracht. In hoofdstuk 4.4 hebben wij in een grote 
multi-ethnische populatie de betekenis van de “goodness of fit (r²)” verder onderzocht. Hoe 
meer verspreiding van punten om de regressielijn, zoals links in de figuur, hoe lager de 
“goodness of fit” en vice versa, zoals rechts in figuur 1 is te zien. We hebben bewezen dat een 
hogere r² ervoor zorgde dat AASI beter was gerelateerd aan determinanten van 
arteriestijfheid. Dit was vooral het geval bij een r² hoger dan 0.36, waarna de relatie van AASI 
met determinanten van arteriestijfheid curvilineair toenam[31]. De hoogte van de r² kan 
daarom dienen als kwaliteitscriterium voor de meting van de AASI.  
 
Figuur 3. Drie patienten met dezelfde ambulatoire arteriele stijfheids index (0.50), ongeveer 
dezelfde aantal bloeddrukmetingen (49-56), maar een verschillende ‘goodness of fit’ van de 
regressielijn (r² van 0.23 t/m 0.86) die de ambulatoire arteriele stijfheids index bepaalt. 
 
       
 
Samenvattend is over de AASI in korte tijd al een grote hoeveelheid aan bewijs gevonden dat 
het verschillende soorten hypertensieve orgaanschade, cardiovasculaire aandoeningen en 
mortaliteit voorspelt. Het wachten is dan ook op de invoering op grote schaal in de klinische 
praktijk. Een van de producenten van 24-uurs bloeddrukmeters, namelijk Spacelabs, heeft de 
AASI berekening al geïmplementeerd in hun apparaten (persoonlijke mededeling van prof. dr. 
J.A. Staessen).  
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enkelen. 
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oefenen tot het behalen van mijn artsexamen. Nu na het behalen van mijn artsexamen is het 
mij nog steeds niet gelukt, echter nu ik op het punt sta om te promoveren, denk ik dat voor mij 
het moment gekomen is om je Theo te noemen. Theo, ik zal niet vergeten dat je mij in een 
moeilijke studieperiode, waarin gemakzucht de overhand dreigde te krijgen, bij de hand hebt 
genomen en uit de misere hebt gesleept. Hiervoor ben ik je erg dankbaar. Daarvoor in de 
plaats kwam een leergierige, hardwerkende en onderzoeksgerichte student en nu arts. Ik 
realiseer me dat ik je regelmatig in de avonduren heb “lastiggevallen” en excuseer mij 
tegenover Saapke, jouw begripvolle partner. Het wekt ongeloof bij andere promovendi als ze 
horen dat jullie me zelfs in mijn onderzoeksperiode in Leuven hebben opgezocht om te zien 
hoe het me daar verging. Theo, hartelijk dank voor de talloze uren die je in mij hebt 
geinvesteerd, het is een eer om jouw student te zijn geweest. 
 
Prof. dr. Jan Staessen. Mijn tweede promotor en wetenschappelijk wonder. Jan, ik heb bij u 
een intensieve research fellowship mogen genieten. Het was een ervaring voor mij om te 
mogen samenwerken met de persoon wiens artikelen ik regelmatig in topbladen als the Lancet 
en JAMA las. Ook al vinden enkelen op mijn huidige werkplek mij een perfectionist, ik denk 
dat zij u niet als referentie kennen. De avonden waarin ik met u heb gewerkt, maakten mij al 
snel duidelijk dat daar wetenschap gebezigd werd op mondiaal topniveau. U bent erg druk 
met uw bezigheden als hoofd van het Studies Coordinating Centre. Ook al is het moeilijk om 
uw tempo en werktijden (11.00-01.00, maar eigenlijk 7 dagen, 24 uur per dag) bij te houden, 
het resultaat is van hoge kwaliteit en kwantiteit. Daarnaast heb ik u leren kennen als een 
warm, sociaal persoon, die op laagdrempelig niveau omging met zijn studenten. Ik heb 
begrepen dat dit voor Belgische begrippen uitzonderlijk is. Dank voor alles, en ik hoop dat we 
in de toekomst kunnen blijven samenwerken.  
 
Dr. J. Deinum en Prof. Dr. J.W.M. Lenders. Beste Jaap en Jacques, als co-promotor 
respectievelijk begeleider hebben jullie mij gedurende mijn onderzoekstijd veel geholpen. 
Jullie visie en kritieken waren origineel en opbouwend. Dank voor het vrijmaken van kostbare 
tijd en jullie waardevolle hulp.  
 
De leden van de manuscriptcommissie, prof.dr. P. Smits, prof.dr. F. Verheugt en prof.dr. M. 
Hopman wil ik danken voor het kritisch evalueren van de dissertatie. 
 
Mijn ouders Mehmet en Hatice. Dankzij jullie onvoorwaardelijke steun en opvoeding heb ik 
zorgeloos en succesvol kunnen studeren. Iets wat jullie, ondanks een hoge intelligentie, door 
omstandigheden, zelf niet hebben kunnen doen. Jullie emotionele en financiele steun was 
essentieel voor mijn onderzoeksperiode in het buitenland. Ik hoop dat jullie daarom extra trots 
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jullie hierbij ten zeerste voor alles, hoewel ik weet dat ik jullie nooit genoeg kan bedanken.  
 
Mijn broer, drs. Ismail Adiyaman. Bedankt voor de morele steun die je me gedurende mijn 
onderzoeksperiode hebt gegeven en voor je hulp bij het klaarmaken van het manuscript. Elke 
keer dat ik het een tijdje niet over de promotie had, bracht jij het weer ter sprake. De snelheid 
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gewoon lange pauzes en snelle internetverbindingen.  
 
Dr. D.G. Dechering. Dirk, met jou samen ben ik mijn co-schappen begonnen. Samen hebben 
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hulp en voor de leuke momenten, zowel op wetenschappelijk als sociaal vlak. Succes met je 
carriere in Münster.  
 
Alle mede-onderzoekers die actief hebben bijgedragen aan de analyse en verwerking van de 
data, te weten: Dr. Jose (Pepe) Boggia (internist in Uruguay, mijn onderzoeksmaatje in 
Leuven), Dr. Lutgarde Thijs (statistisch fenomeen en onderzoeker in Leuven), Dr. Tom 
Richart (onderzoeker in Leuven), Dr. T. Kuznetsova (onderzoeker in Leuven), Dr. T.W. 
Hansen (onderzoeker in Denemarken). Uit Nijmegen: drs. Ismail Aksoy, drs. Nevin Tosun en 
drs. Rutger Verhoeff voor het verzamelen van data die ik heb bewerkt. 
 
Mijn (voor)opleider interne geneeskunde in het Rijnstate Ziekenhuis te Arnhem, Dr. Vera 
Mattijssen, voor het continu bieden van tijd, ruimte en steun om mijn wetenschappelijke werk 
en promotie af te maken.  
 
Mijn (voor)opleider cardiologie in het Rijnstate Ziekenhuis te Arnhem, Dr. Hans Bosker, voor 
de oprechte interesse en de steun die hij mij gaf bij de vorderingen van mijn 
wetenschappelijke werk en carrieremogelijkheden binnen de cardiologie.  
 
Mijn echtgenote Ayşegül. Ayşegül, je steunde mij door dik en dun gedurende de laatste (en 
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De auteur van dit proefschrift werd geboren op 23 april 1981 te Doetinchem. Na het volgen 
van het VWO van 1993 tot 1999 aan het Isala College te Silvolde, begon hij in 1999 aan zijn 
studie geneeskunde aan de Katholieke Universiteit van Nijmegen (inmiddels Radboud 
Universiteit).  
 
Reeds voor het begin van zijn co-schappen in 2005, begon hij na zijn wetenschappelijke 
stage, onder leiding van Prof. dr. Th. Thien aan verschillende onderzoeken die nu een 
onderdeel zijn van het huidige proefschrift (UMC St. Radboud te Nijmegen, Algemene 
Interne Geneeskunde, Hypertensie en Vasculaire Pathologie). Gedurende de co-schappen 
werden in de vrije momenten en vakanties belangrijke vorderingen in het onderzoek gemaakt.  
 
Het artsexamen werd behaald in 2007. Reeds voor het artsexamen is hij, gesteund door een 
Dr. E. Dekker beurs van de Nederlandse Hartstichting, een periode van 4 intensieve maanden 
research fellow geweest bij Prof. dr. J.A. Staessen aan het Studies Coordinating Centre, 
Division of Hypertension and Cardiovascular Research aan de Universiteit van Leuven in 
Belgie. Hier is ook de basis gelegd voor een samenwerkingsverband tussen de Radboud 
Universiteit (Prof. dr. Th. Thien) en de Universiteit van Leuven (Prof. dr. J.A. Staessen), die 
tot op heden nog zijn vruchten afwerpt. Thans is de promovendus reviewer voor de vakbladen 
Hypertension (American Heart Association) en voor the Anatolian Journal of Cardiology 
(Turkish Heart Association). 
 
Eind 2007 is de promovendus een viertal maanden arts-assistent geweest op de afdeling Hart- 
en Vaatziekten in het Rijnstate Ziekenhuis in Arnhem (Dr. H.A. Bosker). Direct aansluitend is 
hij in 2008 in dezelfde kliniek aan zijn vooropleiding Interne Geneeskunde (Dr. L. Verschoor) 
begonnen, in het kader van zijn opleiding tot cardioloog aan het UMC St. Radboud te 
Nijmegen. Het plan is om een B-opleidings jaar cardiologie te volgen in het Rijnstate 
Ziekenhuis te Arnhem (Dr. H.A. Bosker) en aansluitend A-opleiding cardiologie in het UMC 
St. Radboud te Nijmegen (Prof. Dr. F.W.A. Verheugt en Prof. Dr. J. Smeets). Deze zal in 
2013 worden afgerond. 
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